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Abstract 
Mycobacterium tuberculosis (Mtb), the etiological agent of pulmonary tuberculosis, is the 
leading cause of death due to infectious disease worldwide. Due to a lack of new drug 
development, poor fidelity, and repeated exposure to currently available therapeutics, 
Mtb has become multidrug resistant, extensively drug resistant, and even totally drug 
resistant in some patients. With nearly 9 million deaths and 1.4 million new cases 
reported by the World Health Organization (WHO) in 2011, new therapies that act via 
novel mechanisms of action are desperately needed to fight this global health threat.  
Herein we describe our efforts to develop new antitubercular agents by attacking the 
bacteria's need for iron. This approach involves the inhibition of the biosynthetic pathway 
to produce siderophores, small molecule iron chelators responsible for acquiring iron in 
limiting conditions, such as those in a human host. A prototypical inhibitor of the 
initiating enzyme in this pathway, MbtA, had been previously developed by our lab, and 
was used to develop a small set of analogues for in vivo evaluation. We employed 
Sprague-Dawley rats to evaluate the oral bioavailability of our compounds, revealing that 
the pKa of the linker nitrogen of the scaffold had a large effect on compound 
permeability. 
In addition, we studied the mechanism of action of our parent inhibitor, Sal-AMS, 
through the development of a photoaffinity probe to label and pull down proteins for 
target identification. A probe containing a benzophenone moiety for photo-crosslinking 
and a small alkyne handle for attachment of an imaging or enrichment tag was 
synthesized. This probe was successful in identifying the intended enzyme of interest 
  iv 
(MbtA) as a binding partner, but did not yield any additional hits, suggesting Sal-AMS is 
a highly specific inhibitor. 
Studies were also done on the natural product transvalencin Z that had been reported as 
selective against mycobacteria. This compound was very similar in structure to the 
mycobactin siderophores from Mtb. The 4 possible diastereomers of the reported 
structure were synthesized in an attempt to elucidate the absolute stereochemistry of the 
natural product, however, spectroscopic data obtained did not match with the literature 
report. The activity of the diastereomers was tested against a panel of 14 pathogens, but 
our results were observed in stark contrast to those reported by the discovery group. 
Finally, we aided a collaborator in the development and synthesis of a probe against 
DhbE in Bacillus subtilis. Dr. Jun Yin of the University of Chicago was studying the 
substrate specificity of adenylation domains, and chose an enzyme highly homologous to 
our target MbtA. We designed a probe that incorporated a similar inhibitor, DHB-AMS, 
and a long flexible linker with a biotin attached for Dr. Yin's unique yeast cell display 
assay. Dr. Yin was able to utilize these probes to successfully identify mutant adenylation 
enzymes with altered specificity towards nonnative substrates. This technique is an 
exciting new way to potentially access analogues of natural products through 
manipulation of the biosynthetic machinery, instead of through often cumbersome 
organic chemistry. 
These studies have continued to advance our understanding of a new mechanism of 
action against Mtb, and have brought us one step closer to a preclinical candidate. 
  v 
Table of Contents 
Acknowledgements i 
Dedication ii 
Abstract iii 
Table of Contents v 
List of Tables xv 
List of Figures and Schemes xvi 
Preface xx 
 
 
Chapter 1: Challenges in Tuberculosis Drug Discovery 1 
 
1.1 Introduction 1 
1.2 Challenge 1: Heterogeneity in tuberculosis pathology 11 
1.3 Challenge 2: Target validation and vulnerability 15 
1.4 Challenge 3: Lead compound and inhibitor design 19 
1.5 Challenge 4: Mechanisms of action 27 
1.6 Challenge 5: Modeling activity against Mycobacterium tuberculosis 37 
1.7 Challenge 6: Monetary challenge 41 
1.8 Conclusions 43 
1.9 References 44 
 
  vi 
Chapter 2: Synthesis of Adenylation Inhibitors as Antitubercular Agents and Evaluation 
of Their Oral Bioavailability in a Rodent Model 56 
 
2.1 Introduction 56 
 2.1.1 Siderophore inhibitors as antitubercular agents 56 
 2.1.2 Initial evaluation of lead compound Sal-AMS 60 
2.2 Research Objectives 66 
2.3 Results 67 
 2.3.1 Synthesis of Sal-AMS (2-1) and sulfamide linked analogue (2-6) 67 
 2.3.2 Synthesis of 5ʹ-Amino-5ʹ-deoxy-5ʹ-N-[(4-amino-2-
hydroxybenzoyl)sulfamoyl]-adenosine (2-34) 70 
 2.3.3 Synthesis of 5ʹ-Amino-N6-cyclopropyl-5′-deoxy-5ʹ-N-[N-(2-
hydroxybenzoyl)sulfamoyl]adenosine (2-41) 71 
 2.3.4 Synthesis of 2-Phenyl-N6-cyclopropyl-5ʹ-O-[N-(2-
hydroxyl)sulfamoyl]adenosine (2-50) 73 
 2.3.5 Synthesis of acetate prodrugs of Sal-AMS (2-51 and 2-52) 74 
 2.3.6 Oral bioavailability of siderophore biosynthesis inhibitors 76 
2.4 Discussion 91 
 2.4.1 Strategies for increasing oral bioavailability 91 
 2.4.2 Anomalous high oral bioavailability of compound 2-50 92 
 2.4.3 Prodrugs of nucleosides 94 
 2.4.4 Trends in oral bioavailability for siderophore inhibitors 96 
  vii 
2.5 Conclusions 96 
2.6 Experimental details 97 
 2.6.1 General procedures for the synthesis of siderophore biosynthesis        
inhibitors 97 
 2.6.2  Synthesis of N6,N6-bis(tert-Butoxycarbonyl)-2ʹ,3ʹ-O-isopropylidene-5ʹ-O- 
(sulfamoyl)adenosine (2-25) 99 
 2.6.3  Synthesis of N6,N6-bis(tert-Butoxycarbonyl)-2ʹ,3ʹ-O-isopropylidene-5ʹ-O-{N-
[2-(methoxymethoxy)benzoyl]sulfamoyl}adenosine triethylammonium salt 
(2-27) 99 
 2.6.4  Synthesis of N6,N6-bis(tert-Butoxycarbonyl)-5ʹ-{N-[(tert-
butoxycarbonyl)sulfamoyl]amino}-5ʹ-deoxy-2ʹ, 3ʹ-O-
isopropylideneadenosine (2-29) 100 
 2.6.5  Synthesis of N6,N6-bis(tert-Butoxycarbonyl)-5ʹ-(N-tert-butoxycarbonyl-N-
{[(2-methoxymethoxy)benzoyl]sulfamoyl})amino-5ʹ-deoxy-2ʹ,3ʹ-O-
isopropylideneadenosine triethylammonium salt (2-30) 101 
 2.6.6  Synthesis of N6,N6-bis(tert-Butoxycarbonyl)-5ʹ-(N-tert-butoxycarbonyl-N-
{N-[(4-benzyloxycarboxyamino-2-hydroxy)benzoyl]sulfamoyl})amino-5ʹ-
deoxy-2ʹ,3ʹ-O-isopropylideneadenosine triethylammonium salt (2-33) 102 
 2.6.7  Synthesis of Synthesis of 5ʹ-Deoxy-5ʹ-({N-[(2-hydroxy-4-
amino)benzoyl]sulfamoyl}amino)adenosine (2-34) 103 
 2.6.8  Synthesis of 5ʹ-Amino-N6-cyclopropyl-5ʹ-deoxy-2ʹ,3ʹ-O-
isopropylideneadenosine (2-37) 104 
  viii 
 2.6.9  Synthesis of N6-Cyclopropyl-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylidene-5ʹ-
[(sulfamoyl)amino]adenosine (2-39) 105 
 2.6.10 Synthesis of N6-Cyclopropyl-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylidene-5ʹ-({N-[(2-
methoxymethoxy)benzoyl]sulfamoyl}amino)adenosine triethylammonium 
salt (2-40) 106 
 2.6.11 Synthesis of 5ʹ-N-[N-(2-Hydroxybenzoyl)sulfamoylamino]-N6-cyclopropyl-
5ʹ-deoxyadenosine triethylammonium salt (2-41) 107 
 2.6.12 Synthesis of N6-Cyclopropyl-2ʹ,3ʹ-O-isopropylidene-2-phenyl-5ʹ-O- 
(sulfamoyl)adenosine (2-48) 108 
 2.6.13 Synthesis of 2ʹ,3ʹ-O-Di-acetyl-5ʹ-O-{N-[(2-
acetyloxy)benzoyl]sulfamoyl}adenosine triethylammonium salt (2-51) 108 
 2.6.14 Synthesis of 5ʹ-O-[N-(2-Benzyloxybenzoyl)sulfamoyl]-N6, N6-bis(tert-
butoxycarbonyl)-2ʹ, 3ʹ-O-isopropylideneadenosine triethylammonium salt (2-
54) 109 
 2.6.15 Synthesis of 2ʹ,3ʹ-O-Di-acetyl-5ʹ-O-[N-(2-
hydroxybenzoyl)sulfamoyl]adenosine triethylammonium salt (2-52) 110 
 2.6.16 Procedures for the measurement of oral bioavailability of siderophore 
inhibitors in Sprague-Dawley rats 112 
 2.6.17 Procedure for the measurement of stability of prodrugs 2-51 and 2-52 in 
simulated gastric fluid (SGF) 117 
2.7 References 118 
 
  ix 
Chapter 3: A Light-Activated Probe for the Study of Adenylation Domains in 
Mycobacterium tuberculosis 123 
 
3.1 Introduction 123 
 3.1.1 Chemical probes for investigation of target enzymes 123 
 3.1.2 Investigating a secondary target of Sal-AMS (3-1) in Mtb 126 
 3.1.3 Design of a clickable photoaffinity probe for the study of MbtA 128 
3.2 Research Objectives 131 
3.3 Results 132 
 3.3.1 Synthesis of a clickable photoaffinity probe for the study of MbtA 132 
 3.3.2 Control experiments with photoaffinity probe 3-2 and recombinant  
MbtA 135 
 3.3.3 Photoaffinity probe 3-2 labeling MbtA from cell lysates in expression and  
native systems 138 
3.4 Discussion 145 
3.5 Conclusions 147 
3.6 Experimental Data 148 
 3.6.1 General procedures for the synthesis of a photoaffinity probe against       
MbtA 148 
 3.6.2 Synthesis of 5-(Triisopropylsilyl)pent-4-ynoic acid (3-3) 149 
 3.6.3 Synthesis of N-[4-(4-Aminobenzoyl)phenyl]-5-(triisopropylsilyl)pent-4-
ynamide (3-6) 149 
  x 
 3.6.4 Synthesis of 2′,3′-O-Isopropylidene-2-{N-[4-(4-{N-[5-(triisopropylsilyl)pent-
4-ynoyl]amino}benzoyl)phenyl]amino}adenosine (3-8) 150 
 3.6.5 Synthesis of 2′,3′-O-Isopropylidene-2-[N-(4-{4-[N-(pent-4-
ynoyl)amino]benzoyl}phenyl)amino]adenosine (3-9) 151 
 3.6.6 Synthesis of 2′,3′-O-Isopropylidene-2-[N-(4-{4-[N-(pent-4-
ynoyl)amino]benzoyl}phenyl)amino]-5′-O-(sulfamoyl)adenosine (3-10) 152 
 3.6.7 Synthesis of 5ʹ-O-[N-(2-Hydroxybenzoyl)sulfamoyl]-2-[N-(4-{4-[N-(pent-4-
ynoyl)amino]benzoyl}phenyl)amino]adenosine triethylammonium salt         
(3-2) 153 
3.7 References 154 
 
Chapter 4: Total Synthesis and Biological Evaluation of Four Diastereomers of the 
Natural Product Transvalencin Z 158 
 
4.1 Introduction 158 
4.2 Research Objectives 163 
4.3 Results 164 
 4.3.1 Synthesis of transvalencin Z diastereomers 164 
 4.3.2 Biological evaluation of transvalencin Z diastereomers 170 
 4.3.3 Characterization of transvalencin Z diastereomers 171 
4.4 Discussion 174 
4.5 Conclusions 175 
  xi 
4.6 Experimental Data 176 
 4.6.1  General procedures for the synthesis of transvalencin Z diastereomers 176 
 4.6.2  General procedures for microbiological evaluation of transvalencin Z 
diastereomers 177 
 4.6.3  General procedures for mammalian cell toxicity measurements 179 
 4.6.4  Synthesis of 2-(Benzyloxy)benzoic acid (4-10) and N-[2-
(Benzyloxy)benzoyl]-L/D-serine benzyl esters (4-12a and 4-12b) 180 
 4.6.5  Synthesis of (4S) and (4R)-Benzyl-2-[2-(benzyloxy)phenyl]-Δ2-1,3-
oxazoline-4-carboxylate (4-13a and 4-13b) 180 
 4.6.6  Synthesis of (4S) and (4R)-2-[2-Hydroxyphenyl]-Δ2-1,3-oxazoline-4-
carboxylic acid (4-5a and 4-5b) 181 
 4.6.7  Synthesis of (2S) and (2R)-({[(9H-Fluoren-9-yl)methyloxy]carbonyl}amino)-
6-formamidohexanoic acid (4-16a and 4-16b) 182 
 4.6.8  Synthesis of (2S) and (2R)-Benzyl-2-({[(9H-fluoren-9-
yl)methyloxy]carbonyl}amino)-6-formamidohexanoate (4-17a 
and 4-17b) 182 
 4.6.9  Synthesis of (2S) and (2R)-Benzyl-2-amino-6-formamidohexanoate (4-6a  
and 4-6b) 183 
 4.6.10 Synthesis of (2S, 9S) and (2R, 9R)-Benzyl-6-formamido-2-[(2-
hydroxyphenyl)-Δ2-1,3-oxazoline-4-carboxamido]hexanoate  
(4-18a and 4-18b) 184 
 4.6.11 Synthesis of (2S, 9R) and (2R, 9S)-Benzyl-6-formamido-2-[(2-
  xii 
hydroxyphenyl)-Δ2-1,3-oxazoline-4-carboxamido]hexanoate 
(4-18c and 4-18d) 185 
 4.6.12 Synthesis of (2S, 9S) and (2R, 9R)-6-Formamido-2-[(2-hydroxyphenyl)-Δ2-
1,3-oxazoline-4-carboxamido]hexanoic acid (4-4a and 4-4b) 186 
 4.6.13 Synthesis of (2S, 9R) and (2R, 9S)-6-Formamido-2-[(2-hydroxyphenyl)-Δ2-
1,3-oxazoline-4-carboxamido]hexanoic acid (4-4c and 4-4d) 187 
4.7 References 188 
 
Chapter 5: Biotinylated Probes for the Study of Adenylation Domains in Bacillus   
subtilis 192 
 
5.1 Introduction 192 
 5.1.1 Nonribosomal peptide synthetases (NRPS) 193 
 5.1.2 Adenylation domains 194 
 5.1.3 Analogues of natural products through native synthetases 195 
 5.1.4 DhbE as a model system 196 
5.2 Research Objectives 197 
5.3 Results  198 
 5.3.1 Synthesis of chemical probes for the study of DhbE 198 
 5.3.2 Construction of an adenylation domain library of DhbE displayed on yeast 
cells 202 
 5.3.3 Identification of DhbE mutants with altered specificity for 3-HBA and  2-
  xiii 
ABA 204 
5.4 Discussion 206 
5.5 Conclusions 208 
5.6 Experimental Data 209 
 5.6.1 General procedures for the synthesis of biotinylated probes against          
DhbE 209 
 5.6.2 Synthesis of N-Hydroxysuccinimidyl 3-(methoxymethyloxy)benzoate  
(5-12) 210 
 5.6.3 Synthesis of 2-[3-(2-{2-[2-(tert-
Butoxycarbonylamino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-2′,3′-O-
isopropylidene-5′-O-{N-[3-(methoxymethoxy)benzoyl]sulfamoyl}adenosine 
(5-13) 211 
 5.6.4 Synthesis of 2-[3-(2-{2-[2-({dPEG®4-
biotinyl}amino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-5′-O-{N-[3-
(hydroxy)benzoyl]sulfamoyl}adenosine triethylammonium salt (5-2) 212 
 5.6.5 Synthesis of 2-[3-(2-{2-[2-(tert-
Butoxycarbonylamino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-2′,3′-O-
isopropylidene-5′-O-{N-[2-(amino)benzoyl]sulfamoyl}adenosine 
triethylammonium salt (5-15) 213 
 5.6.6 Synthesis of 2-[3-(2-{2-[2-({dPEG®4-
biotinyl}amino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-5′-O-{N-[2-
(amino)benzoyl]sulfamoyl}adenosine triethylammonium salt (5-3) 214 
  xiv 
5.7 References 215 
 
Chapter 6: Conclusions and Future Directions 218 
 
Chapter 7: Bibliography 223 
  xv 
List of Tables 
Table 2.1: Properties of Sal-AMS 60 
Table 2.2: Enzymatic activity of siderophore inhibitors against MbtA 76 
Table 2.3: Bioavailability of INH and MbtA inhibitors in Sprague-Dawley rats 78 
Table 3.1: Inhibition of MbtA and Mtb by Sal-AMS and a photoaffinity probe 136 
Table 3.2: LC–MS/MS identification of proteins labeled by photoaffinity probe  
3-2 141 
Table 4.1: MIC data for isolated transvalencin Z and synthetic diastereomers 171 
Table 4.2: 1H and 13C NMR data for transvalencin Z and synthetic diastereomers 173 
Table 5.1: Alignment of DhbE mutants selected with probes 5-2 and 5-3 by yeast cell 
surface display. 205 
Table 5.2: Pyrophosphate (PPi) release rate of the aryl acid adenylation reaction 
catalyzed by wtDhbE and mutants 206 
  xvi 
List of Figures and Schemes 
Figure 1.1: First line antibiotics against Mycobacterium tuberculosis 4 
Figure 1.2: INH activation by KatG 5 
Figure 1.3: Activation of PZA to POA 8 
Figure 1.4: Structure of bedaquiline 8 
Figure 1.5: Life cycle of Mtb 12 
Figure 1.6: Spectrum of pulmonary tubercular infections 13 
Figure 1.7: Estimated timeline for development of new Mtb therapeutics 20 
Figure 1.8: General steps to fragment-based drug design 24 
Figure 1.9: Internal hydroxyl radical formation via the Fenton reaction 28 
Figure 1.10: Bioactivation of ETA 33 
Figure 1.11: Structures of investigational compounds PA-824 and BTZ038 35 
Figure 1.12: Hollow fiber infection model 41 
Figure 2.1: Structure of mycobactins and carboxymycobactins from Mtb 57 
Figure 2.2: Role of MbtA in mycobactin biosynthesis 58 
Figure 2.3: Design of prototypical inhibitor Sal-AMS 59 
Figure 2.4: SAR domains for the study of Sal-AMS 62 
Figure 2.5: Summary of SAR results from previous work 64 
Figure 2.6: Sal-AMS analogue design to improve pharmacokinetic properties 66 
Figure 2.7: Concentration-time profiles for dosing of INH 79 
Figure 2.8: Concentration-time profiles for dosing of Sal-AMS 80 
Figure 2.9: Concentration-time profiles for dosing of compound 2-6 81 
  xvii 
Figure 2.10: Concentration-time profiles for dosing of compound 2-34 82 
Figure 2.11: Concentration-time profiles for dosing of compound 2-41 83 
Figure 2.12: Concentration-time profiles for dosing of compound 2-50 (N=2) 84 
Figure 2.13: Concentration-time profiles for oral dosing of compound 2-50 (N=1) 85 
Figure 2.14: Concentration-time profiles for dosing of prodrug 2-51 86 
Figure 2.15: Stability of prodrug 2-51 in pooled rat plasma 87 
Figure 2.16: Stability of prodrug 2-51 in simulated gastric fluid (SGF) 88 
Figure 2.17: Concentration-time profiles for dosing of prodrug 2-52 89 
Figure 2.18: Stability of prodrug 2-52 in pooled rat plasma 90 
Figure 2.19: Stability of prodrug 2-52 in simulated gastric fluid (SGF) 91 
Figure 3.1: Design of chemical probes 125 
Figure 3.2: Design of prototypical inhibitor Sal-AMS 127 
Figure 3.3: Design of a photoaffinity probe based on Sal-AMS 129 
Figure 3.4: Design of a photoaffinity probe pulldown experiment 131 
Figure 3.5: In vitro labeling of MbtA using probe 3-2 137 
Figure 3.6: Dose-response of Sal-AMS competition with probe 3-2 138 
Figure 3.7: Photoaffinity probe labeling of adenylating enzymes in crude cell  
lysates 139 
Figure 3.8: Proposed pathways for iron uptake by Mtb 146 
Figure 4.1: Natural products and derivatives as antitubercular agents 160 
Figure 4.2: Reported structure of transvalencin Z 161 
Figure 4.3: Structural differences between Mycobactin S and T 162 
  xviii 
Figure 4.4: HPLC trace of epimerized product from EDC coupling of 4-5a and  
4-6a 168 
Figure 4.5: HPLC stack plot of synthetic transvalencins 4-4a–d 172 
Figure 5.1: The NRPS pathway for synthesis of bacillibactin in Bacillus subtilis 194 
Figure 5.2: Chemical probes 5-1, 5-2, and 5-3 targeted against DhbE 198 
Figure 5.3: Yeast cell display 203 
Figure 5.4: Co-crystal structure of wtDhbE and DHB-AMP 204 
Scheme 2.1: Synthesis of Sal-AMS (2-1) 68 
Scheme 2.2: Synthesis of a sulfamide linked analogue of Sal-AMS (2-6) 70 
Scheme 2.3 Synthesis of Sal-AMS analogue 2-34 71 
Scheme 2.4: Synthesis of Sal-AMS analogue 2-41 72 
Scheme 2.5: Synthesis of Sal-AMS analogue 2-50 73 
Scheme 2.6: Synthesis of a tri-acetate prodrug of Sal-AMS 75 
Scheme 2.7: Synthesis of a di-acetate prodrug of Sal-AMS 76 
Scheme 3.1: Improved coupling conditions for step 1 of the synthesis of a  
photoaffinity probe 3-2 133 
Scheme 3.2: First steps in an improved synthesis of a photoaffinity probe 3-2 134 
Scheme 3.3: Completed improved synthesis of a photoaffinity probe 3-2 135 
Scheme 4.1: Retrosynthetic analysis of transvalencin Z 164 
Scheme 4.2: Synthesis of oxazoline building blocks for transvalencin Z 165 
Scheme 4.3: Mechanism for dehydrative cyclization using Burgess' reagent 166 
Scheme 4.4: Proposed mechanism for molybdenum catalyzed cyclization 167 
  xix 
Scheme 4.5: Synthesis of lysine building blocks for transvalencin Z 168 
Scheme 4.6: Penultimate DEPBT coupling for transvalencin Z 169 
Scheme 5.1: Synthesis of DhbE probe 5-1 199 
Scheme 5.2: Synthesis of building block 5-12 for synthesis of DhbE probe 5-2 200 
Scheme 5.3: Synthesis of 3-hydroxybenzoic acid (3-HBA) probe 5-2 201 
Scheme 5.4: Synthesis of 2-aminobenzoic acid (2-ABA) probe 5-3 202 
 
  xx 
Preface 
Please note the following: 
 
Chapter 1: Reproduced in part with permission from Nelson, K. M., Aldrich, C. C. 
Challenges in Tuberculosis Drug Discovery. Manuscript in progress for submission to J. 
Med. Chem. Please see supplementary page for full citation. 
 
Chapter 3: Reproduced in part with permission from Duckworth, B. P., Wilson, D. J., 
Nelson, K. M., Boshoff, H. I., Barry, C. E. 3rd, Aldrich, C. C. Development of a Selective 
Activity-Based Probe for Adenylating Enzymes: Profiling MbtA Involved in Siderophore 
Biosynthesis from Mycobacterium tuberculosis. ACS Chem. Biol. 2012, 7, 1653–1658. © 
2012 American Chemical Society 
 
Chapter 4: Reproduced in part with permission from Nelson, K. M., Salomon, C. E., and 
Aldrich, C. C. Total Synthesis and Biological Evaluation of Transvalencin Z. J. Nat. 
Prod. 2012, 75, 1037–1043. © 2012 American Chemical Society 
 
Chapter 5: Reprinted in part from Chemistry and Biology, 20, Zhang, K.; Nelson, K. M.; 
Bhuripanyo, K.; Grimes, K. D.; Zhao, B.; Aldrich, C. C.; Yin, J. Engineering the 
Substrate Specificity of the DhbE Adenylation Domain by Yeast Cell Surface Display, 
92–101, 2013, with permission from Elsevier 
 
  1 
Chapter 1. Challenges in Tuberculosis Drug Development 
 
 
The following chapter is an original review by Kathryn M. Nelson regarding the 
challenges in tuberculosis drug development. Figure 1.5 is reproduced from Science with 
permission (see caption). 
 
1.1 Introduction 
The development of antibiotics in the middle of the twentieth century revolutionized the 
way we treat bacterial infections. The boom of antibiotic drug discovery and 
development began with the discovery of penicillin and sulphonamides during the 1920s 
and 1930s. Intense decades of research followed which produced many new drug classes 
and derivatives through the 1970s: aminoglycosides (1944), tetracyclines (1945), 
cephalosporins (1948), macrolides (1949), glycopeptides (1956), quinolones (1961), and 
carbapenems (1976), among others. These agents have become a standard part of our 
medical regimen both for the treatment and prevention of infection that has increased our 
global health and life expectancy over the past five generations.1 Since the 1980s 
however, there has been a stark decline in the output of new antibacterial compounds, and 
an even bigger drop in the introduction of new chemical classes or compounds acting 
through novel mechanisms of action.2 This narrowing of the antibacterial pipeline plus 
the continuing rise in bacterial drug resistance has led to a critical need for new drugs.1,3,4 
While multidrug-resistant (MDR) bacteria were previously limited to secondary 
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infections in healthcare institutions, these pathogens are more frequently being found in 
community environments.4,5 The list of especially concerning pathogens continues to 
grow, with outbreaks of highly drug resistant pathogens continuing to emerge among not 
only the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species), but also Escherichia coli, Salmonella (in cases of typhoid fever), Clostridium 
difficile, Neisseria gonorrhea, and Mycobacterium tuberculosis (Mtb).4 Methicillin-
resistant Staphylococcus aureus (MRSA) infections are especially illustrative of the high 
health and financial burden that this increase of drug resistance plays on our economy. 
MRSA is estimated to cause approximately 19,000 deaths and upwards of $9.7 billion in 
additional healthcare costs per year in the United States alone.5,6 Alarming as these 
numbers are, no other infection presents a greater global health threat than the rise of 
multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB). 
Tuberculosis (TB), caused by the acid-fast bacillus Mycobacterium tuberculosis  (Mtb), is 
the leading cause of infectious disease mortality worldwide due to a bacterial pathogen.7–
9 According to the World Health Organization (WHO), there were 1.4 million deaths 
attributed to TB, and 8.7 million new cases reported in 2011.7 Mtb is readily transmitted 
by aerosolized droplets from the coughing or sneezing of an actively infected individual. 
Innate and adaptive immune responses often physically contain the infection, causing 
Mtb to switch to a nearly non-replicative state that is considered noninfectious. Roughly 
one-third of the world's population is estimated to be infected with this quiescent form of 
Mtb, which can be triggered to an active infection through stress on the immune system, 
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malnutrition, or other dietary factors. Even more alarming, co-infection of TB and 
HIV/AIDS  is now responsible for the majority of HIV-related deaths.7 The ease of 
bacterial transmission, slow growth of the pathogen during infection, its ability to survive 
in a latent state, and its unique and highly lipophilic cell wall have all limited the 
usefulness of many otherwise broad spectrum antibiotics. The current recommended drug 
therapy is known as DOTS (directly observed therapy short-course), and requires 6–9 
months of drug treatment involving a drug cocktail of four first-line antitubercular agents, 
namely isoniazid, rifampin, ethambutol, and pyrazinamide. This extended period of 
chemotherapy increases the chances for non-compliance to therapy, greatly contributing 
to the rise of MDR and XDR-TB. Most recently, reports of totally drug-resistant TB 
(TDR-TB) have been recorded where strains were unresponsive to all the currently 
approved therapeutics.10,11 MDR-TB is any strain that shows resistance to isoniazid and 
rifampin, the two most powerful of the four first-line agents. XDR-TB strains are 
resistant to isoniazid, rifampin, at least one fluoroquinoline, and at least one of three 
injectable second-line agents (capreomycin, amikacin, or streptomycin).12 In 2012, 84 
countries had reported cases of XDR-TB, with approximately 9% of MDR-TB cases 
actually proving to be XDR.7 The emergence of these highly drug-resistant strains, 
coupled with the severe shortage in new antitubercular agents over the past four decades, 
provides clear motivation for the development of new TB drugs with shortened periods of 
treatment that are effective against drug-resistant strains, preferably active through novel 
mechanisms of action. 
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The first line of anti-TB agents includes isoniazid (INH, 1-1), rifampin (RIF, 1-2), 
ethambutol (ETB, 1-3), and pyrazinamide (PZA, 1-4) (Figure 1.1).13 First reported as an 
anti-TB agent in 1952, INH is still one of the most potent anti-TB compounds in use 
today.14 Isoniazid is bactericidal for rapidly growing Mtb, but is bacteriostatic for 
nonreplicating bacilli with a minimum inhibitory concentration (MIC) of 0.025–0.050 
µg/mL. INH activity requires bioactivation by KatG, a catalase/peroxidase, to give an 
isonicotinoyl radical (1-5) that reacts nonenzymatically with cellular pyridine nucleotides 
to give INH-NAD adducts (1-6, Figure 1.2).15,16 The INH-NAD adducts are slow, tight-
binding, reversible inhibitors of InhA, an NADH-dependent enoyl-acyl carrier protein 
(enoyl-ACP) reductase that ultimately block mycolic acid synthesis, a necessary process 
for Mtb cell wall biosynthesis.17 Resistance to INH is conferred through selection of 
Figure 1.1. First line antibiotics against Mycobacterium tuberculosis. 
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bacilli with spontaneous mutations to the genes katG or inhA.18 While INH is usually 
well tolerated for a long period of treatment, it does show inhibition of several 
cytochrome P450s, the most clinically relevant being CYP2C19 and CYP3A4.19 Because 
of this activity, INH can slow the elimination of co-administered drugs such as the HIV 
type 1 protease inhibitors, making this therapy more dangerous for co-infected 
HIV/AIDS patients.20  
 
Rifampin (1-2, Figure 1.1), was first reported in 1959, approved for use as an anti-TB 
agent in Italy in 1968, and received FDA approval in 1971.21,22 It is produced semi-
synthetically in 5 steps from the natural product rifamycin B, and shows bactericidal 
activity against Mtb with an MIC of 0.03–0.125 µg/mL.23,24 The mechanism of action for 
RIF-mediated bacterial killing is through inhibition of bacterial DNA-dependent RNA 
polymerase (RNAP), thereby preventing the necessary RNA transcription process. In 
binding to one of the β-subunits of RNAP, RIF blocks the growing RNA transcript as it is 
extruded out of the active site, leading to premature transcript truncation.25,26 Resistance 
to RIF occurs through random point mutations or short insertions/deletions to the RNAP 
β-subunit gene (rpoB), lowering the affinity for the drug.27 While RIF is generally well 
tolerated in most patients, it can have drastic effects on HIV protease inhibitor levels via 
Figure 1.2. INH activation by KatG to the bioactive form INH-NAD. 
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inhibition of drug-metabolizine enzymes, especially CYP3A4. The antiretroviral level of 
protease inhibitors are reduced by greater than 90%, limiting the usefulness for this drug 
in HIV/AIDS patients.28,29 Consequently, rifabutin, a less potent pregnane-X-receptor 
(PXR) activator is recommened for patients on antiretroviral therapy. 
Ethambutol (1-3, Figure 1.1) was synthesized and first described in 1961 as a moderately 
active anti-TB compound.30 With a bacteriostatic MIC of less than 2 µM, the benefit of 
EMB is its low toxicity and highly favorable synergy with other first-line agents.31,32 The 
synergistic properties of EMB are readily understood through its mechanism of action. 
Ethambutol inhibits arabinogalactan biosynthesis, an integral part of the mycobacterial 
cell wall, which enhances the membrane permeability of other drugs.33 Monoresistance to 
EMB is rarely seen, with resistance usually only occurring in MDR-TB strains. About 
70% of these resistant strains show a mutation in the glycosyltransferase embB, which 
suggests this to be the primary cellular target.34 Since monoresistance is so rarely seen, 
some have suggested using mutations in the embB gene as biomarkers of MDR- and 
XDR-TB.35 Ethambutol is generally well tolerated and the main side effect is ocular 
toxicity causing reduced visual acuity, constriction of visual fields, and color blindness. 
All of these effects are usually reversible if the therapy is discontinued, and intermittent 
visual testing is highly recommended while on EMB therapy.36  
Finally, pyrazinamide (1-4, Figures 1.1 and 1.3) is a largely bacteriostatic agent whose 
antitubercular activity was first described in 1952.37,38 Still the most mysterious of the 
first-line agents against TB, PZA is only active in vivo under acidic conditions, with a 
reported MIC of 16–50 µg/mL at pH 5.5.39 The acidic environment in macrophages 
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allows PZA to inhibit non-replicating Mtb during active inflammation, which is only 
observed during initial infection (dosed only in the first 2 months of therapy). The 
currently accepted mechanism of action for PZA suggests that it is passively uptaken by 
Mtb, then hydrolyzed by a promiscuous amidase (PncA) to release pyrazinoic acid (POA, 
1-7) (Figure 1.3).40  
Accumulation of POA lowers the intracellular pH and disrupts the transmembrane proton 
gradient and consequently the proton motive force required for the biosynthesis of ATP.41 
This nonspecific mode of action for PZA is supported by the inability to isolate any 
mutant strains resistant to POA, only to PZA. Mutants that are resistant to PZA show 
mutations almost exclusively in pncA, a cytosolic metalloenzyme.42 Recently, additional 
evidence for action of POA against the ribosomala protein S1 (RpsA) has been reported 
by Shi and co-workers.43 Their study identified RpsA as a binding partner of POA, and 
identified clinical isolates of resistant bacteria that contain mutations to the gene for 
RpsA expression. Their work suggests that POA inhibits the bacteria's ability to manage 
stalled ribosomes under stressful conditions such as acidic pH, starvation, and hypoxia–
all of which are hallmarks of initial Mtb infection.43 Ultimately, mutation to pncA would 
also eliminate the ability of PZA to act via this mechanism of action also, and seems to be 
more common for conferring resistance. Pyrazinamide is reported to be nontoxic, with 
the most prominent side effect being arthralgia (non-inflammatory joint pain) due to 
increases in uric acid levels in serum.44 These effects are usually not severe enough to 
stop treatment. It should also be noted that combination antitubercular therapy shows an 
increased risk of hepatotoxicity (2% for INH + RIF + PZA versus 0.8% for INH + RIF), 
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however the mechanism by which this toxicity is increased is unknown.45  
 
 
On December 31st, 2012, the Food and Drug Administration (FDA) approved the first 
new antitubercular agent in over 40 years.  The compound is Janssen Therapeutics' 
(owned by parent Johnson & Johnson) bedaquiline 1-8 (Figure 1.4). First reported in 
2005, bedaquiline acts by inhibiting ATP synthase function, leading to ATP depletion 
and imbalance of pH homeostasis.46,47  
 
 
Some of the exciting characteristics of this new compound include its ability to be 
bactericidal over long periods of treatment, and its broad spectrum of activity against 
Figure 1.4. Structure of bedaquiline. 
Figure 1.3. Activation of PZA 1-4 to POA 1-7 by the action of Mtb amidase PncA. 
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MDR-TB strains.46 Preclinical development showed little to no adverse effects in healthy 
individuals, however irregular heart rhythms and an increased incidence in deaths was 
noted during studies with MDR-TB infected patients (11.4% vs. 2.5% on placebo). This 
increase in deaths did not seem to correlate to the abnormal heart rhythms as most deaths 
occurred a year after patients stopped therapy, with a variety of causes of death.48 
Bacteria did develop resistance to bedaquiline when used as a monotherapy during 
preclinical development, so it was only administered along with standard MDR-TB 
therapy regimens. Resistance in most strains was identified as mutations to the atpE gene, 
which encodes the C subunit of ATP synthase.47 This membrane-bound subunit has been 
suggested as the binding partner to bedaquiline, mutation of which leads to significantly 
lowered binding affinities.49 In two separate tests, patients given bedaquiline became 
sputum negative for bacilli in 83 days and 57 days versus 125 days for patients taking a 
placebo. Due to the favorable results from these studies, the FDA fast-tracked the 
approval of bedaquiline for use in MDR-TB cases in the U.S., and only as part of a 
combination therapy.48,50 Part of the challenge now for bedaquiline is to properly 
administer it so as to prevent the emergence of resistant bacteria for as long as possible. 
Many patients in areas where TB is endemic do not have access to facilities that can 
diagnose the drug-sensitivity of their infection, often resulting in the administration of 
drugs to which they are already resistant. If bedaquiline were added to this type of 
regimen, it would be like giving it as a monotherapy, encouraging the development of 
resistance. If sensitivity-testing can become more accessible for regions where MDR-TB 
has a high impact, bedaquiline has a good chance of having a major impact on the ability 
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to cure MDR patients. This new therapy is only the beginning of a new fight against TB, 
and hopefully more new therapies will follow to replace those whose efficacy has been 
diminished due to resistance development. 
The challenges posed to those bold enough to work towards novel anti-TB therapeutics 
are daunting. To some extent, TB drug discovery faces the same challenges as any other 
therapeutic area: the identification and validation of an essential target to act upon, and 
the ability to find and develop useful lead compounds for in vitro and in vivo evaluation. 
In other ways, however, treatment of MDR-TB presents unique challenges that have 
stymied researchers for years. Firstly, Mtb displays a unique pathology that is still not 
well understood, and hinders research on chemotherapeutic efficacy in vivo. The target 
identification and lead compound discovery process has also proved more cumbersome 
than with other diseases, especially in comparison to other bacteria due to latency and 
slow growth of the organism. Our understanding of how antimycobacterial agents work 
continues to evolve, and with it our ability to assess through structural biology and 
metabolomics how investigational compounds produce bactericidal effects. Validation of 
essential gene targets in Mtb has proved more challenging due to the unique, naturally 
more resistant cell wall and membrane of mycobacteria. Consequently, the traditional 
strategies for inhibitor design, e.g. high-throughput screening (HTS), virtual screening, 
substrate mimics, etc., have not produced successful lead compounds on a timeline that 
can keep up with bacterial drug resistance. Furthermore, our ability to assess compounds 
in animal models is limited as there are few predictive in vitro models, and we continue 
to discover shortcomings in experimental models of tuberculosis in lower species animal 
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models. Other important considerations in TB drug development include an increased 
scrutiny on bioactivation and drug-drug interactions, especially with antiretrovirals, due 
to the large population of TB infected individuals co-infected with HIV. Finally, there are 
many monetary challenges to TB drug discovery. Governmental and special interest 
groups have donated large sums of money to TB drug development in the last ten years, 
with a large portion of that money landing in academic institutions. Big pharmaceutical 
companies have largely removed themselves from antimycobacterial drug discovery, 
limiting the ability of researchers to fund the clinical trials required for regulatory 
approval. Herein, we highlight six major challenges to the TB drug researcher, the current 
state of research in those areas, and hope to draw some conclusions about future 
directions for antitubercular drug development. 
 
1.2 Challenge 1: Heterogeneity in tuberculosis pathology 
 
A continuing challenge in TB drug development is therapeutic efficacy across strains and 
stages of the bacterial life-cycle.51 Not only do medicinal chemists face the challenge of 
overcoming drug resistance, but a heterogeneous mixture of disease states must be 
targeted simultaneously. One of the most unique challenges in TB drug development is 
the spectrum of cell types that must be susceptible to a drug for successful therapy. 
Inhaled active bacilli are first phagocytosed by alveolar macrophages leading to either 
development of active granuloma lesions, or  trafficking to the lymph nodes where T cell 
responses are initiated in an immune-suppressed infection (Figure 1.5).52,53 
  12 
 
 
Active infection results in a high bacterial burden producing high levels of lesions and 
acute pulmonary distress. The time and frequency of exposure, innate drug resistance of 
the inoculum, and the presence of co-infections or other complications all contribute to 
the severity of active infection.53 Alternatively, host immune responses may suppress 
bacterial replication leading to persistence through adaptive nonreplicating conditions; 
previously defined here as latent infection. Our ability to define latency relies solely on 
Figure 1.5. Reprinted with permission from Russell, D. G.; Barry, C. E., 3rd; and Flynn, J. 
L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328, 852–856 
Reprinted with permision from the author, © AAAS publishing.51 The life cycle of Mtb. 
The infection begins when Mtb bacilli are inhaled and phagocytosed by alveolar 
macrophages. The infected cells invade the subtending epithelium, which leads to the 
recruitment of monocytes and extensive neovascularization of the infection site. The 
macrophages in the granulomas differentiate to form epithelioid cells, multinucleate giant 
cells, and foam cells filled with lipid droplets. Lymphocytes appear to be restricted 
primarily to this peripheral area. Disease progression is characterized by the loss of 
vascularization, increased necrosis, and the accumulation of caseum in the granuloma 
center. Bacilli are released into the airways when the granuloma cavitates and collapses 
into the lungs. 
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immunosensitization in the absence of clinical signs and symptoms, and more recently 
has been illustrated to be more complicated than originally thought due to the dynamic 
nature of the organism even during latency (Figure 1.6).53,54  
 
The pathology of active infection presents a complex mixture of lesions ranging from 
areas of swelling of aveoli to highly organized granulomas, some of which have intimate 
contact with host airways. Upon initial invasion by Mtb bacilli, a pro-inflammatory 
response leads to invasion of the epithelium and recruitment of monocytes from 
circulation. Vascularization of the infection site allows for conglomerated macrophages 
to differentiate forming the beginnings of a variety of granulomatous lesions. Epithelioid 
cells, multinucleated giant cells, and foam cells filled with liquid droplets are all common 
to active infection. Further diversification is achieved through the development of a 
fibrous extracellular matrix surrounding the macrophages that resists penetration by 
foreign bodies. Progression of the disease state is enhanced by increased necrosis and 
Figure 1.6. Generalized spectrum of pulmonary tubercular infections. Adapted 
from Barry, et. al.53 
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accumulation of cells, forming a caseum in the center of the granuloma. The progression 
of granulomas to this necrotic state leads to the transmission of Mtb. Granulomas excised 
from active TB patients show rapid bacterial growth in macrophages located both at the 
surface as well as within the liquefied center.55,56 Erosion of airways by these granulomas 
then allows the release of free mycobacteria via cavitation within the bronchus that can 
be aerosolized through coughing up of sputum (Figure 1.5).51 This complex cycle of 
pulmonary disease pathology is dynamic and constantly changing throughout the timeline 
of infection.  
Due to the innate human immune response, upwards of 90% of Mtb exposed individuals 
can suppress active infection resulting in latency of infection, with a 5–10% chance for 
these individuals to reactivate later in life. Factors leading to latency are not well 
understood, but it is hypothesized to evolve from the bacterial response to the host 
organism. Lesions in latent infection are much less frequent, and bacterial load and 
replication is much lower in latent lesions.53 Host defenses activated through IFN-γ-
mediated signaling result in reactive oxygen and nitric oxide release, which are cidal for 
Mtb at low levels.57 However, higher levels of these reactive species seem to activate 
adaptive pathways through a key transcriptional regulator, DosR, allowing many key 
metabolic processes in Mtb to be shutdown.58 Other mechanisms normally initiated by a 
host upon infection have also been implicated in triggering this latent stage of the 
bacteria, including ubiquitin-mediated proteolysis and intracellular autophagy.59,60 In 
addition, some granulomas developed during latent infection form hypoxic 
microenvironments that halt the replication and spread of the bacteria.61 It is 
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hypothesized that these granulomas containing nonreplicating bacilli serve as a reservoir 
to harbor cells for release during times of immunosuppresion, e.g. contraction of HIV, or 
TNF-α suppression.62,63 The absolute mechanism of reactivation is unclear, since the 
constant release of mycobacterial antigens (detectable by immunosensitization) by latent 
infection illustrates the interplay between host and pathogen even in a nonreplicative 
phase.64 These highly variable phenotypes demonstrate the vast heterogeneity of the 
clinical manifestation of TB that we are only now beginning to understand. Therapeutics 
must overcome multiple obstacles in order to effectively treat such a multi-faceted 
disease. First, they must be able to cross macrophage membranes without being modified 
or shuttled back out by the host cell. Second, latency offers an additional layer of 
complexity as it changes the bacterial metabolic pathways resulting in variable gene 
expression levels that can severely reduce efficacy or eliminate potency. And third, the 
heterogeneity between the granuloma lesions–e.g. fibrous coating, necrotic lesions, 
cavitary lesions–results in differential responses to treatment.54 This laundry list of 
challenges facing TB drug development may be an explanation for the continued lack of 
a single anti-TB agent and reliance on a frontline combination therapy. Challenges that 
exist in our understanding of TB pathology contribute to our inability to effectively 
identify new target pathways/enzymes, as well as develop potent bactericidal compounds. 
 
1.3 Challenge 2: Target validation and vulnerability 
 
The advances in genomic sequencing and recombinant protein techniques have increased 
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the popularity of a strictly rational, target-based approach to new therapy design. While 
this approach has been successful for a number of indications (HIV, cancer, 
cardiovascular disease, diabetes), there has been a lack of success for antibacterial drug 
development.3,65,66 Part of this is likely due to the fact that a few well-established targets 
have been exhausted by development of iterative generations of therapeutics to combat 
growing resistance. New targets and new chemical scaffolds have been left largely 
unexplored. One very neglected area of target-based approaches is the validation of a 
gene/gene product/molecular mechanism as essential, vulnerable, and sensitive to 
modulation by an external stimulus. The essentiality of a target is often improperly 
determined in an in vitro manner, which will not determine if bacterial growth and 
virulence will be attenuated in the in vivo setting. Genetic methods for target essentiality 
typically begin with allelic-replacement mutagenesis (gene knockout) assay. If the gene 
for a target of interest is known, a common misconception is that lack of growth of a 
genetic knockout strain validates essentiality of the target. This observation only suggests 
that the target may be essential for bacterial growth. Follow-up testing to confirm this 
should include conditional knockouts containing inducible plasmids for growth recovery, 
as well as evaluation of levels of suppression required to prevent bacterial growth. Not 
only should these assays be performed in an agar plate assay, but also within a living 
organism‒e.g a mouse or rat disease-state model. Rubin and co-workers developed a 
unique mutation assay and used it to identify growth-attenuating genes in a mouse 
infection model of Mtb.67,68 Prior to their report, these techniques had been somewhat 
limited in scope. For example, signature tagged mutagenesis (STM) is a technique 
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utilizing a series of 50–100 transposons that have been tagged with known nucleotide 
sequences used to monitor their presence within a pool of mutants.69 This technique 
requires a mutation to be known (or predicted) and also involves an intense amount of 
labor to identify each growth-attenuated mutant.69,70 An alternative is to use PCR 
analysis, e.g. in genetic footprinting, to map conditional mutants at a fixed site on a 
chromosome. This allows for a larger analysis than STM, but requires multiple analyses 
of the same site for confirmation.71,72 These techniques have been developed in an effort 
to reduce the amount of genetic sequencing and analysis required in whole-genome 
sequencing of resistant mutants. 
Vulnerability of a target can be assessed by varying the level of gene expression through 
a knockout model containing an inducible plasmid activated by an inducer, e.g. 
isopropyl-β-D-thiogalactopyranoside, IPTG. Careful examination of bacterial growth in 
response to lowered expression rates can determine the level of inhibition needed to 
effectively stop bacterial growth. This conditional knockout model is not always practical 
depending on the bacteria's response to lowered gene expression. An alternate approach 
utilizes antisense RNA sequences that can downregulate the expression of proteins in 
Mtb. Antisense RNA sequences are especially attractive when they can be applied in 
vivo, allowing an animal's natural immune response to become part of the evaluation.3 In 
vivo evaluation is highly desirable because most inhibitors will not inactivate their targets 
to 100% of their possible efficacy, and a target that only needs to be inactivated to 80% is 
much more vulnerable than one that needs to be inactivated to 99%.73 Antisense 
techniques often only cause knockdown of mRNA of approximately 80% due to in vivo 
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complications like permeability, natural defense systems against nonnative sequences, 
etc. Unfortunately, the ability to construct a phenotypically well-regulated conditional 
knockout or downregulated mutant of Mtb has been severely hindered by the complexity 
of the organism. 
The sensitivity of a pathway to small molecule manipulation is largely dependent on the 
step in the pathway being targeted. The ideal situation is to develop a small molecule 
inhibitor for the rate-limiting step in a biological process. This can often be a moot point 
in developing new therapies against tuberculosis, because so little may be known about 
the pathway of interest, let alone the kinetics of the individual steps. In a full genetic 
screen of Mtb, Sassetti and Rubin found that 55% of the genes important for in vivo 
growth had no functional prediction, and a full 25% of important genes had no obvious 
homologues outside of mycobacteria or closely related species.68 Many target enzymes 
are also studied for their kinetic parameters, but very few full pathways are studied for 
global kinetic behavior.73 A global view is a better approach for determining the most 
advantageous target within a pathway, preventing the choice of a less important, less 
sensitive target. Schnappinger and co-workers evaluated the BioA enzyme of Mtb biotin 
biosynthesis in depth, illustrating the three important parameters mentioned here: 
essentiality, vulnerability, and sensitivity.73 The unfortunate challenge revealed by this 
work is the determination that BioA must be inhibited upwards of 99% to achieve the full 
therapeutic benefit of pathway inhibition. Recent work by Sassetti and co-workers has 
revealed exciting new possibilities for re-igniting antibiotic sensitivity in Mtb. Their work 
involves investigating the regulation of the metabolic pathways important for the 
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reduction in growth and metabolite activity characteristic of latent infections. Their 
research found the pathway for triacylglycerol (TAG) synthesis from glycerol and acyl-
CoA to be induced by the DosR regulator, the earliest response to hypoxia seen in many 
granulomas.74 This redirection of carbon into triglycerides was critical for bacteria 
becoming antibiotic tolerant. By inhibiting this pathway, Sassetti shows that antibiotic 
sensitivity is regained, creating a novel strategy to improve the efficacy of current 
antibiotic therapy.74 
New discoveries like those by Rubin, Schnappinger, Sassetti, and others are vital to 
generating a list of new, vulnerable targets within Mtb for therapeutic development. The 
identification of an essential, vulnerable, and sensitive target is just the beginning, 
however, of the development of a novel agent. 
 
1.4 Challenge 3: Lead compound and inhibitor design 
 
Once an enzymatic target has been identified and validated, a lead compound is needed to 
develop effective candidates for clinical development. Lead compound and optimization 
stages of new Mtb drug development account for at least 50% of the time needed to 
develop a new therapeutic (Figure 1.7).3  
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An important emerging factor of marrying a lead compound and target is the relatively 
narrow focus which the popular target-based approach brings to a drug design strategy. In 
an isolated compound-target system, optimized lead compounds may act very differently 
than they would within a disease-state model. With a library of techniques being 
developed for the identification of new lead compounds, researchers need to weigh the 
pros and cons for each approach in relation to their goals in order to successfully move 
forward in the drug design process. The following attempts to highlight some of the 
considerations important to popular design strategies. 
With the advent of high-throughput screening (HTS), we have seen many research groups 
move towards this method for identifying lead compounds for drug discovery. 
Traditionally, this employs the use of a single enzymatic target that has been validated as 
essential in other testing. As this target-based approach matures, we are beginning to see 
that it is not a foolproof method for lead compound development. Inhibitors that are 
identified from a target-based biochemical assay may fail to show whole cell activity for 
a myriad of reasons: poor permeability, susceptibility to bacterial efflux mechanisms, 
redundancy in the pathway of interest, rapid development of resistance, and lack of 
Figure 1.7. Estimated timeline for the development of a new Mtb therapeutic, with unlimited 
resources. Lead identification and optimization often accounts for at least 50% of the time to 
release of a new therapeutic.3 
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vulnerability of the target to inhibition in vivo. Discussions of the merits of HTS for 
antibacterial and mycobacterial drug discovery can be found elsewhere and will not be 
detailed here.3,75 In an attempt to address some of these shortcomings, some groups are 
moving towards blending the traditional phenotypic or whole-cell testing with a high-
throughput format that will quickly generate information about in vivo action against the 
pathogen of interest, as opposed to simple biochemical activity against a target. This 
newer approach to screening presents its own set of challenges, such as miniaturizing a 
whole-cell assay so that it can be reliably replicated thousands of times, and the need to 
subsequently determine the mechanism of action of identified inhibitors.3 Several hybrid 
strategies have emerged and shown promise for identifying new scaffolds for Mtb drug 
development. Researchers at Southern Research Institute screened a focused library of 
scaffolds biased in design by mimicking current kinase inhibitor scaffolds and binding 
sites. They first virtually screened the library against a panel of kinases with published 
crystal structures before screening a smaller subset in a whole-cell assay against Mtb.76 
Other researchers have developed a hybrid technique called target-based whole-cell 
screening (TB-WCS) that makes use of conditional mutant strains wherein the target of 
interest is regulated using antisense interference or inducible promoter strategies.77 This 
approach seems to combine some of the best of both worlds of screening techniques. 
With compounds biased towards a target of interest, you can determine if the compound 
1) acts on the target of interest (or at least the pathway of interest), and 2) achieves 
enough cellular penetration to achieve reasonable whole cell activity with each 
compound screened. As is illustrated in the study by Abrahams, et. al., however, this 
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approach will not be broadly applicable to all essential targets within Mtb because it 
requires the ability to isolate viable conditional mutants in specific genetic backgrounds. 
Even in this study, they were only able to successfully evaluate two of the three essential 
targets in which they were interested.77  
Aside from HTS, other target-based strategies for inhibitor design include the related 
techniques of structure-based and virtual design.78 When a crystal structure of a known, 
biologically relevant target is available, it is possible to use computer programs to design 
compounds that could block interactions important for native activity. If the co-crystal 
structure with a known inhibitor is available, direct interactions can be evaluated and the 
compound structure adjusted to increase binding affinity (and, by extension, activity 
against Mtb) according to the available space in the crystal structure. The structural 
biology techniques and access to equipment needed for the generation of high resolution 
crystal structures is expensive and can be challenging to obtain, making this an 
uncommon technique for most researchers. It is more likely that a crystal structure of the 
enzyme of interest, or at least of homologous enzymes will be available. From this data, 
researchers can often rationally design compounds or modifications to lead compounds to 
create inhibitors with improved enzymatic activity. Some approaches apply computer 
modeling programs before synthesizing inhibitors. This in silico design/screening has 
recently lead to reports of lead compounds against new targets in Mtb.79,80 One report 
focuses on a well-studied enzyme, dihydrofolate reductase (DHFR), which has been 
successfully targeted in cancer chemotherapeutics and some antibacterial therapeutics, 
but current investigational compounds show a distinct lack of activity against 
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mtDHFR.79,81 By modeling of simple tripeptides as lead compounds, the investigators 
were able to identify sequences with predicted nanomolar activity against mtDHFR, three 
orders of magnitude more potent than any other reported compounds, and a predicted 
120-fold selectivity over hDHFR.79 While peptides are not often found to be useful drug 
candidates themselves, peptidomimetic strategies could be employed to modify the lead 
compound to a more drug-like structure. Where this report falls short is in the enzymatic 
validation of the virtually screened compounds. While many chemistry groups often lack 
the structural biology/computational capabilities to perform these virtual screens, 
structural biology groups may lack the chemical expertise to validate their computational 
models, a step that we believe is too valuable to leave for other researchers. A similar 
study was also performed on the Mtb shikimate kinase (SK). This target is highly 
attractive as the shikimate biosynthetic pathway is essential in bacteria but absent in 
mammals.82 With 3D crystal structures available of the SK enzyme, the investigators 
were able to design small peptidic molecules that were predicted to bind with 10-fold 
higher affinity than a previously described compound.80 This study again shows the 
versatility and usefulness of rational, structural design and the utility of virtual screening 
to rank desired compounds according to likelihood of activity. The true promise of this 
lead compound is as yet unknown, however, as enzymatic and whole-cell activity have 
not been reported. 
Another approach that relies on correlating crystallographic structural information and 
cellular activity is fragment-based design. Briefly, this technique investigates low-
molecular-weight molecules (< 250 Da) for binding within an active site by soaking them 
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into crystals of the enzyme of interest at high (mM) concentrations (Figure 1.8). 
Structural determination of how these fragments bind to the target of interest (either 
through X-ray crystallography or NMR techniques) can then be used to design linkers to 
tether together complimentary fragments creating a macromolecular inhibitor structure. A 
more thorough discussion of these techniques can be found elsewhere.75,78,83  
 
Abell and co-workers successfully employed a fragment-based strategy to design 
inhibitors of PanC, an adenylating enzyme in the pantothenate biosynthetic pathway in 
Mtb that catalyzes the condensation between pantoic acid and β-alanine, producing 
pantothenate.84 After screening a library of 1300 compounds by WaterLOGSY NMR, 
they identified a lead compound with a KD of 1 mM. This lead compound, 5-
methoxyindole, was then incrementally grown by adding fragments and observing the 
Figure 1.8. General steps to fragment-based drug design: (A) known target with crystal 
structure solved; (B) crystal structure determined after soaking low-molecular weight 
fragments at mM concentrations; (C) medicinal chemistry used to tether fragments into a 
macromolecular inhibitor design. 
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effect on the relative binding of the inhibitor. This iterative process enabled them to 
develop an inhibitor with a KD of 1.8 µM, 1000-fold greater than their starting 
compound.84 This process involved many different evaluation platforms: additional 
WaterLOGSY NMR, X-ray crystallography, isothermal titration calorimetry (ITC), and 
thermal shift assay. Fragment-based design, like structural or virtual design, also requires 
a wide range of resources: chemical expertise, protein expression and purification, and 
structural determination. These resources can be difficult and expensive to compile. 
Integrated systems biology approaches known as "omics" technologies (including 
genomics, transcriptomics, proteomics, and metabolomics) have developed as potential 
tools for research into disease states and therapeutic response.85–87 These approaches rely 
heavily on the observance of biomarkers from affected individuals. A biomarker is a 
biological character that is objectively measured and evaluated as an indicator of a 
physiological or pathological process, or pharmacological response(s) to a therapeutic or 
preventative measure.88 In drug discovery, a biomarker could play a key role by reducing 
the attrition of drugs at a late-stage in the development pipeline, thereby significantly 
reducing the overall cost of drug development. An ideal biomarker would be able to 
evaluate delivery of drugs to their target of interest, predict pathophysiological 
mechanisms of reaction/response, and predict clinical effects (e.g. predicting drug 
interactions, particularly in relation to HIV/AIDS and Mtb therapeutics).89 Nearly any 
tissue or bodily fluid can be used for biomarker evaluation, however the fluid that gives 
the most general information and is the most easily collected is peripheral blood. Blood 
samples contain genes, transcripts, proteins, lipids, and metabolites at appreciable levels 
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for analysis. Recently, early success has been reported with metabolomic analysis to 
differentiate between similar Mtb strains. Metabolomics is the study of global changes in 
the profile of small-molecule metabolites expressed by cellular processes throughout the 
body, such as metabolic and catabolic intermediates, hormones, signaling molecules, 
secondary metabolites, and small structural lipids.90 In their study, du Preez and Loots 
used gas chromatography-mass spectrometry (GC‒MS) analysis of bacterial cultures to 
identify metabolites that differ between wild-type and rifampin-resistant TB. Their 
analysis allowed them to identify the resistant strains, but also clearly differentiate 
between the different rpoB gene mutations in each resistant strain.91 While this study was 
conducted only within bacteria and not within infected patients, it illustrates the utility of 
metabolomics as a way to identify biomarkers that could potentially predict if a patient 
will be drug resistant. Development of this method for diagnostics would require very 
high sensitivity as the bacterial burden is very small with respect to the rest of the body. 
A complimentary strategy involving structural biology and medicinal chemistry to 
evaluate enzymatic activity in conjunction with whole-cell activity against Mtb should be 
employed when developing lead compounds. No one strategy has proved adequate to 
produce successful lead compounds on its own, but a multidisciplinary approach that 
evaluates a target and inhibitor from multiple angles promises to identify compounds that 
have the best potential to become clinical candidates. 
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1.5 Challenge 4: Mechanisms of action 
 
With the advances seen in molecular biology techniques and the tightening of regulations 
for the safety of patients, there is increasing pressure to identify the mechanism of action 
for a new therapeutic. As discussed above, we still have much to learn about how Mtb 
processes are connected to, and affected by, one another. Recent investigations into the 
mechanism of action (MOA) for many antibacterial compounds, including 
antimycobacterial agents, has illustrated just how complex this interrelationship can be. 
The MOAs of most antibacterial agents in use today, including anti-TB drugs, 
predominantly fall into four classes: inhibition of DNA replication and repair, 
interference with protein biosynthesis, inhibition of cell wall turnover, and inhibition of a 
unique biochemical process (e.g. DHFR inhibitors).92,93 These molecular interactions 
have long been thought to be the causative effect in the bactericidal activity seen in many 
approved antimycobacterial agents. While each class of antibacterial compounds has 
distinct drug-target interactions, it has become accepted that there may be similar 
downstream effects that ultimately lead to bacterial cell death.92,94–98 While this research 
has been largely performed on simpler Gram-positive and Gram-negative organisms, this 
evidence is compelling enough to extend its implications to include mycobacterial 
species as well. In an attempt to further understand how bactericidal compounds exert 
their activity, J. J. Collins and colleagues began observing cellular changes in model 
organisms like E. coli and S. aureus upon treatment with various antibacterial 
compounds. They observed that DNA gyrase inhibitors induce a breakdown in the iron 
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regulatory pathway, promoting the formation of reactive oxygen species (ROS). More 
specifically, hydroxyl radicals were formed via internal iron and the Fenton reaction 
through the reduction of hydrogen peroxide by ferrous iron (Figure 1.9).95  
 
 
Direct observation of hydroxyl radicals formed during treatment with antibiotics can be 
achieved using the dye hydroxyphenyl fluorescein (HPF). Iron chelators, e.g. 2,2ʹ-
dipyridyl, and hydroxyl radical scavengers, e.g. thiourea, were used as controls to 
confirm the dye's specificity for hydroxyl radicals in a biological matrix. The 2,2ʹ-
dipyridyl prevents hydroxyl radical formation by sequestering unbound iron, and thiourea 
is known to be a potent mitigator of damaging hydroxyl radicals in both eukaryotic and 
prokaryotic systems. Following validation of their methods, Collins and co-workers 
tested representative compounds from each of the three antibacterial compound classes 
Figure 1.9. Internal hydroxyl radical formation via the Fenton reaction. Disregulation 
of this pathway leads to a build-up of hydroxyl radicals, a commonly observed 
consequence of antibacterial compounds. 
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listed above.92 Not only were they able to confirm that all bactericidal antibiotics show 
significant increases in hydroxyl radical formation, but they also confirmed that 
bacteriostatic protein synthesis inhibitors e.g. erythromycin and tetracycline, did not 
induce the formation of hydroxyl radicals. The generation of free iron for the formation 
of hydroxyl radicals likely comes from leaching of iron from iron-sulfur clusters, a 
process well-accepted to be precipitated by superoxide and the Haber-weiss reaction. 
Superoxide generation in E. coli is largely due to the respiratory electron transport chain, 
driven by oxygen and the conversion of NADH to NAD+. Genes involved in the NADH-
coupled electron transport chain were upregulated in bacteria treated with bactericidal 
drugs of any MOA (see above). In a separate study, Collins and co-workers showed that 
aminoglycosides and other ribosomal inhibitors also induce free radical formation 
through misfolding of proteins.94 These studies were confirmed through the generation of 
single-gene knockout mutants of E. coli that sensitized the bacteria to even minor 
disturbances in membrane protein folding and translocation.  
Most recently, Walker and co-workers have reported observations on DNA damage by 
bactericidal antibiotics.98 Their study shows the oxidation of nucleosides, especially 
deoxyguanosine into 8-oxo-deoxyguanosine (8-oxo-dG), can cause double-strand DNA 
breaks (DSBs) that are lethal to the bacterial cell. Base excision repair enzymes will 
normally remove lesions like 8-oxo-dG before they become problematic. However, if 
there is an elevated level of ROS present to create these lesions and multiple strand 
breaks are generated, the cell may not be able to maintain proper cell cycling and 
metabolism. This type of mechanism is now implicated for the cell killing activity of the 
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aminogylcoside kanamycin.98 As suggested in their conclusions, antibacterial adjuvants 
may be developed that target DNA repair enzymes. These types of compounds could 
increase the effectiveness of an antibiotic, prolonging its clinical relevance. The main 
bacterial response to DNA damage, i.e. the SOS response, induces more highly error-
prone DNA polymerases that allow the bacteria to mutate its DNA in order to survive the 
xenobiotic stress. Inhibition of this response could potentiate all of the major classes of 
bactericidal antibiotics by shutting down this key mitigator of ROS damage to DNA.97 
All of the above studies highlight that while we may design antibacterial compounds to 
maximize a specific drug-target interaction, the direct results of that interaction may not 
be the truly bactericidal event we expect it to be. Downstream consequences to 
modulating cellular processes may be just as, if not more, important than the initial 
interaction. 
Not only are ROS implicated in mechanisms for bacterial cell death, they are also 
implicated in mechanisms of bacterial drug resistance. There are a number of known 
mechanisms by which bacteria generate genetic resistance to antibiotics: the exchange of 
genetic material with another organism, the activation of latent genetic elements, and the 
mutagenesis of its own DNA.99 As discussed above, bactericidal antibiotics often induce 
the production of ROS through a breakdown of iron regulatory dynamics causing a spike 
in the production of potential DNA damaging agents like hydroxyl radicals. These 
oxidative species can generate lesions in DNA that are not properly repaired by the 
relatively promiscuous DNA polymerases within bacteria and, if the cell remains viable, 
the mutation persists. While this process can occur in vivo even in the absence of 
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antibiotic, sublethal doses of a compound will increase the number of mutagenic events 
occurring. This increase in genetic variation from generation to generation dramatically 
increases the chance for the bacteria to develop resistance to the antibiotic treatment.95 
Further evidence for ROS as a method of bacterial genetic mutation ultimately leading to 
antibiotic resistance was recently presented by Kohanski and co-workers.96 They 
successfully developed a method to track ROS-mediated mutagenesis and its correlation 
to antibiotic resistance. In a systematic manner it was shown that antibiotics increase the 
overall mutation rate during bacterial growth, and that this increase is heavily dependent 
on the formation of ROS.96 Treatment of bacteria with antibiotics under anaerobic 
conditions or in the presence of a hydroxyl radical scavenger like thiourea showed 
mutation rates near the basal levels of untreated cells. Following treatment with a 
sublethal dose of a single antibiotic under aerobic conditions, mutation rates were 
elevated and an increase in MIC for a wide range of antibiotics was observed.96  
While the above discussion is the currently accepted model for the bactericidal effects of 
many antibiotics, recent reports have begun to question this model.100,101 In back-to-back 
publications, the laboratories of James Imlay and Kim Lewis have independently shown 
that ROS may not be the ultimate executioners of bactericidal antibiotics. 
Liu and Imlay re-tested a number of the reported conditions from the work of Collins and 
co-workers, and found that the antibiotics in questions were just as active under anaerobic 
conditions--when ROS are not being produced.100 In the same report, they also showed 
that a transcription factor in E coli known to be upregulated under H2O2 stress was not 
induced by treatment of ampicillin or norfloxacin. They concluded from their results that 
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classic bactericidal antibiotics do not promote H2O2 formation, which was proposed to 
lead to DNA damage, and that oxygen appears dispensible for antibiotic toxicity.100 They 
do admit that there may be other general stress mechanisms that may be important for 
bactericidal activity of antibiotics, as they cannot offer any additional insight into their 
activity from these studies. 
Keren and co-workers corroborate and compliment the work of Liu and Imlay.101 This 
report focuses more on the use of thiourea, hydroxyphenyl fluorescein (HPF) as 
indicators of ROS generation in bacterial culture. They found that the reported protective 
effects of thiourea could be abolished simply by increasing antibiotic concentration to 
therapeutically relevant levels.101 Additional results confirm that antibiotics are just as 
active under anaerobic conditions, when ROS cannot be generated, similar to Liu, et. al. 
Finally, they suggest some reasons for the conflicting evidence produced regarding ROS 
and antibiotics: 1) the concentration of the antibiotic used can have a large effect on the 
efficacy of bacterial killing, 2) the mechanism of thiourea protection is unclear, and may 
not involve ROS scavenging, 3) HPF fluorescent shifts can be observed under both 
aerobic and anaerobic conditions suggesting it is not a specific indicator of ROS.101 
The above exemplifies that difficulty in understanding the mechanism of action for 
bactericidal antibiotics, however all of the above authors agree that better understanding 
of the mechanism by which a compound acts would aid the design of a better analogue 
from a lead structure.97,100,101 In some instances, drugs need to be bioactivated in order to 
exert their bactericidal or bacteriostatic action on the infectious pathogen. In the past, this 
was often elucidated after the drug had already been approved and widely used to treat 
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infections. For example, both INH and PZA are bioactivated to their bactericidal agents 
(as described above).15,16,40 Ethionamide (1-9, ETA) has been shown to behave in a 
similar manner to INH (Figure 1.10). First discovered in 1956, ETA was developed as an 
analogue of nicotinamide, which had been shown to be moderately active against Mtb.102 
ETA is bioactivated by the monooxygenase EthA to give a sulfinic acid (11) that can 
undergo radical chemistry, producing an imidoyl radical (1-12) that can form adducts 
with NAD (1-13).103 ETA-NAD adducts are potent tight-binding inhibitors of InhA, just 
like INH, and were shown to bind in a nearly identical orientation to INH-NAD adducts 
through co-crystal structures.103  
 
Whether due to our better understanding of bacterial cell pathways or our increasingly 
sophisticated screening techniques, new compounds are being identified that require 
Figure 1.10. Bioactivation of ETA. ETA-NAD adducts bind to InhA almost identically to 
INH-NAD adducts. 
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bioactivation for activity. PA-824 is a new anti-TB compound in the nitroimidazole class 
(1-14, Figure 1.11). Traditionally a source of antiprotozoal agents, random screening 
efforts have identified chemicals of this class with highly potent antitubercular activity.104 
It has been shown that PA-824 is bactericidal and appears to act through the release of 
nitric oxide (NO), a highly reactive nitrogen species that mammals innately use against 
mycobacterial infections.105 The proposed mechanism of activation is through F420 
deazaflavin-dependent nitroreductase (Ddn) reduction of the C-3 of PA-824 to give a 
dihydroimidazole intermediate.105 This intermediate more readily loses nitrous acid, 
which is disproportionated to nitric oxide (NO). Additional experiments suggested that 
nitrogen species (like NO) are likely responsible for PA-824's bactericidal activity under 
anaerobic conditions (typical of quiescent Mtb), whereas metabolism in aerobic 
conditions likely produces ROS that are responsible for bacterial killing.106,107 As 
expected, mutations involving Ddn genes were the most common to produce resistance in 
bacteria when studied.108 No adverse side effects have been reported in the Phase I 
clinical safety trials of PA-824, and limited Early Bactericidal Activity (EBA) studies 
have shown no adverse effects.109 PA-824 shows synergistic cooperation with PZA, the 
combination therapy showing the best anti-TB activity in vitro.110  
 
 
 
 
 
  35 
 
Related compounds currently under investigation are the benzothiazinones (e.g. BTZ038 
1-15, Figure 1.11). BTZ compounds also contain a nitroaromatic core and appear to act 
through a novel mechanism of action. These compounds have shown extraordinary 
activity against Mtb, with MIC values upwards of 20-fold below that of INH.111  
Genetic analysis has confirmed the target of BTZ compounds to be 
decaprenylphosphoryl-β-D-ribose oxidase (DprE1) and decaprenylphosphoryl-D-2-keto 
erythro pentose reductase (DprE2), which are responsible for the essential epimerization 
of arabinan precursors in mycobacterial cell wall components.111,112 Without these 
arabinan molecules, the cell wall cannot be completed, leading to cell destabilization and 
ultimately lysis. Further study showed that some sort of activation of BTZ molecules 
must happen within the mycobacteria, as they have been shown to modify cysteine 
residues within the DprE1 target enzyme.112 Still ongoing in the study of this class of 
Figure 1.11. Structures of PA-824, and BTZ038. Both investigational compounds have 
shown required bioactivation for Mtb activity. 
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compounds is the search for an independent enzyme that first reduces the BTZ nitro 
group to a reactive nitroso intermediate. It is also possible for this to happen within 
DprE1 itself, although no evidence has yet been given to support that hypothesis. A 4-
week efficacy study in mice did show a decrease in bacterial burden, however the 
possible side effects in mammalian cells have not yet been fully addressed.111 While the 
starting point for development may arise from random screenings, rationally designing or 
exploiting prodrug or bioactivatable moieties into inhibitors could be a very effective 
strategy for bypassing some of the difficult pathological problems associated with Mtb, as 
well as increase the likelihood of oral absorption and distribution in vivo. 
There are many research groups actively pursuing new anti-TB compounds, but there are 
additional challenges to be faced once a clinical candidate has been identified. New 
compounds will likely need to work in synergy with existing Mtb therapies to help slow 
the development of drug-resistant bacteria. Many investigational compounds have shown 
drastically improved efficacy in combination with first-line agents, especially PZA. As 
more mycobacterial strains develop resistance to these compounds, these combinations 
will also lose efficacy. New compounds that are able to be incorporated into multiple 
drug regimens, not just combinations involving the frontline agents, are highly desirable 
to avoid this consequence. New anti-TB compounds also need to be evaluated for their 
efficacy in concert with antiretroviral therapies. As discussed earlier, there is an 
especially alarming rate of disease and death in TB/HIV co-infection. Rifampin, a known 
CYP3A4 and P-glycoprotein (P-gp) efflux pump inducer, dramatically reduces the levels 
of antiretrovirals in vivo, which can cause serum levels to fall below IC50 levels, allowing 
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drug resistant viruses to be selected. Compounds currently in development should be 
evaluated for their ability to induce (or inhibit) these important metabolic processes so as 
to avoid complications in co-therapy. 
 
1.6 Challenge 5: Modeling activity against Mycobacterium tuberculosis 
 
When a compound has been identified as a potential drug candidate through rigorous 
SAR and enzymatic studies, further preclinical evaluation is required before being able to 
enter human clinical trials. A great hurdle in Mtb drug discovery has been the 
development of predictive in vitro and in vivo models that genuinely reflect the outcome 
for human Mtb infection. Herein we will attempt to highlight best practices and some of 
the challenges still faced in Mtb models. For a more exhaustive review, see other 
publications.113–115 
Mtb is a highly transmittable pathogen that requires Biosafety Level 3 (BSL-3) facilities 
to perform bacterial culture and/or animal work. These facilities are not readily available 
to all researchers, nor can all of them afford such sophisticated equipment. Other, less 
pathogenic, bacteria have been used as surrogates for Mtb for in vitro study. Most 
extensively used are Mycobacterium smegmatis, and Mycobacterium bovus BCG.116 The 
genome of M. smegmatis was first sequenced in 2001 and shown to have closer 
homology to Mtb than originally thought.117,118 M. smegmatis was shown to have close 
homologues of 12 of the 19 genes thought to be involved in virulence in Mtb.117 Adding 
this to a lack of pathogenicity in humans (BSL-1 pathogen) and short generation time of 
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3–4 hours, M. smegmatis is an attractive surrogate for the study of compounds against 
Mtb enzymes and growth. Caution should be exercised, as others have pointed out, that 
relying on M. smegmatis too rigorously may cause false positive results, or miss Mtb 
active compounds all together.119 Further study of the utility of M. smegmatis and BCG 
reveal evidence for these concerns. Whole-cell screenings of a LOPAC library and the 
NIH Diversity Set and Spectrum Collection versus M. smegmatis, M. bovus BCG, and M. 
tuberculosis showed striking differences in the number of Mtb inhibitors identified. M. 
smegmatis missed 50% of the LOPAC library hits in Mtb, and 48% in the NIH collection. 
In comparison, M. bovus BCG missed only 34% of the LOPAC hits and 7% of the NIH 
hits.116 Until better in vitro models are developed that show more correlative activity 
compared to Mtb, these inconsistencies must be taken into consideration when 
investigating new compounds. 
Compounding the difficulties with in vitro modeling are the challenges for in vivo animal 
models. Mouse models are currently the most heavily utilized model for infectious 
disease for a number of reasons: ease of handling, affordability of housing and care, the 
availability of inbred, mutant, and genetically altered strains, and the wide range of 
reagents developed for their study.120 While these models are extremely useful in early 
stages of preclinical development to evaluate the efficacy of an investigational compound 
to eradicate disease, there are drawbacks to comparing these results to human disease. As 
previously discussed, many people are infected with what is termed latent TB where they 
present an immunological response to the bacterial stimulus, but show no clinical or 
microbiological evidence of infection.121 Mice do not develop the latent disease to the 
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same extent unless antibiotics are introduced, and this does not adequately reflect the 
human condition. Pathologically, mice do not form granulomas with the same spectrum 
of heterogeneity as those seen in human disease (e.g. caseous and necrotic lesions). These 
differences in manifestation of the disease can have a direct impact on how well the 
results of a mouse study will translate to human disease, and it is difficult to predict these 
effects. Both guinea pigs and rabbits have also been studied and have shown 
manifestation of TB disease more closely resembling the human infection. Rabbits are 
usually infected with M. bovus because Mtb susceptible animals, while reported in legacy 
literature, have been lost. Both models suffer from a lack of immunological reagents 
available for more detailed study, and rabbits require substantially more material for 
efficacy testing due to their larger size.113 Non-human primates (NHPs) are likely the best 
candidate species for an animal model of TB due to their genomic, physiological, and 
immunological similarities to humans.115 The major drawback to the utilization of NHPs 
is the large expense of the animals, and their housing and care in a BSL-3 level facility. 
Recently, there has been a resurgence in the use of cynomolgus macaques due to their 
faithful representation of human disease both in the manifestation of latently infected 
individuals, and the heterogeneity in the pathology of disease.113,115 These models have 
contributed greatly to our understanding of the disease itself, as well as our current and 
developing therapies against it.  
Preclinical development should also work towards a better understanding of some of the 
pharmacodynamic properties of investigational compounds. The two most extensively 
used in vitro models for the susceptibility of bacteria to treatment are the Wayne-Hayes 
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hypoxia model and the hollow fiber infection model (HFIM). The HFIM model, 
originally described by Hollingshead in relation to observing tumor cell lines, attempts to 
model the pharmacodynamics of a living system.122 Drusano and co-workers adapted it 
by using a semi-permeable fiber that can be inoculated with colony-forming units (CFUs) 
of Mtb that are allowed to grow in fiber.123 Media is then pumped through the fiber where 
it equilibrates throughout the chamber and allows nutrients to reach the bacteria for 
growth (Figure 1.12). An antibiotic or investigational compound can then be injected 
into the flowing media to be disseminated into the fiber, allowing for simulation of 
pharmacokinetic profiles. The cells within the fiber are removed after a predetermined 
amount of time and evaluated for parameters such as viability and acquired resistance. 
These hollow fibers can also be implanted within mice for similar evaluation from an in 
vivo system.122 The Wayne-Hayes model, originally described in 1996, slowly introduces 
hypoxia to culturing Mtb to force them into a quiescent, or latent, state.124 Treatment of 
these cultures with antibiotics will then evaluate a compound's ability to fight latent 
infection as compared to more actively replicating bacteria. This is one of the relatively 
few ways of modeling even a part of the conditions seen in latent infection. Other 
systems rely on nutrient starvation to force the bacteria into a lowered metabolic state, 
and still others use multiple stresses to help achieve multiple outcomes of latent 
infection.114  
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Models of Mtb infection have progressed tremendously in the last two decades. While 
there is still no single model that best evaluates all aspects of Mtb infection, the use of 
multiple models should give reasonable confidence as to the promise of a new therapeutic 
candidate. Unfortunately, this evaluation can come at significant financial burden, which 
has only become more difficult to overcome as many countries are experiencing 
economic turmoil. 
 
1.7 Challenge 6: Monetary challenge 
 
Over the past two decades, funding for new drug discovery research has become 
increasingly competitive. Funding agencies are becoming more stringent in their 
requirements for funding a proposed project, and many important projects are not 
Figure 1.12. Hollow fiber infection model. Adapted from Drusano, et al.123 
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acquiring adequate funding to be conducted. Outside of academics, large pharmaceutical 
companies must pick disease indications to invest in, and often choose those with the 
greatest possibility for return. Mtb is largely a problem in poorer countries, where there 
are fewer and less advanced medical facilities available for their citizens. Many of these 
countries would not be able to afford an expensive new anti-TB therapy, even if it would 
help many ease a significant health burden. For these, and other business reasons, many 
companies are not investing in anti-TB research. This difficult funding situation only 
hurts the ability of TB research to move forward.  
There are also some practical financial hurdles to Mtb therapy development that need to 
be overcome. Once a compound is approved for Phase II clinical trials, large cohorts of 
patients who are actively infected with Mtb must be found, enrolled, and monitored 
throughout a study. These trials must be rigorously documented and controlled in order to 
prove the efficacy of a new therapeutic to the FDA and other regulatory bodies. Groups 
of patients of this size are often only found in countries on the African and Asian 
continents, usually far away from where the candidate compound has been developed. It 
is a huge financial challenge to set-up a trial facility, transport and hire a staff to run the 
trial, and then monitor and document the results to the satisfaction of the regulatory 
committees. As the TB crisis continues to grow, governments of countries with large TB 
burdens have begun to partner with researchers to help fund and facilitate these studies, 
doing what they can to encourage new therapy development. 
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1.8 Conclusions 
 
The global need for new Mtb therapeutics continues as the field grows its knowledge 
regarding the pathogen, host immune response, and techniques for new therapy 
development. In order to efficiently address this growing pandemic, we need to continue 
to utilize complementary strategies to evaluate new therapeutic agents from multiple 
angles. This will allow promising candidates to move through the development pipeline 
faster, as well as terminate programs that will have irreconcilable problems in preclinical 
or clinical development. There is still a great need for better predictive models of Mtb 
behavior, both in vitro and in vivo, that will correlate to human infection. This could be 
through better understanding of NHP models, or through the development of better tools 
for lower-order animal models (e.g. guinea pigs and rabbits) that may be more accessible 
to more researchers. To develop these models and tools, we need to continue to 
investigate the basic pathology and life cycle of this highly complex and well-adapted 
pathogen. 
New compounds need to be identified through complimentary approaches that combine 
the specificity of a target-based approach with the physiological evaluation of a 
phenotypic or whole-cell approach. This will allow for the quickest evaluation of the 
viability of a lead for future development, reducing both the time and cost required to 
develop a preclinical candidate. A combined effort will create the knowledge and 
opportunity needed to develop the next generation of antitubercular compounds that will 
remove this public health threat from the global theater. 
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Chapter 2. Synthesis of Adenylation Inhibitors as Antitubercular 
Agents and Evaluation of Their Oral Bioavailability in a Rodent Model 
 
 
The following chapter is original work designed by Kathryn M. Nelson and Dr. Courtney 
C. Aldrich. The organic synthesis and animal dosing, blood draws, and sample work-up 
was performed by KMN, with minimal assistance from Dr. Kishore Viswanathan. LC–
MS/MS analysis was performed by Dr. Benjamin Duckworth, with data interpretation by 
KMN and Dr. Duckworth. The enzymatic binding constants were determined by Daniel 
Wilson or Dr. Viswanathan. The MIC data against Mycobacterium tuberculosis were 
determined by Dr. Helena I. Boshoff of the National Institutes of Health. All previously 
published figures are appropriately cited. Plasma stability assays were performed by Dr. 
Duckworth, with data analysis shared by Dr. Duckworth and KMN. Simulated gastric 
fluid assays were performed and analyzed by KMN. 
 
2.1 Introduction 
 
2.1.1 Siderophore inhibitors as antitubercular agents 
 
There is a dire need for new antitubercular agents that target new mechanisms of action. 
Iron is an essential micronutrient for almost all known bacterial organisms, with few 
notable exceptions including Borrelia burgdorferi.1 The concentration of free iron in 
  57 
human serum is approximately 10-24 M, which is too low to support bacterial colonization 
and growth.2 In an effort to overcome this iron limitation, pathogens such as 
Mycobacterium tuberculosis (Mtb) synthesize small molecule iron (Fe3+) chelators, 
termed siderophores, for iron acquisition. Pathways of siderophore biosynthesis, 
secretion, and re-import are especially important for scavenging iron in limiting 
environments such as a human host. The inhibition of the biosynthesis of these molecules 
has emerged as a promising strategy for new drug development.3–6 Mtb biosynthesizes a 
suite of siderophore structures called the mycobactins and carboxymycobactins, 
differentiated by the identity of the long chain attached at the central lysine residue in the 
core structure (Figure 2.1). The biosynthetic pathway for mycobactin synthesis in Mtb 
has been shown to be essential for growth and virulence in iron-limiting conditions, 
making it especially attractive as a drug target.7  
 
 
Several observations have established the necessity of mycobactins for Mtb pathogenesis. 
The targeted genetic inactivation of mbtB, a gene involved in the biosynthesis of 
Figure 2.1. Structure of mycobactins and carboxymycobactins in Mtb. 
The central lysine residue contains either a long alkyl or acyl chain 
depending on the type of siderophore produced. 
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mycobactins, resulted in a mutant able to replicate under iron-replete conditions but 
unable to grow under iron-deficient conditions.8 A ΔmbtB Mtb mutant was attenuated for 
growth in macrophages and incapable of establishing an infection in an 
immunocompromised mouse model.8 Finally, the in vivo gene expression profiles of Mtb 
show that the iron-responsive gene mbtB is highly upregulated in an infection model.9 
Mycobactins are biosynthesized by a mixed non-ribosomal peptide synthetase-polyketide 
synthase (NRPS-PKS) assembly line initiated by the adenylating enzyme MbtA (Figure 
2.2).  
 
MbtA activates salicylic acid, to form an acyl-adenylate intermediate, followed by the 
transfer of the acyl-adenylate onto the N-terminal thiolation domain of MbtB. 7,10 Our lab 
and others have developed a potent nanomolar bisubstrate inhibitor of MbtA, 5′-O-[N-
Figure 2.2. MbtA is the first step in the biosynthesis of all mycobactins in Mtb, loading 
the salicylic acid cap to begin the NRPS-PKS biosynthetic pathway. 
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(salicyl)sulfamoyl]adenosine (Sal-AMS, 2-1), as a mimic of the acyl-adenylate 
intermediate that has impressive antitubercular activity under iron-deficient conditions 
with a minimum inhibitory concentration (MIC) of 0.39 μM.3,4,11 The design of this 
inhibitor takes advantage of both the salicylic acid and ATP binding domains, but 
replaces the labile acyl phosphate with a more stable isosteric acyl sulfamate (Figure 
2.3). 
 
 
This compound is the first to have demonstrated selectivity for aryl acid adenylating 
enzymes (AAAEs) as a class of enzymes, showing potency against enzymes from a 
number of different bacteria.3,11,12 Because MbtA is the initiating enzyme in the NRPS-
PKS biosynthetic pathway for all mycobactins and carboxymycobactins, this enzyme is a 
universal target for the inhibition of siderophores in Mtb. 
 
Figure 2.3. Design of 5'-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS,2-1). This 
bisubstrate mimic incorporates a stable acyl sulfamate isotere in replacement of the labile 
acyl phosphate. Partially adapted from Vannada, et. al.13 
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2.1.2 Initial evaluation of lead compound Sal-AMS 
 
Our first inhibitor against MbtA, Sal-AMS, has been thoroughly studied in vitro. As 
shown in Table 2.1, Sal-AMS has been shown to be a slow, tight-binding inhibitor 
against MbtA, with picomolar binding affinity (KD) and nanomolar activity with respect 
to the natural substrates (appKi) (Table 2.1). 
 
 
 
Parameter Value 
MbtA appKi 6.6 nM4 
MbtA KDa 1 pM14 
MIC (Mtb H37Rv)b 0.39 µM4 
CC50 (Vero cells)c > 100 µM15 
ClogPd 0.29 
pKae 3.0 
 
As such a tight binding inhibitor of MbtA, the residence time (tR) of Sal-AMS in the 
active site of the enzyme becomes a substantial factor (Equations 1, 2).  
aConfirmed by isothermal titration calorimetry. bMIC, the 
concentration required to achieve no observable growth during assay. 
cInhibition of cellular growth using an MTT assay and African green 
monkey Cercopithecus aethiops kidney cells (Vero, ATCC). 
dCalculated using ChemBioDraw 13.0 eCalculated using 
MarvinSketch 5.12.3 
Table 2.1. Observed and calculated values for enzymatic and whole-
cell activity and physicochemical characteristics of Sal-AMS 2-1. 
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From our knowledge of an structurally and functionally homologous adenylating enzyme, 
EntE, that activates 2, 3-dihydroxybenzoic acid from E. coli, we estimate the residence 
time of Sal-AMS in MbtA to be approximately 36 days.16 This lengthy residence within 
the enzyme active site effectively renders the enzyme inert until it is degraded and 
recycled by the cell. This means that inactivation of MbtA can be achieved at 
concentrations in serum well above the MIC measured against Mtb. Sal-AMS already 
shows impressive activity against whole-cell Mtb in iron limiting conditions at 0.39 µM, 
relatively close to the activity of isoniazid (INH, 0.1 µM), which is still one of the most 
potent compounds used against Mtb infection today (see Chapter 1 for more discussion of 
TB therapeutics).  
Although this data looks very promising for drug development, we anticipate Sal-AMS to 
have a low oral bioavailability based on its unfavorable physicochemical properties. 
While it has become standard practice to evaluate lead drug compounds according to 
Lipinski's seminal work on drug-like compounds,17 it has been pointed out by him and 
others that antibacterial compounds are often exceptions to these rules.17–19 It is still 
important to consider, however, the calculated partition coefficient (ClogP, 0.29) and the 
pKa of the sulfamate nitrogen (3.0) in Sal-AMS, which indicate that nearly 100% of the 
compound in solution is in a charged state at physiological pH. With this highly polar, 
highly charged character, this compound is unlikely to be able to pass easily through cell 
(1) 
(2) 
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membranes, and is likely to be quickly excreted renally. To address these issues, we have 
examined the structure-activity relationship (SAR) studies previously conducted in the 
lab. These studies thoroughly and systematically examined the impact of each domain of 
Sal-AMS on enzyme inhibition of MbtA from M. tuberculosis as well as whole-cell 
antitubercular activity. These SAR studies have explored the aryl,14 linker,13,20,21 
glycosyl,12 and nucleobase15,22 domains (Figure 2.4). 
 
 
These results have provided a comprehensive understanding of the minimal structural 
requirements to maintain enzymatic and whole-cell activity, and have also served to 
define positions amenable to modification (Figure 2.5). We have been able to use this 
data in our effort to design more pharmacokinetically favorable compounds, while 
maintaining a high level of activity against our target of interest. The aryl and linker 
regions are both very intolerant to modification. As shown below, even deviation from a 
2-hydroxyl to a 2-amino substitution on the aryl ring (2-2) results in a 116-fold loss in 
enzymatic activity, and a complete loss of Mtb growth inhibition. Limited modifications 
at the 4-position of the aryl ring were tolerated, with a 4-amino substitution (2-5) 
Figure 2.4. Structure-activity relationship domains previously investigated for Sal-AMS, 2-1. 
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resulting in a moderate (six-fold) loss in MbtA inhibition, and a four-fold loss in Mtb 
growth inhibition. Changing the linker from a sulfamate (2-1) to a sulfamide (2-6) 
modestly improved both enzymatic and whole-cell activity, but any other changes 
dramatically reduced activity. Modifications at the glycosyl ring were generally tolerated. 
At least one hydroxyl group appears necessary for activity (2-11 vs. 2-12 and 2-13), but 
the ribose ring can be substituted for a carbocyclic ring with retention of activity (2-10). 
The largest modifications were tolerated in the adenine base. The N6 position could not 
be substituted for other heteroatoms (2-15), but small alkyl substitutions retained (2-16, 
2-17), and even improved (2-18) MbtA and Mtb inhibition. Molecular dynamics 
simulations of MbtA revealed plasticity in the nucleobase binding pocket that could allow 
the binding of Sal-AMS derivatives with large substituents at the C-2 of the purine (2-20, 
2-21, 2-22).23 2-Ph-Sal-AMS, 2-20, was the most potent inhibitor yet identified with an 
appKi of 0.27 nM, and exceptionally potent antitubercular activity under iron-deficient 
conditions at 0.049 μM.15,22,23 
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Figure 2.5. Some results of SAR studies on Sal-AMS, 1. This table contains only 
representative examples from each study. For more detailed results, see the indicated 
references within the table. aAssay performed by Daniel Wilson, with 7 nM MbtA, 10 mM 
ATP, 250 μM salicylic acid, 1 mM PPi.bAssay performed by Dr. Helena I. Boshoff, grown 
in normal pH 6.6 glycerol-alanine-salts (GAS) medium without ferric ammonium citrate. 
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From the SAR studies discussed above, we propose to synthesize new analogues that 
possess improved pharmacokinetic properties while still maintaining potent enzymatic 
and antitubercular activity in two different ways (Figure 2.6). The first is through 
modifications predicted to increase the pKa on the sulfamate nitrogen. Replacing the 
oxygen in the sulfamate linker with a nitrogen to make a sulfamide linker is predicted to 
increase the pKa of the acidic nitrogen by 1-2 units. Addition of an electron donating 4-
amino substitution on aryl ring is also calculated to slightly increase the pKa. These two 
modifications could potentially increase the pKa to around 5. In the second approach, we 
plan to increase the lipophilicity (based on ClogP) of the compound through the addition 
of aliphatic substitutions and/or small ester prodrugs. Firstly, in a prodrug approach, we 
could acetylate the 2ʹ, 3ʹ hydroxyl and phenol groups. This modification should increase 
the lipophilicity of the compounds relative to Sal-AMS, allowing for permeation through 
the intestinal wall. Once absorbed into the enterocyte, esterases in the plasma or liver can 
nonspecifically cleave the acetates to produce the parent compound. Second, addition of 
small aliphatic groups at the N-6 position of the adenine base and larger aromatic groups 
at the C-2 position of the base are calculated to increase the ClogP. The most promising 
substitutions (i.e. N6-cyclopropyl and C-2 phenyl) will be synthesized and evaluated first, 
with further analogues being synthesized based on these results. 
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2.2 Research objectives 
 
The principle aim of this research was to evaluate the siderophore biosynthesis inhibitors 
in cannulated rats for pharmacokinetic evaluation. This required the synthesis of greater 
than 30 mg of each final compound and validation of purity. Purity of greater than 98% 
was achieved by semi-prepartive or preparative reverse-phase high performance liquid 
chromatography (RP-HPLC) of all final compounds, and analytical purity RP-HPLC 
prior to administration.  
For our initial evaluation of in vivo pharmacokinetics, we chose to administer and 
Figure 2.6. Sal-AMS inhibitor design based on results from SAR studies. (A) 
Modifications predicted to increase the pKa of the sulfamate nitrogen. (B) 
Modifications predicted to increase the ClogP, and thereby increase the lipophilicity 
of the compounds. aCalculated using MarvinSketch 5.12.3. bCalculated using 
ChemBioDraw 13.0. 
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observe compound bioavailability in Sprague-Dawley rats. Rats were chosen because of 
their larger size and ability to complete a single crossover study with one animal. This 
reduces the potential inter-animal variability seen when using mice (e.g. C57Bl/6), as 
each time point requires a separately dosed and sacrificed mouse due to the small volume 
of blood that can be obtained. The results obtained and reported herein will aid in the 
development of the next generation of compounds that will eventually lead to a 
preclinical candidate for efficacy studies against Mtb. 
 
2.3 Results 
 
2.3.1 Synthesis of Sal-AMS (2-1) and sulfamide linked analogue (2-6) 
 
In order to compare the oral bioavailability of our compounds to the parent, we first had 
to synthesize a large quantity of Sal-AMS (2-1) for these studies. The synthesis of this 
compound has been reported in our previous publications,4 however a slightly modified 
route was developed during this scale-up synthesis (Scheme 2.1). 
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Beginning from the commercially available 2ʹ,3ʹ-O-isopropylidene adenosine 2-23, we 
first protected the 5ʹ-hydroxyl with tert-butyldimethylsilyl chloride (TBSCl) in 
quantitative yield. Reaction with excess di-tert-butyl dicarbonate then led to the N6-bis-
Boc protected intermediate. Deprotection of the 5ʹ-hydroxyl with tetra-n-butylammonium 
fluoride (TBAF) resulted in protected intermediate 2-24. This three-step process can be 
scaled up to more than 10 grams with excellent yields. Following production of 2-24, 
sulfamoylation was accomplished in DMF with triethylamine as a base.24 A simple 
aqueous work-up was often enough to obtain clean product without column 
chromatography when the N6 position was protected. Sulfamate 2-25 was coupled with 
Scheme 2.1. Synthesis of Sal-AMS (2-1) using a slightly modified route to what 
has previously been reported by our lab.4 See discussion below for improvement 
in sulfmoylation from 2-24 to 2-25. 
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N-hydroxysuccinimidyl-2-(methoxymethyloxy)benzoate 2-26 in the presence of cesium 
carbonate to give the penultimate, fully protected Sal-AMS precursor 2-27 in moderate 
yield. Global deprotection was achieved with 80% aqueous trifluoroacetic acid (TFA). 
The crude product was then thoroughly dried and immediately purified by RP-HPLC. 
The final product was a white solid after lyophilization. It was possible to purify Sal-
AMS 2-1 by normal phase silica chromatography, however we required > 95% purity for 
administering these compounds to animals. This purity level was never successfully 
achieved after normal phase chromatography. 
Initial synthesis of the sulfamide linked analogue (2-6) was hindered by many protecting 
group steps that made throughput of intermediates difficult. In response to this challenge, 
a Mitsunobu reaction was developed by Dr. Paul Sibbald in our lab that successfully 
installed a protected sulfamide linker in a single step (Scheme 2.2). This reaction 
required precise control of the equivalents of all reagents added in order to be successful. 
Compounds 2-24 (1.0 equiv) and 2-28 (1.1 equiv) were dissolved with 
triphenylphosphine (Ph3P, 1.1 equiv) in THF and cooled to 0 °C. Diisopropyl 
azodicarboxylate (DIAD, 1.1 equiv) was then added as a solution in THF by syringe 
pump over 90 minutes. The reaction was stirred at 23 °C for at least 16 hours (longer if 
scaled up larger than 1.0 g) to give sulfamide 2-29. Following sulfamide installation, 
cesium carbonate (Cs2CO3) mediated coupling with 2-26 gave 2-30 in moderate yield. 
Global deprotection with aqueous TFA followed by RP-HPLC resulted in compound 2-6 
as the triethylammonium salt. This improved route cut the number of required steps in 
half (from 6 to 3 beginning from 2-24) for this synthesis, greatly improving throughput 
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for this compound. 
 
 
2.3.2 Synthesis of 5ʹ -Amino-5ʹ-deoxy-5ʹ-N-[(4-amino-2-hydroxybenzoyl)sulfamoyl]-
adenosine (2-34) 
 
The next analogue to be synthesized in this set replaced the sulfamate linker with a 
sulfamide linker, and added the 4-amino substitution on the aryl ring in an effort to 
further increase the pKa of the linker's acidic nitrogen. In analogous fashion to the 
sulfamide linker synthesis in Scheme 2.2 above, we began from sulfamide 2-29 (Scheme 
2.3). A CDI-mediated coupling generated the penultimate protected product 2-33 in 
moderate yields. Activation of 2-31 with CDI led to a highly activated cyclic anhydride 
(2-32) that was generated in situ, then reacted directly with sulfamide 2-29 with catalytic 
cesium carbonate. A two-step deprotection via catalytic hydrogenolysis followed by 
Scheme 2.2. Synthesis of a sulfamide linked analogue of Sal-AMS (2-6). 
  71 
treatment with 80% aqueous TFA afforded the desired nucleoside 2-34. RP-HPLC 
purification gave high purity (> 95%) product in moderate yield. 
 
2.3.3 Synthesis of 5ʹ-Amino-N6-cyclopropyl-5′-deoxy-5ʹ-N-[N-(2-
hydroxybenzoyl)sulfamoyl]adenosine (2-41) 
 
Our next analogue incorporated both a sulfamide linker in an attempt to raise the pKa of 
the acidic nitrogen, and an N6-cyclopropyl group in an effort to increase the lipophilicity 
of the compound. 
The synthesis began the same as we have previously reported for N6-substituted Sal-AMS 
analogues (Scheme 2.4).22 This analogue was completed prior to the development of the 
Mitsunobu chemistry to directly install the sulfamide linker. Consequently, we first 
installed an azide at the 5ʹ position of 2-36 with DPPA as an azido source in a Mitsunobu 
Scheme 2.3. Route for the synthesis of a sulfamide-linked and 4-amino aryl substituted 
analogue of Sal-AMS (2-34). 
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reaction,25 followed by reduction to give the 5ʹ-amino 5ʹ-deoxy intermediate 2-37. 
Addition of the sulfamide was achieved in high yield with the dimethylaminopyridinium-
activated substrate 2-38 previously described.26 Deprotection of the carboxybenzyloxy 
(Cbz) group gave the free sulfamide 2-39 that was then coupled with succinimide 2-26 
which gave the penultimate protected intermediate 2-40. Final deprotection with aqueous 
TFA led to final compound 2-41. Initial purification by filtration over a plug of silica gel 
removed impurities prior to HPLC purification. 
 
 
 
Scheme 2.4. Route for synthesis of N6-cyclopropyl, sulfamide linked Sal-AMS 
analogue 2-41. 
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2.3.4 Synthesis of 2-Phenyl-N6-cyclopropyl-5ʹ-O-[N-(2-
hydroxyl)sulfamoyl]adenosine (2-50) 
 
The most lipophilic analogue targeted contains the N6-cyclopropyl group as well as a C-2 
phenyl substitution on the adenine base. Beginning from guanosine, chemistry elegantly 
described by Matsuda and co-workers provided the N6-chloro-2-iodo intermediate 2-43 
(Scheme 2.5).27  
 
Scheme 2.5. Route to access the N6-cyclopropyl-2-phenyl derivative of Sal-AMS (2-50). 
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The synthesis of this compound has been previously reported by our group,23 however 
this synthesis employed the improved sulfamoylation conditions described above. After 
three steps, which can be scaled to upwards of 25 grams successfully, 6-chloro-2-iodo-
2ʹ,3ʹ,5ʹ-O-acetyladenosine (2-43) was converted to N6-cyclopropyl-2-iodoadenosine by 
reaction with neat cyclopropylamine at room temperature. Following protection of the 2ʹ - 
and 3ʹ -hydroxyl groups as the acetonide with 2, 2ʹ -dimethoxypropane (2-44), a 
palladium-catalyzed Suzuki coupling was used to install the phenyl group at the C-2 
position (2-47). The phosphine ligand (2-46) was observed to slowly oxidize to the 
corresponding oxide and thus was stored in a glove box under N2 atmosphere. The 5ʹ-
hydroxyl was first sulfamoylated by the modified triethylamine-mediated reaction 
described above, then coupled with succinimide 2-26 to give the fully protected 
intermediate 2-49. TFA-mediated deprotection afforded compound 2-50 recovered in 
moderate yields after RP-HPLC purification. This compound was much easier to monitor 
by thin-layer chromatography (TLC) during all the above reactions due to its increased 
lipophilicity. Similar to Sal-AMS, even though 2-50 could be purified by normal phase 
silica chromatography, RP-HPLC was required for the high level of purity necessary for 
administration to animals. 
 
2.3.5 Synthesis of acetate prodrugs of Sal-AMS (2-51 and 2-52) 
 
A simple acetate prodrug was the first prodrug design attempted for Sal-AMS. Acetates 
are quickly hydrolyzed by non-specific esterases in vivo.28 The tri-acetate derivative of 
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Sal-AMS was prepared by direct acetylation of Sal-AMS employing acetic anhydride and 
pyridine in DMF (Scheme 2.6). These conditions were notable since competitive 
acetylation at the N6 position of adenosine was not observed. 
 
Compound 2-51 was first purified on normal phase silica and isolated as an approximate 
5:1 mixture of tri-and di-acetates 2-51 and 2-52. Further purification by RP-HPLC was 
required to obtain pure 2-51.  
We were interested in examining whether there is a difference in the bioavailabilities of 
the di- and tri-acetate prodrugs 2-51 and 2-52. The amount of di-acetate 2-52 obtained by 
direct acetylation was inadequate, thus we developed a synthetic route to this compound 
beginning from sulfamate 2-25 coupled with N-hydroxysuccinimidyl-2-
(benzyloxy)benzoate 2-53 to provide 2-54 (Scheme 2.7). TFA-mediated deprotection of 
the acetonide followed by acetylation of the resultant free 2ʹ and 3ʹ alcohols afforded 2-
55. Catalytic hydrogenolysis and RP-HPLC purification led to the di-acetate product 2-52 
in moderate yield. 
 
 
Scheme 2.6. Synthesis of a tri-acetate prodrug of Sal-AMS (2-51). 
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2.3.6 Oral bioavailability of siderophore biosynthesis inhibitors 
 
Our lab had previously synthesized and evaluated the enzymatic activity and 
antitubercular activity of compounds 2-1 and 2-6. The other analogs had not yet been 
analyzed. Table 2.2 summarizes the inhibitory activities against MbtA of the compounds 
synthesized to date. Enzymatic activities were measured by either Daniel Wilson or Dr. 
Kishore Viswanathan from our lab. 
 
 appKi (nM) 
Sal-AMS (2-1)12 6.6 ± 1.5 
Compound 2-612 3.7 ± 0.6 
Compound 2-34 8.9 ± 0.7 
Compound 2-41 1.1 ± 0.4 
Compound 2-50 0.7 ± 0.1 
Compound 2-51 n.d.a 
Compound 2-52 n.d. 
 
 
 
Table 2.2. Enzymatic activity of siderophore inhibitors against MbtA. 
an.d. = not determined 
Scheme 2.7. Direct synthesis of a di-acetate prodrug of Sal-AMS (2-52). 
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Compounds 2-51 and 2-52 were not analyzed as they are prodrugs for Sal-AMS and not 
expected to bind MbtA or be active against Mtb alone. 
We chose to evaluate these compounds in female Sprague-Dawley rats obtained with 
indwelling catheters in the right jugular vein and left femoral vein for infusion and blood 
draws, respectively. The rats allowed us to complete entire corssover bioavailability 
studies with a single animal instead of having to sacrifice animals at each time point. This 
should decrease the error possible in our studies, and improve our confidence in the data. 
Table 2.3 summarizes the results detailed below. We initially chose to dose orally (PO) 
at 25 mg/kg and intravenously (IV) at 2.5 mg/kg, hoping to achieve a bioavailability of at 
least 10% with our best candidate. 
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Compound Dosing route 
Dose 
(mg/kg) t1/2 (min) 
C0 or Cmax 
(µg/mL) 
AUC (min 
* µg/mL) F 
INH 
IV 6 19 124 371 65% PO 30 81.5 ± 7.8a 13.5 ± 0.4 1634 ± 186 
IV29 20 23.4 n.d.b 1842 ± 126 n.d.b 
Sal-AMS 
2-1 
IV 2.5 11.1 ± 2.3 48.4 ± 12.8 427 ± 94 1.2 ± 0.3% PO 25 81 0.42 ± 0.16 49.7 ± 8.4 
Compound 
2-6 
IV 2.5 10.6 ± 0.7 28.8 ± 4.7 250 ± 49 5.9 ± 1.3% PO 25 105 ± 17 0.61 ± 0.06 152 ± 19 
Compound 
2-34 
IV 2.5 14.0 ± 3.1 7.1 ± 6.0 50.2 ± 38.6 5.2 ± 4.1% PO 25 273 ± 154 0.10 ± 0.02 10.6 ± 2.1 
Compound 
2-41 
IV 2.5 15.1 ± 1.3 25.4 ± 6.9 209 ± 76 1.0 ± 0.4% PO 25 78.2 ± 10.3 0.14 ± 0.03 18.1 ± 2.1 
Compound 
2-50 
IV 2.5 15.5 ± 10.6 28.4 ± 9.7 184 ± 30 0.3 ± 0.1% 
PO 25 (n = 2) 33.3 0.111 ± 0.001 4.0 ± 0.9 25 (n = 1) 118 14.8 1361 88% 
Compound 
2-51 
IV 2.5 22.4 ± 1.0 7.4 ± 0.9 173 ± 11 0.2 ± 0.2% PO 25 n.db 0.03 ± 0.01 2.9 ± 0.8 
Compound 
2-52 
IV 2-52 2.5 19.8 ± 12.0 3.4 ± 0.6 18.9 ± 2.8 
0% IV 2-1 2.5 13.4 ± 2.9 1.4 ± 0.2 25.8 ± 5.6 
PO 25 < LODc < LOD < LOD 
 
 
 
We began our studies by administering a known antitubercular agent, isoniazid (INH). 
This is a well studied compound, with many published results regarding its oral dosing 
and detection in rat plasma.29–33 Dosing in duplicate we were able to successfully 
reproduce similar t1/2 and AUC values compared to other reported rodent models dosed at 
similar levels (Figure 2.7).29 Notably, the half-life of INH in rats is reported at 24 
minutes, and our model gave a half-life of 19 minutes. The half-life of INH in humans is 
reported to be approximately 90 minutes for fast acetylators (a measure of INH 
metabolism) and 220 minutes for slow acetylators.30 
Table 2.3. Summary of bioavailability measured for isoniazid (INH) and MbtA inhibitors in a 
rodent model. 
aThe true half-life of a compound is measured during IV dosing as the serum half-life. While a 
half-life can be determined during oral (PO) dosing, this value will vary based on other factors 
such as uptake and absorption and therefore does not represent the true half-life of the 
compound. bNot determined. cLOD = Limit of detection. 
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Satisfied that the sampling technique from rats produced reliable data, we began to dose 
our synthetic compounds. For our purposes, we will be using the half-life (t1/2) value in a 
qualitative manner, attempting to maximize the half-life in this rat model before moving 
our best compound forward into a second animal or efficacy study. As expected, Sal-
AMS (Figure 2.8) shows poor oral bioavailability (1.2%) and a very fast half-life (t1/2 = 
11.1 min). While we are not satisfied with a bioavailability of 1.2%, we were encouraged 
to see that the Cmax achieved here (0.42 µg/mL) is more than two times the MIC observed 
against Mtb (0.18 µg/mL). 
 
 
INH IV INH PO 
N = 2 IV PO 
Dose (mg/kg) 6 30 
t1/2 (min) 19 81.5 ± 7.8 
C0 or Cmax (µg/mL) 124 13.5 ± 0.4 
AUC0–inf (min*µg/mL) 1356 153 ± 189 
Figure 2.7. Concentration-time profiles and measured values for oral and 
intravenous dosing of isoniazid (INH) in rats. 
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The next compound we evaluated was the sulfamide linked analogue (2-6, Figure 2.9). 
As a reminder, this compound was designed to increase the pKa of the nitrogen in the 
linker. It is calculated that compound 2-6 has a pKa of 4.1, compared to 3.0 for Sal-AMS 
(2-1). Sulfamide 2-6 showed a similar half-life (10.6 min), and a 50% increase in Cmax 
(0.61 µg/mL) with a five-fold increase in bioavailability at nearly 6%. This suggests to us 
that an increase in pKa could be a viable modification for improving the oral 
bioavailability of our compounds. 
 
N = 3 IV PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 11.1 ± 2.3 81 
C0 or Cmax (µg/mL) 48.4 ± 12.8 0.42 ± 0.16 
AUC0–240 (min*µg/mL) 427 ± 94 49.7 ± 8.4 
Figure 2.8. Concentration-time profiles and measured values for oral and 
intravenous dosing of Sal-AMS (2-1) in rats. 
Sal-AMS (2-1) IV Sal-AMS (2-1) PO 
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We hypothesized that compound 2-34 could improve the oral bioavailability further, if 
increasing the pKa of the linker nitrogen does impact absorption, however the calculated 
impact of this modification is smaller than the impact of the sulfamide modification (pKa 
increases from 4.1 to 4.2). Using the data shown in Figure 2.10, the oral bioavailability 
of compound 2-34 was calculated at 5.2%, but with a high variability at 4.1%. This 
comes from a larger deviation among the IV doses administered to the animals. This 
value is virtually the same as that seen for compound 2-6. Although we did not see an 
increase in oral bioavailability, we saw a 40% increase in the half-life of this compound 
(14 min vs. 10 min for 2-6). The maximum concentration was also slightly lower than 
that achieved with compound 2-6.  
Cmpd 2-6 IV Cmpd 2-6 IV 
N = 3 IV PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 10.6 ± 0.7 105 ± 17 
C0 or Cmax (µg/mL) 28.8 ± 4.7 0.61 ± 0.06 
AUC0–240 (min*µg/mL) 250 ± 49 67.9 ± 11.9 
Figure 2.9. Concentration-time profiles and measured values for oral and 
intravenous dosing of compound 2-6 in rats. 
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Another modification that we hoped would continue to build on the success from 
compound 2-6 was compound 2-41, incorporating both the sulfamide linker and an 
aliphatic group to increase the pKa of the linker and the lipophilicity of the molecule, 
respectively (Figure 2.11). Compound 2-41 contains an N6-cyclopropyl group that is 
predicted to increase the octanol-water partition coefficient of the molecule slightly 
(ClogP) from 0.29 to 0.31, and the sulfamide linker increasing the pKa of the acidic 
nitrogen that had already displayed increased bioavailability. Unfortunately, the N6-
cyclopropyl addition did not display an additive effect in improving the oral 
bioavailability. The bioavailability actually dropped back to 1.0%, nearly the identical 
level for Sal-AMS. We were encouraged, however, to see that the half-life of compound 
2-41 increased by nearly 50% to 15 minutes. 
N = 3 IV PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 14.0 ± 3.1 273 ± 154 
C0 or Cmax (µg/mL) 7.1 ± 6.0 0.10 ± 0.02 
AUC0–240 (min*µg/mL) 50.2 ± 38.6 10.6 ± 2.1 
Figure 2.10. Concentration-time profiles and measured values for oral and 
intravenous dosing of compound 2-34 in rats. 
Cmpd 2-34 IV Cmpd 2-34 PO 
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The next compound we tested was the N6-cyclopropyl-2-phenyl derivative (2-50). This 
compound was designed to dramatically increase the ClogP, with a calculated value of 
3.80. We first analyzed this change with the same sulfamate linkage as Sal-AMS so it 
was more directly comparable to the parent compound (Figure 2.12). As shown in Table 
2.3, this compound was our worst yet tested, with a bioavailability of 0.3%. It is possible 
that this compound has now become too lipophilic to adequately solubilize in the aqueous 
environment of the gut. We did observe that 2-50 was not soluble in water or the 0.5% 
sodium carboxymethylcellulose solution used in dosing the other compounds. We found 
that a 25% wt/vol solution of hydroxypropyl β-cyclodextrin was required to completely 
solubilize this compound, indicating it had dramatically increased in lipophilicity. 
Cmpd 2-41 IV Cmpd 2-41 PO 
N = 3 IV PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 15.1 ± 1.3 78.2 ± 10.3 
C0 or Cmax (µg/mL) 25.4 ± 6.9 0.14 ± 0.03 
AUC0–240 (min*µg/mL) 209 ± 76 18.1 ± 2.1 
Figure 2.11. Concentration-time profiles and measured values for oral and 
intravenous dosing of compound 2-41 in rats. 
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We also had an anomalous result with one of our animals during this study. One of three 
animals displayed impressive absorption of compound 2-50 with a bioavailability of 88% 
(Figure 2.13). Additional discussion regarding this phenomenon can be found in 
discussion section 2.4.2. 
 
 
Cmpd 2-50 IV Cmpd 2-50 PO 
N = 2 IV PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 15.5 ± 10.6 33.3 
C0 or Cmax (µg/mL) 28.4 ± 9.7 0.111 ± 0.001 
AUC0–240 (min*µg/mL) 184 ± 30 4.0 ± 0.9 
Figure 2.12. Concentration-time profiles and measured values for oral and 
intravenous dosing of compound 2-50 for 2 rats. 
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Finally, we tested the bioavailability of our two acetate prodrug compounds. We analyzed 
our plasma samples for the concentrations of both Sal-AMS and the parent prodrug at 
each time point, expecting that the promoieties would help the compound pass through 
the intestinal wall, and then be quickly cleaved once in the bloodstream. First, the tri-
acetate compound 2-51 was delivered in the same 25% wt/vol hydroxypropyl β-
cyclodextrin solution as used for compound 2-50. Negligible oral bioavailability was 
observed. We were unable to observe any of the parent compound in the plasma samples, 
but were greatly interested in the change in the oral concentration-time profile of Sal-
AMS that we observed when dosing this compound (Figure 2.14). During oral dosing, 
we initially saw a standard absorption followed by elimination of Sal-AMS. After 2 
Cmpd 2-50 PO 
N = 1 PO 
Dose (mg/kg) 25 
t1/2 (min) 118 
C0 or Cmax (µg/mL) 14.8 
AUC0–240 (min*µg/mL) 1361 
Figure 2.13. Single animal anomalous result from 
oral dosing of compound 2-50 in one rat. 
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hours, however, we saw the concentration of Sal-AMS in plasma again begin to increase. 
At the last time point of the study (8 hours) the concentration was still rising, even above 
that of the initial Cmax. 
 
A simple plasma stability time course was run on the prodrug, monitoring the loss of each 
acetate promoiety. As shown in Figure 2.15, the tri-acetate compound is very quickly 
degraded, however the di- and mono-acetate compounds have much longer half lives in 
plasma. We do see a slow increase in Sal-AMS over time, and this slower-than-expected 
prodrug cleavage may be a secondary explanation for the second increase in Sal-AMS 
concentration seen in the later plasma time points in Figure 2.14. See discussion section 
Cmpd 2-51 IV 
(Obs Sal-AMS) 
Cmpd 2-51 PO 
(Obs Sal-AMS) 
N = 3 IV PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 22.4 ± 1.0a n.d.b 
C0 or Cmax (µg/mL) 7.4 ± 0.9 0.032 ± 0.008 
AUC0–240 (min*µg/mL) 173 ± 11 2.9 ± 0.8 
Figure 2.14. Concentration-time profiles and measured values for oral and 
intravenous dosing of the tri-acetyl Sal-AMS prodrug, compound 2-51 in rats. 
aThe t1/2 for Sal-AMS is artificially inflated because it includes the time for 
prodrug absorption and cleavage, meaning it is not a true measure of the half-
life for the compound. bn.d. = not determined. 
  87 
2.4.3 below for more on this phenomenon. 
 
We also performed a pH stability test in simulated gastric fluid (SGF) at pH 1.2. These 
results, shown in Figure 2.16, indicate that the tri-acetate prodrug is also very stable to 
the acidic pH of gastric fluids (83% remaining after 2 h). While some di-acetate and 
mono-acetate were identified by mass spectrometry, we never observed liberation of the 
parent compound Sal-AMS. These results show that the tri-acetate compound is either 
not efficiently absorbed, or was not completely converted to Sal-AMS once absorbed. In 
either case, this makes the stability data in plasma important for understanding the in vivo 
behavior of this compound. 
 
 
 
Figure 2.15. Stability of tri-acetate prodrug compound 2-51 at 10 µM in 
pooled female Sprague-Dawley rat plasma. The tri-acetate compound is very 
quickly degraded in plasma. The di-acetate (22% remaining) and mono-
acetate (73% remaining) compounds are much longer lived, making the 
overall increase in Sal-AMS (2-1, 5% released) slow. 
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Finally, we evaluated the di-acetate prodrug, which has a free phenol hydroxyl. This 
compound was also dosed in the 25% wt/vol hydroxypropyl β-cyclodextrin solution and 
we were unable to observed any compound in the plasma samples from oral dosing. As 
shown in Figure 2.17, we were unable to detect quantifiable levels of either Sal-AMS (2-
1) or compound 2-52 after oral dosing. When looking at the IV dosing data, we were able 
to see both compound 2-52 and 2-1, which were both quickly eliminated. We did see a 
moderate inflation to the t1/2 of Sal-AMS when measured during IV dosing (13 min here 
vs. 11 min when dosed directly), likely due to time required for prodrug cleavage. 
 
 
 
 
 
Figure 2.16. Stability of compound 2-51 at 100 µM in simulated gastric 
fluid (SGF) pH 1.2. The tri-acetate is very stable (83% remaining after 2 h), 
with only small amounts of di-acetate (3.7% after 2 h) and mono-acetate 
(12.3% after 2 h) identified. No Sal-AMS (2-1) was observed during the 
course of the study. 
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The IV data indicates that compound 2-52 remains intact in biological fluids as we were 
able to measure its half-life after IV dosing. The same plasma stability assay was done on 
compound 2-52 and extraordinary stability of the di-acetate compound was observed 
(Figure 2.18). This is especially surprising as the di-acetate degradation product of the 
tri-acetate prodrug degrades into both the mono-acetate compound and eventually the 
parent Sal-AMS (as shown in Figure 2.15). More Sal-AMS was liberated from the di-
acetate prodrug than the tri-acetate prodrug, however the prodrug cleavage is inefficient 
at best. 
 
 
N = 3 IV (Cmpd 2-52) IV (Sal-AMS, 2-1) PO 
Dose (mg/kg) 2.5 25 
t1/2 (min) 19.8 ± 12.0 13.4 ± 2.9 < LQa 
C0 or Cmax (µg/mL) 3.4 ± 0.6 1.4 ± 0.2 < LQ 
AUC0–60 (min*µg/mL) 18.9 ± 2.8 25.8 ± 5.6 < LQ 
Figure 2.17. Concentration-time profiles and measured values for oral and intravenous 
dosing of the di-acetate Sal-AMS prodrug, compound 2-52 in rats. The oral dosing 
samples did not show any quantifiable amounts of compound 2-52 or Sal-AMS (2-1). 
aLQ = limit of quantitation 
Cmpd 2-52 IV Cmpd 2-52 IV 
(Obs Sal-AMS) 
Cmpd 2-52 PO 
(Obs Sal-AMS) 
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The degradation product observed with a mass matching a di-acetate during the plasma 
stability test of the tri-acetate showed the same retention time as synthetic compound 2-
52, suggesting that it is the same compound. Why the synthetic compound would be so 
stable compared to the degradation product from the tri-acetate compound is still under 
investigation. We continued with our analysis of 2-52 by also running it in the same pH 
stability assay in SGF, pH 1.2 (Figure 2.19). Compound 2-52 was stable in the low pH 
solution, suggesting that the parent di-acetate prodrug needs to be absorbed for this 
compound to reach circulation. 
 
 
 
 
 
Figure 2.18. Stability of di-acetate prodrug compound 2-52 at 10 µM in pooled 
female Sprague-Dawley rat plasma. The di-acetate compound (78% remaining) is 
surprisingly stable in plasma. The mono-acetate (9% remaining) very slowly 
appears in plasma, and the overall increase in Sal-AMS (2-1, 11% released) is 
slow. 
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2.4 Discussion 
 
2.4.1 Strategies for increasing oral bioavailability 
 
Orally bioavailable formulations are highly desirable for new therapeutics. As discussed 
in Chapter 1 above, Mtb is highly endemic in areas where healthcare access is limited. In 
such areas, orally bioavailable medications that can be stored and taken in the home are a 
necessity for fidelity to long-term treatment. As no previous animal work had been 
performed in our lab, we sought the council of Dr. Rory Remmel, a collaborator of ours 
and a drug metabolism expert, to advise us on our model development. 
We designed our compounds keeping in mind the guidelines first promoted by Dr. 
Christopher Lipinski in his seminal paper discussing approaches to estimate the solubility 
and permeability of compounds intended for drug development.17 Beginning with 
Figure 2.19. Stability of compound 2-52 at 100 µM in simulated gastric 
fluid (SGF) pH 1.2. The di-acetate is stable to the acidic conditions (93% 
remaining after 2 h), with very little mono-acetate (7% after 2 h) identified. 
No Sal-AMS (2-1) was observed during the course of the study. 
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evaluation of Sal-AMS (2-1), we find that we do not violate any of the four "rule of 5" 
guidelines. We do recognize, however that Sal-AMS is a highly polar compound with a 
linker that will be mostly charged at physiological pH, making membrane permeability 
less likely. Our design goals to lower the charge on the linker group, while bringing the 
ClogP into the 2–5 range would help us remain within the rule of 5 guidelines, but 
improve some of these permeability problems.  
Other recent work regarding properties that can influence oral bioavailability was also 
considered. Not only is high polar surface area known to be detrimental for intestinal 
absorption,34,35 but both molecular flexibility and hydrogen bond formation by amide 
bonds have been indicated as negative for oral absorption.36,37 Analogues that increase 
lipophilicity should address the high polar surface area concerns, and there is only a 
single amide bond in these compounds, so we do not expect high levels of water 
complexation. A recent review from Veber and colleagues also found that rotatable bond 
count was a surprisingly useful correlate to oral bioavailability.38 With seven rotatable 
bonds, we meet the criteria of 10 or fewer put forth by Veber, et. al. as desirable for oral 
bioavailability.38 All of these considerations made us hopeful that we would be able to 
improve the oral bioavailability of Sal-AMS with our current set of analogues.  
 
2.4.2 Anomalous high oral bioavailability of compound 2-50 
 
The animal with abnormally high amounts of compound 2-50 after oral dosing was found 
have an infection associated with its femoral vein catheter. During the study, we noticed 
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the animal appeared to be favoring its left front leg, and to have some swelling in that 
area. The veterinarian staff at the University of Minnesota diagnosed the animal with an 
abscessed infection. Approximately 2 hours into the study, the animal was administered 1 
mg/kg ketoprofen followed by 60,000 IU/kg penicillin intramuscularly. Sulfamethazine 
was added to the drinking water as an added antibacterial for the next 2 days. We do not 
believe that these additional doses of therapeutics affected the absorption or elimination 
of compound 2-50, as the curve in Figure 2.13 shows the compound to be over halfway 
eliminated at the time of administration (2 hours) and continues a monoexponential 
decline. We also continued to observe the animal throughout the remainder of the study 
and the following 2 days and saw normal eating and defecating, indicating normal 
gastrointestinal functions. After the 2 days, we saw that the animal was not improving, so 
it was sacrificed and necropsied by Dr. Krista Walkowiak of the University of Minnesota 
veterinarian staff to determine the cause of the abscess. There was foreign material 
associated with the catheter tubing that was identified by Harlan Laboratories as bedding 
material likely left behind during surgery. During necropsy, we also looked for any open 
sores or cuts in the esophagus or intestinal tract that may have affected absorption, but 
did not observe any abnormalities. 
After discussions with University of Minnesota veterinarians and our collaborator Dr. 
Rory Remmel, we hypothesize that the inflammation, stress and possible sepsis 
experienced by this animal due to the infection may have been able to loosen the 
intestinal tight junctions, thereby allowing for greater drug absorption. There is some 
literature evidence suggesting that stress and inflammation can affect the tight junctions 
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of both the intestine and the colon.39,40 
 
2.4.3 Prodrugs of nucleosides 
 
Natural nucleosides do not efficiently pass through cell membranes by passive diffusion, 
but have both Na+-dependent concentrative transporters and Na+-independent 
equilibrative transporters that facilitate their penetration of the gastrointestinal tract.41 
While this may seem like an exciting pathway for exploiting delivery of therapeutic 
compounds, it has also been shown that nucleoside transporters have low turnover 
capacities. Typical drug concentrations in the intestine would quickly saturate these 
transporters, and their impact on drug absorption can therefore be minimal.41 
Multiple prodrug approaches have been successfully used to deliver nucleoside-based 
therapeutic compounds for the treatment of diseases such as HIV, hepatitis B virus 
(HBV), hepatitis C virus (HCV), and some cancers. Nucleoside analogues also continue 
to be investigated for new therapeutic development. A prodrug is usually a 
pharmacologically inactive analogue of the parent drug that can either spontaneously or 
enzymatically be converted to the active drug once in the body.41 Prodrugs therefore need 
to be sufficiently stable for administration, while labile enough for efficient release once 
absorbed. 
While a prodrug strategy was not originally the focus for this project, it was a suggested 
potential route for increasing lipophilicity while keeping the highly active parent 
compound as the therapeutic agent. The simple acetate prodrug was easily accessible, as 
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described in section 2.3.5, which allowed us to incorporate these candidates into our first 
group of compounds for animal evaluation.  
We hypothesize that the later increase in Sal-AMS appearance observed in Figure 2.14 is 
due to two factors: limited solubility of the prodrug in biological fluids, and the 
inefficient cleavage of the promoieties in vivo. Compounds 2-51 and 2-52 were 
solubilized in 25% wt/vol hydroxypropyl β-cyclodextrin for oral administration, and may 
only be slowly solubilized once in the aqueous gastrointestinal tract for passage through 
the intestinal wall. This could make it appear as if Sal-AMS is slowly being absorbed, 
which occurs when compounds become too water-insoluble, making their bioavailability 
dissolution-rate limited.42 If this were the only factor affecting the absorption of these 
compounds, it may be possible to adjust the solubilizing excipient or mixture to improve 
absorption. A wide variety of excipients, cosolvents, and emulsifying agents are only 
some of the currently approved components used in oral formulations today.43 Additional 
study of both compounds through plasma and pH stability studies, however, have shown 
us that these promoieties are unexpectedly stable. The di-acetate 2-52 shows very little 
apparent degradation after 2 hours in rat plasma at 37 °C (Figure 2.18), and both 
prodrugs are stable to SGF over 2 hours at 37 °C (Figures 2.16 and 2.19). The plasma 
stability data observed for the di-acetate 2-52 was not consisent with that of tri-acetate 2-
51. The rate of cleavage of 2-52 appears to begin with first-order kinetics, then levels off 
at approximately 15–30 minutes. This assay needs to be repeated in order to draw 
conclusions regarding the synthetic di-acetate compound's stability in rat plasma. Without 
efficient cleavage of these promoieties, even a dramatic increase in absorption will not 
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effectively increase the delivery of the active compound. 
 
2.4.4 Trends in oral bioavailability for siderophore inhibitors 
 
Increasing the pKa of the sulfamate linker nitrogen proved the most beneficial 
modification for oral bioavailability, increasing bioavailability from 1.2% to 5.2% and 
5.9% for compounds 2-1, 2-34, and 2-6, respectively. Addition of lipophilic moieties did 
not increase bioavailability, and actually decreased overall absorption. This could be due 
to both the insolubility of our analogues in the aqueous environment of the 
gastrointestinal tract (e.g. compound 2-50), and possibly the lack of recognition of these 
compounds by formerly exploited nucleoside transporters (e.g. compound 2-41). A 
prodrug strategy did not substantially improve the bioavailability of Sal-AMS (2-1), but it 
appears that this may be due to multiple factors that include insolubility of the prodrugs, 
and their surprising stability in plasma. A modified prodrug design that is more readily 
cleaved in plasma and more soluble in biological fluids may help improve these results. 
 
2.5 Conclusions 
 
This project has successfully started the next step for preclinical development of 
siderophore biosynthesis inhibitors for the treatment of Mtb. We synthesized a small set 
of compounds based on enzymatic and whole-cell testing against a target enzyme (MbtA) 
and organism (Mtb). We then started the in vivo evaluation of our compounds in the hope 
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of identifying a candidate compound and determining an acceptable dose to progress into 
an animal efficacy study. Our first set of compounds, while not as successful as we would 
like, has informed us about the structural design of our analogues. It is recognized that 
the pKa of our compounds have the greatest effect on bioavailability, and addition of 
lipophilic groups has not yet resulted in any increased absorption. It is important to 
observe that while we had previously discovered modifications that could be made to 
retain and improve the enzymatic and whole-cell activity of these compounds against 
MbtA and Mtb, these modifications do not necessarily translate into good oral 
bioavailability and pharmacokinetic parameters. Based on what was learned from our 
initial in vitro SAR studies, we are now embarking on in vivo SAR studies, which will 
help use develop the best compound for preclinical development. 
 
2.6 Experimental details 
 
2.6.1 General procedures for the synthesis of siderophore biosynthesis inhibitors 
 
All reactions were performed under an inert atmosphere of dry argon in oven-dried (150 
°C) glassware. 1H and 13C NMR experiments were recorded on a Varian 600 MHz 
spectrometer (Palo Alto, CA). Proton chemical shifts are reported in ppm from an 
internal standard of residual chloroform (7.26 ppm), methanol (3.31 ppm), or dimethyl 
sulfoxide (2.50 ppm). Carbon chemical shifts are reported in ppm from an internal 
standard of residual chloroform (77.0 ppm) or methanol (49.1 ppm). Proton chemical 
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data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad, ovlp = overlapping), coupling constant, and 
integration. High resolution mass spectra were acquired on an Agilent TOF II TOF/MS 
(Agilent Technologies, Santa clara, CA) instrument equipped with either an ESI or APCI 
interface. Semi-preparative reverse-phase HPLC was performed on a Varian Prostar 210 
solvent system equipped with a UV/Vis detector (Varian, Inc., Palo Alto, CA) with a 
Phenomenex Gemini 10 µm C18 110 Å (250 × 10.0 mm) column (Phenomenex, 
Torrance, CA) at a flow rate of 5.0 mL/min with detection at 254 nm; preparative 
reverse-phase HPLC was performed on a Varian Prostar 210 solvent system equipped 
with a UV/Vis detector (Varian, Inc./Agilent Technologies, Santa Clara, CA) with a 
Phenomenex Gemini 10 µm C18 110 Å (250 × 21.2 mm) column (Phenomenex, 
Torrance, CA) at a flow rate of 20 mL/min with detection at 254 nm. Flash 
chromatography was performed on an ISCO Combiflash Companion® purification 
system (Teledyne Isco, Lincoln, NE) with prepacked silica gel cartridges and the 
indicated solvent system.  
All commercial reagents (Sigma-Aldrich, Fisher, Fluka, Strem) were used as provided. 2-
Iodoadenosine was obtained from Tokyo Chemical Industry Co. (Portland, OR, USA). 
Sulfamoyl chloride was prepared by the method of Heacock without recrystallization.44 
An anhydrous solvent dispensing system (JC Meyer Solvent Systems, Laguna Beach, 
CA) with two packed columns of neutral alumina was used for drying THF, DMF and 
DCM and the solvents were dispensed under Argon. 
Compounds: 2-1,4 2-6,4 2-24,45 2-26,4  2-28,47 2-31,14 2-36,22 2-38,47 2-43,27 2-44,23 2-
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47,23 2-49–50,23 and 2-53,4 were prepared as described, and all spectroscopic data agreed 
with reported values. 
 
2.6.2 N6,N6-bis(tert-Butoxycarbonyl)-2ʹ,3ʹ-O-isopropylidene-5ʹ-O-
(sulfamoyl)adenosine (2-25) 
 
A stirring solution of 2-24 (1.5 g, 2.96 mmol, 1 equiv) and Et3N (0.42 mL, 3.01 mmol, 
1.02 equiv) in DMF (7 mL) was cooled to 0 °C. Sulfamoyl chloride (0.854 g, 7.39 mmol, 
2.5 equiv) was added as a solid and the reaction mixture was stirred at 0 °C for 2 h, then 
allowed to warm to 23 °C. After 14 h at 23 °C, the reaction mixture was concentrated to a 
crude oil, then redissolved in EtOAc (50 mL). The organic layer was washed excessively 
with DI H2O (5 × 30 mL), followed by saturated aqueous NaCl (30 mL). The organic 
layer was then dried over MgSO4, filtered, and concentrated under reduced pressure to 
afford the title compound (1.40 g, 80%) as a colorless foamy oil; spectroscopic data 
agrees with literature values.46 
 
2.6.3 N6,N6-bis(tert-Butoxycarbonyl)-2ʹ,3ʹ-O-isopropylidene-5ʹ-O-{N-[2-
(methoxymethoxy)benzoyl]sulfamoyl}adenosine triethylammonium salt (2-27) 
 
To a stirring solution of 2-25 (1.0 g, 1.7 mmol, 1 equiv) in DMF (17 mL) cooled to 0 °C 
was added 2-26 (0.71 g, 2.6 mmol, 1.5 equiv) as a solid followed by Cs2CO3 (1.67 g, 5.1 
mmol, 3.0 equiv). The reaction mixture was allowed to warm to 23 °C and stirred for 16 
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h. The reaction was filtered and concentrated under reduced pressure to a dark oil, and 
purification by flash chromatography (linear gradient 0–6% MeOH/DCM with 1% Et3N) 
afforded the title compound (800 mg, 55%) as a clear oil. Rf = 0.50 (5% MeOH/DCM 
with 1% Et3N); 1H NMR (600 MHz, CD3OD) δ 1.28 (t, J = 7.2 Hz, 9H), 1.37 (s, 3H), 
1.39 (s, 18H), 1.64 (s, 3H), 3.19 (q, J = 7.2 Hz, 6H), 3.44 (s, 3H), 4.36 (dd, J = 11.4, 3.6 
Hz, 1H), 4.40 (dd, J = 11.4, 2.4 Hz, 1H), 4.66 (s, 1H), 5.18 (s, 2H), 5.28 (d, J = 6.0 Hz, 
1H), 5.49 (t, J = 3.0 Hz, 1H), 6.42 (s, 1H), 6.99 (t, J = 7.8 Hz, 1H), 7.14 (d, J = 8.4 Hz, 
1H), 7.29 (t, J = 7.8 Hz, 1H), 7.45 (d, J = 7.2 Hz, 1H), 8.85 (s, 1H), 8.91 (s, 1H); 13C 
NMR (150 MHz, CD3OD) δ 9.4, 25.7, 27.7, 28.1, 48.0, 53.7, 56.8, 69.9, 83.6, 85.5, 85.8, 
86.0, 92.5, 96.5, 115.5, 117.1, 122.7, 129.9, 130.5, 131.2, 146.9, 151.2, 151.7, 153.3, 
154.7, 155.8; HRMS (ESI–): calculated for C32H41N6O13S [M – H]– 749.2458, found 
749.2482 (3.2 ppm error). 
 
2.6.4 N6,N6-bis(tert-Butoxycarbonyl)-5ʹ-{N-[(tert-butoxycarbonyl)sulfamoyl]amino}-
5ʹ-deoxy-2ʹ, 3ʹ-O-isopropylideneadenosine (2-29) 
 
To a stirring solution of 2-24 (0.60 g, 1.2 mmol, 1.0 equiv), 2-28 (0.255 g, 1.3 mmol, 1.1 
equiv), and Ph3P (0.341 g, 1.3 mmol, 1.1 equiv) in THF (30.75 mL) cooled to 0 °C was 
added DIAD (0.25 mL, 1.3 mmol, 1.1 equiv) as a solution in THF (10.25 mL) by syringe 
pump over 90 min. After complete addition, the reaction mixture was allowed to warm to 
23 °C and continued to stir. After 16 h, the mixture was concentrated under reduced 
pressure to a dark yellow oil and immediately purified by flash chromatography (linear 
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gradient 0–100% EtOAc/hexanes) to give the title compound as a foamy oil (0.789 g, 
96%). Rf = 0.25 (1:1 EtOAc/hexanes); 1H NMR (600 MHz, CDCl3) δ 1.43 (s, 21H), 1.49 
(s, 9H), 1.60 (s, 3H), 3.98 (dd, J = 14.4, 6.6 Hz, 1H), 4.04 (dd, J = 15.6, 6.0 Hz, 1H), 4.39 
(q, J = 6.0 Hz, 1H), 5.18 (t, J = 6.0 Hz, 1H), 5.38 (d, J = 6.6 Hz, 1H), 6.19 (d, J = 1.2 Hz, 
1H), 8.20 (s, 1H), 8.85 (s, 1H); 13C NMR (150 MHz, CDCl3) δ 25.6, 27.4, 27.9, 28.2, 
48.4, 82.1, 84.1, 84.5, 85.0, 85.4, 90.0, 115.3, 129.6, 144.2, 150.5, 150.8, 151.7, 152.3, 
152.6; HRMS (ESI–): calculated for C28H42N7O11S [M – H]– 684.2668, found: 684.2685 
(2.5 ppm error). 
 
2.6.5 N6,N6-bis(tert-Butoxycarbonyl)-5ʹ-(N-tert-butoxycarbonyl-N-{[(2-
methoxymethoxy)benzoyl]sulfamoyl})amino-5ʹ-deoxy-2ʹ,3ʹ-O-
isopropylideneadenosine triethylammonium salt (2-30) 
 
To a stirring solution of 2-29 (0.52 g, 0.75 mmol, 1.0 equiv) in DMF (7.5 mL) cooled to 0 
°C was added Cs2CO3 (0.74 g, 2.25 mmol, 3.0 equiv) followed by 2-26 (0.32 g, 1.13 
mmol, 1.5 equiv). The reaction mixture was allowed to stir at 0 °C for 30 min, then 
stirred at 23 °C for 20 h. The reaction mixture was then filtered and concentrated under 
reduced pressure to a yellow-orange oil that was purified by flash chromatography (linear 
gradient 0–10% MeOH/DCM with 1% Et3N) to give the title compound (0.38 g, 53%) as 
an off-white solid. Rf = 0.37 (10% MeOH/DCM with 1% Et3N); 1H NMR (600 MHz, 
CDCl3) δ 1.14 (t, J = 7.2 Hz, 9H), 1.37 (s, 9H), 1.39–1.41 (m, 21H), 1.64 (s, 3H), 3.47 (s, 
3H), 3.57 (q, J = 7.2 Hz, 6H), 4.22 (d, J = 6.0 Hz, 2H), 4.64 (td, J = 6.0, 2.4 Hz, 1H), 
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5.15 (s, 2H), 5.21 (dd, J = 6.0, 3.6 Hz, 1H), 5.24 (d, J = 7.8 Hz, 1H), 6.30 (s, 1H), 6.95 (t, 
J = 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 7.21 (t, J = 7.8 Hz, 1H), 7.54 (d, J = 7.8 Hz, 
1H), 8.69 (s, 1H), 8.87 (s, 1H); 13C NMR (150 MHz, CDCl3) δ 7.9, 25.5, 27.4, 28.0, 46.1, 
52.8, 56.3, 81.4, 82.3, 83.7, 84.5, 85.0, 90.3, 96.5, 114.3, 118.0, 121.9, 129.0, 129.8, 
131.3, 144.0, 150.0, 150.3, 151.6, 152.2, 152.5, 153.0, 154.5; HRMS (ESI–): calculated 
for C37H50N7O14S [M – H]– 848.3142, found 848.3146 (0.5 ppm error). 
 
2.6.6 N6,N6-bis(tert-Butoxycarbonyl)-5ʹ-(N-tert-butoxycarbonyl-N-{N-[(4-
benzyloxycarboxyamino-2-hydroxy)benzoyl]sulfamoyl})amino-5ʹ-deoxy-2ʹ,3ʹ-O-
isopropylideneadenosine triethylammonium salt (2-33) 
 
To a stirring solution of 2-31 (0.75g, 2.62 mmol, 3 equiv) in DMF (4.4 mL) was added 
CDI (0.51 g, 3.15 mmol, 3.6 equiv) and the mixture heated to 60 °C for 2 h. The reaction 
mixture was cooled to 23 °C, and 2-36 (0.60 g, 0.87 mmol, 1.0 equiv) was added as a 
solution in DMF (4.4 mL) followed by solid Cs2CO3 (0.43 g, 1.31 mmol, 1.5 equiv), and 
stirred for 15 h. The crude reaction mixture was concentrated under reduced pressure to a 
dark oil and purified by flash chromatography (linear gradient 0–5% MeOH/DCM with 
1% Et3N) to give the title compound as a waxy light yellow solid (0.46 g, 50%). Rf = 0.61 
(10% MeOH/DCM with 1% Et3N); 1H NMR (600 MHz, CD3OD) δ 1.09 (t, J = 7.2 Hz, 
9H), 1.36 (s, 9H), 1.38 (s, 18H), 1.40 (s, 3H), 1.61 (s, 3H), 2.67 (q, J = 7.2 Hz, 6H), 4.05 
(dd, J = 15.0, 6.6 Hz, 1H), 4.18 (dd, J = 15.0, 7.2 Hz, 1H), 4.63 (td, J = 7.2, 3.0 Hz, 1H), 
5.17 (s, 2H), 5.27 (dd, J = 5.4, 3.0 Hz, 1H), 5.57 (dd, J = 6.0, 3.0 Hz, 1H), 6.33 (d, J = 2.4 
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Hz, 1H), 6.82 (d, J = 9.0 Hz, 1H), 7.06 (s, 1H), 7.30 (d, J = 7.2 Hz, 1H), 7.36 (t, J = 7.8 
Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 8.74 (s, 1H), 8.89 (s, 1H); 13C 
NMR (150 MHz, CD3OD) δ 10.9, 25.7, 27.7, 28.2, 28.5, 47.3, 53.8, 67.7, 83.8, 84.0, 
85.4, 87.3, 92.1, 106.8, 109.9, 115.5, 116.0, 129.1, 129.3, 129.7, 130.7, 131.9, 134.6, 
138.1, 145.0, 147.3, 151.2, 151.6, 153.3, 154.4, 154.5, 155.4, 162.4, 173.6; HRMS (ESI–
): calculated for C43H53N8O15S [M – H]– 953.3357, found 953.3328 (3.0 ppm error). 
 
2.6.7 5ʹ-Deoxy-5ʹ-({N-[(2-hydroxy-4-amino)benzoyl]sulfamoyl}amino)adenosine (2-
34) 
 
To a Parr flask purged with Ar was added Pd/C (0.05 g, 0.47 mmol, 10% by weight), 
followed by 2-33 (0.50 g, 0.52 mmol, 1 equiv) dissolved in anhydrous MeOH (5.2 mL). 
The flask was evacuated and back-filled with H2 five times before filling the flask to 40 
psi H2 and shaking on a Parr shaker at 23 °C. After 1 h, reaction was filtered over a pad 
of celite and concentrated under reduced pressure to a clear oil that was used directly. 
To a flask containing the crude reaction mixture from above chilled to 0 °C was added 
80% aqueous TFA (5.2 mL) that had also been chilled to 0 °C. The reaction was stirred 
for 1 h at 0 °C, 12 h at 4 °C, and 5 h at 23 °C. The reaction was concentrated under 
reduced pressure to remove all traces of TFA. Purification by preparative reverse-phase 
HPLC on a Phenomenex Gemini 10 μm C18 110 Å (250 × 21.2 mm) column was done at 
a flow rate of 20 mL/min with a gradient of 5–25% MeCN in 10 mM aqueous 
triethylammonium bicarbonate over 10 min, followed by 25% MeCN for 5 min. The 
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retention time of the product was 9.0 minutes (k′ = 2.0) and the appropriate fractions were 
pooled and lyophilized to afford the title compound (90 mg, 34%) as a white solid. 1H 
NMR (600 MHz, CD3OD) δ 1.20 (t, J = 7.2 Hz, 9H), 2.95 (q, J = 7.2 Hz, 6H), 3.29–3.31 
(m, 2H), 4.23 (dd, J = 6.6, 4.2 Hz, 1H), 4.35 (dd, J = 5.4, 3.0 Hz, 1H), 4.85–4.86 (m, 1H), 
5.93 (d, J = 6.6 Hz, 1H), 6.05 (s, 1H), 6.12 (d, J = 9.0 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 
8.30 (s, 1H), 8.31 (s, 1H); 13C NMR (150 MHz, CD3OD) δ 10.1, 46.6, 47.7, 73.2, 75.0, 
86.1, 90.6, 101.9, 107.4, 110.9, 120.9, 132.4, 142.0, 150.7, 154.3, 154.6, 157.5, 163.7, 
175.0; HRMS (ESI−): calculated for C 17H19N8O7S [M − H] − 479.1103, found 479.1095 
(1.7 ppm error). 
 
2.6.8 5ʹ-Amino-N6-cyclopropyl-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylideneadenosine (2-37) 
 
DIAD (3.4 mL, 17.3 mmol, 1.5 equiv) was dissolved in THF (284 mL) that had been 
cooled to 0 °C. Ph3P (4.5 g, 17.3 mmol, 1.5 equiv) was added as a solution in THF (61 
mL), and the solution stirred at 0 °C for 15 min. Compound 2-43 (4.0 g, 11.5 mmol, 1.0 
equiv) was added as a solution in THF (61 mL), and the solution stirred at 0 °C for 15 
min. DPPA (4.96 mL, 23.0 mmol, 2.0 equiv) was added directly and the solution allowed 
to stir at 0 °C for 15 min then at 23 °C for 4.5 h. The reaction was quenched with distilled 
H2O (200 mL). The mixture was extracted with CH2Cl2 (3 × 200 mL), and the combined 
organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure 
to a clear oil that was dried under high vacuum for at least 4 h before being used directly 
in the next step. 
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To a Parr flask purged with Ar was added Pd/C (0.185 g, 1.73 mmol, 10% by weight, 
added in 2 portions), followed by half the crude reaction mixture from above dissolved in 
anhydrous MeOH (49.5 mL). The flask was evacuated and back-filled with H2 5 times 
before filling the flask to 30 psi H2 and shaking on a Parr shaker at 23 °C. After 1.75 h, 
the reaction was filtered over a pad of celite, concentrated under reduced pressure to a 
dark oil, and purified by flash chromatography (linear gradient 0–10% MeOH/DCM). 
The same procedure was repeated with the second half of the crude reaction mixture to 
give the title compound as a foamy oil (0.76 g, 44% over 2 steps). Rf = 0.05 (10% 
MeOH/DCM); 1H NMR (600 MHz, CD3OD) δ 0.61–0.64 (m, 2H), 0.85–0.88 (m, 2H), 
1.35 (s, 3H), 1.57 (s, 3H), 2.92 (d, J = 5.4 Hz, 2H), 3.35 (s, 1H), 4.21–4.24 (m, 1H), 5.01 
(dd, J = 6.6, 3.6 Hz, 1H), 5.46 (dd, J = 6.6, 3.0 Hz, 1H), 6.13 (d, J = 3.0 Hz, 1H), 8.21 (s, 
1H), 8.28 (s, 1H); 13C NMR (150 MHz, CD3OD) δ 7.7, 25.7, 27.7, 44.6, 55.0, 83.3, 85.0, 
88.3, 91.70, 91.71, 115.7, 121.4, 141.7, 154.0, 157.2; HRMS (ESI+): calculated for 
C16H23N6O3 [M + H]+ 347.1826, found 347.1821 (1.4 ppm error). 
 
2.6.9 N6-Cyclopropyl-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylidene-5ʹ- 
[(sulfamoyl)amino]adenosine (2-39) 
 
To a stirring solution of 2-37 (0.5 g, 1.44 mmol, 1.0 equiv) in CH2Cl2 (20.6 mL) was 
added 2-38 (0.63 g, 1.88 mmol, 1.3 equiv) and the mixture stirred at 23 °C for 14 h. The 
crude reaction was concentrated under reduced pressure to a foamy oil that was used 
directly in the next step. 
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To a Parr flask purged with Ar was added Pd/C (0.075 g, 0.7 mmol, 10% by weight), 
followed by the crude reaction mixture from above dissolved in anhydrous MeOH/THF 
(10 mL/5 mL). The flask was evacuated and back-filled with H2 five times before filling 
the flask to 30 psi H2 and shaking on a Parr shaker at 23 °C for 22 h. The reaction was 
filtered over a pad of celite, concentrated under reduced pressure to a clear oil, and 
purified by flash chromatography (linear gradient 0–10% MeOH/DCM) to give the title 
compound as a clear foamy oil (0.35 g, 62% over 2 steps). Rf = 0.13 (10% MeOH/DCM); 
1H NMR (600 MHz, CD3OD) δ 0.63 (dd, J = 8.4, 4.2 Hz, 2H), 0.87 (dd, J = 7.2, 4.8 Hz, 
2H), 1.34 (s, 3H), 1.59 (s, 3H), 3.35–3.36 (m, 1H), 3.37–3.41 (m, 2H), 4.46 (d, J = 2.4 
Hz, 1H), 5.09 (dd, J = 6.0, 2.4 Hz, 1H), 5.31 (dd, J = 6.0, 4.2 Hz, 1H), 6.02 (d, J = 4.2 
Hz, 1H), 8.15 (s, 1H), 8.34 (s, 1H); 13C NMR (150 MHz, CD3OD) δ 7.7, 25.7, 27.8, 46.1, 
50.0, 83.2, 84.5, 85.3, 93.1, 115.8, 121.5, 141.8, 154.1, 157.3; HRMS (ESI–): calculated 
for C16H22N7O5S [M – H]– 424.1409, found 424.1415 (1.4 ppm error). 
 
2.6.10 N6-Cyclopropyl-5ʹ-deoxy-2ʹ,3ʹ-O-isopropylidene-5ʹ-({N-[(2-
methoxymethoxy)benzoyl]sulfamoyl}amino)adenosine triethylammonium salt (2-40) 
 
To a stirring solution of 2-39 (0.2 g, 0.47 mmol, 1.0 equiv) in DMF at 0 °C was added 2-
26 (0.20 g, 0.71 mmol, 1.5 equiv) followed by Cs2CO3 (0.46 g, 1.41 mmol, 3 equiv). The 
mixture was stirred at 0 °C for 30 min, then warmed to 23 °C and stirred for 12.5 h. The 
crude reaction was concentrated under reduced pressure to a brown oil and purified by 
flash chromatography (linear gradient 0–10% MeOH/EtOAc with 1% Et3N) to give the 
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title compound as a 1:1 mixture with 2-26 that was taken on directly to the next step. 
 
2.6.11 5ʹ-N-[N-(2-Hydroxybenzoyl)sulfamoylamino]-N6-cyclopropyl-5ʹ-
deoxyadenosine triethylammonium salt (2-41) 
 
To a flask containing 2-40 (0.13 g, 0.19 mmol, 1.0 equiv) cooled to 0 °C was added 80% 
aqueous TFA (2.0 mL) that had also been chilled to 0 °C. After 30 min at 0 °C, the 
reaction was concentrated under reduced pressure to remove all traces of TFA. 
Purification by preparative reverse-phase HPLC on a Phenomenex Gemini 10 μm C18 
110 Å (250 × 21.2 mm) column at a flow rate of 20 mL/min isocractic at 22% MeCN in 
10 mM aqueous triethylammonium bicarbonate for 10 min, followed by washing the 
column with 90% MeCN for 5 min prior to re-equilibration. The retention time of the 
product was 7.2 minutes (k′ = 1.4) and the appropriate fractions were pooled and 
lyophilized to afford the title compound (70.2 mg, 61%) as a white solid. 1H NMR (600 
MHz, CD3OD) δ 0.63-0.66 (m, 2H), 0.87-0.90 (m, 2H), 1.12 (t, J = 7.8 Hz, 9H), 2.65 (s, 
1H), 2.77 (q, J = 7.2 Hz, 6H), 3.33 (d, J = 4.2 Hz, 2H), 4.25 (q, J = 4.2 Hz, 1H), 4.37 (q, 
J = 3.0 Hz, 1H), 4.87 (solvent ovlp, 1H), 5.93 (d, J = 6.6 Hz, 1H), 6.75–6.79 (m, 2H), 
7.26 (t, J = 7.8 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 8.24 (s, 1H), 8.40 (s, 1H); 13C NMR 
(176 MHz, CD3OD) δ 7.7, 10.5, 40.6, 46.7, 47.4, 73.2, 74.9, 86.0, 90.8, 118.0, 119.2, 
121.2, 121.5, 131.0, 134.0, 141.8, 154.2, 157.3, 162.1, 174.3; HRMS (ESI–): calculated 
for C20H22N7O7S [M – H]– 504.1307, found 504.1313 (1.1 ppm error). 
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2.6.12 N6-Cyclopropyl-2ʹ,3ʹ-O-isopropylidene-2-phenyl-5ʹ-O-(sulfamoyl)adenosine 
(2-48) 
 
To a stirring solution of 2-47 (0.1 g, 0.24 mmol, 1.0 equiv) in DMF (1.0 mL) cooled to 0 
°C was added Et3N (0.3 mL, 0.24 mmol, 1.02 equiv) and solid sulfamoyl chloride (0.07 
g, 0.59 mmol, 2.5 equiv) and the reaction allowed to stir at 0 °C for 1 h, then stirred for 
an additional 15 h at 23 °C. The reaction mixture was concentrated under reduced 
pressure to an opaque solid before diluting into EtOAc (30 mL). The organic layer was 
washed with deionized H2O (3 × 30 mL) followed by saturated aqueous NaCl (30 mL). 
The organic layer was dried over MgSO4, filtered, and concentrated under reduced 
pressure to a foamy white solid (0.95 g, 80%): all spectroscopic data agrees with 
literature values.23 
 
2.6.13 2ʹ,3ʹ-O-di-Acetyl-5ʹ-O-{N-[(2-acetyloxy)benzoyl]sulfamoyl}adenosine 
triethylammonium salt (2-51) 
 
To a stirring solution of 2-1 (0.1 g, 0.18 mmol, 1.0 equiv) in DMF was added pyridine 
(0.05 mL, 0.68 mmol, 3.8 equiv) followed by acetic anhydride (0.11 mL, 1.13 mmol, 6.4 
equiv) and the mixture allowed to stir at 23 °C for 21 h. The crude reaction mixture was 
concentrated under reduced pressure to a yellow oil and purified by flash chromatography 
(linear gradient 0–5% MeOH/DCM with 1% Et3N) to afford an approximately 5:1 
mixture of 2-51 and 2-52. 2-51 was purified by semi-preparative reverse-phase HPLC on 
  109 
a Phenomenex Gemini 10 μm C18 110 Å (250 × 10.0 mm) column at a flow rate of 5 
mL/min with a linear gradient 20-70% MeCN in 10 mM aqueous triethylammonium 
bicarbonate for 10 min, followed by 70% MeCN for 5 min. The retention time of the 
product was 6.6 minutes (k′ = 1.6) and the appropriate fractions were pooled and 
lyophilized to afford the title compound (57.8 mg, 46%) as a white solid. Rf = 0.25 (10% 
MeOH/DCM with 1% Et3N); 1H NMR (600 MHz, CD3OD) δ 1.27 (q, J = 7.2 Hz, 9H), 
2.00 (s, 3H), 2.13 (s, 3H), 2.26 (s, 3H), 3.17 (t, J = 6.0 Hz, 6H), 4.40 (dd, J = 14.4, 3.6 
Hz, 1H), 4.44 (dd, J = 9.6, 3.0 Hz, 1H), 4.54 (d, J = 3.0 Hz, 1H), 5.70–5.71 (m, 1H), 5.89 
(t, J = 6.0 Hz, 1H), 6.29 (d, J = 6.0 Hz, 1H), 7.02 (d, J = 7.8 Hz, 1H), 7.23 (t, J = 7.8 Hz, 
1H), 7.41 (t, J = 7.2 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 8.19 (s, 1H), 8.59 (s, 1H); 13C 
NMR (150 MHz, CD3OD) δ 9.4, 20.3, 20.6, 21.4, 48.0, 69.1, 73.2, 75.3, 82.9, 87.0, 
120.2, 124.1, 126.7, 131.9, 132.2, 133.1, 141.3, 150.8, 150.9, 154.2, 157.2, 171.0, 171.5, 
172.0, 173.8; HRMS (ESI–): calculated for C23H23N6O11S [M – H]– 591.1151, found 
591.1170 (3.2 ppm error). 
 
2.6.14 5ʹ-O-[N-(2-Benzyloxybenzoyl)sulfamoyl]-N6, N6-bis(tert-butoxycarbonyl)-2ʹ, 
3ʹ-O-isopropylideneadenosine triethyammonium salt (2-54) 
 
To a stirring solution of 2-25 (0.54 g, 0.92 mmol, 1.0 equiv) in DMF (9.2 mL) cooled to 0 
°C was added 2-53 (0.45 g, 1.38 mmol, 1.5 equiv) followed by Cs2CO3 (0.60 g, 1.84 
mmol, 2.0 equiv) and the mixture was stirred at 23 °C for 21 h. The crude reaction 
mixture was concentrated under reduced pressure to a yellow oil that was taken up in 
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EtOAc (200 mL) and filtered. The precipitate was washed with additional EtOAc (200 
mL), and the combined filtrate was concentrated under reduced pressure and purified by 
flash chromatography (linear gradient 0–5% MeOH/EtOAc with 1% Et3N) to give the 
title compound as a white foamy oil (0.51 g, 62%). Rf = 0.37 (10% MeOH/EtOAc with 
1% Et3N); 1H NMR (600 MHz, CD3OD) δ 1.13 (t, J = 7.2 Hz, 9H), 1.35 (s, 3H), 1.40 (s, 
18H), 1.61 (s, 3H), 2.83 (q, J = 7.2 Hz, 6H), 4.19–4.20 (m, 2H), 4.41 (dd, J = 6.0, 3.6 Hz, 
1H), 5.12–5.13 (m, 3H), 5.38 (dd, J = 6.0, 3.6 Hz, 1H), 6.37 (d, J = 3.0 Hz, 1H), 6.95 (t, J 
= 7.8 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 7.25 (t, J = 7.8 Hz, 1H), 7.31–7.34 (m, 3H), 7.46 
(d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.2 Hz, 2H), 8.84 (s, 1H), 8.89 (s, 1H); 13C NMR (150 
MHz, CD3OD) δ 10.2, 25.7, 27.8, 28.2, 47.4, 69.8, 71.6, 83.1, 85.4, 86.0, 86.2, 92.5, 
115.3, 121.3, 121.9, 128.9, 129.2, 129.3, 129.6, 129.9, 130.3, 131.7, 131.9, 138.7, 146.8, 
151.2, 151.7, 153.3, 154.6, 157.2, 176.9; HRMS (ESI–): calculated for C37H43N6O12S [M 
– H]– 795.2665, found 795.2659 (0.8 ppm error). 
 
2.6.15 2ʹ,3ʹ-O-di-Acetyl-5ʹ-O-[N-(2-hydroxybenzoyl)sulfamoyl]adenosine 
triethylammonium salt (2-52) 
 
To a flask containing 2-54 (0.51 g, 0.56 mmol, 1.0 equiv) chilled to 0 °C was added 80% 
aqueous TFA (6 mL) that had also been chilled to 0 °C and the mixture stirred at 0 °C for 
1 h then at 23 °C for 3 h. The reaction mixture was concentrated under reduced pressure 
to a yellow oil and dried under high vacuum to remove all traces of TFA, then dissolved 
as a stirring solution in dry DMF (6.1 mL) to which was added pyridine (0.17 mL, 2.1 
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mmol, 3.8 equiv) followed by acetic anhydride (0.33 mL, 3.5 mmol, 6.4 equiv) and the 
mixture stirred at 23 °C for 16 h. The reaction was concentrated under reduced pressure 
to remove all traces of DMF before being used directly in the next step. 
To a round-bottomed flask containing the crude product from above (0.25 g, 0.33 mmol, 
1.0 equiv) purged with argon was added anhydrous MeOH (3.4 mL) followed by Pd/C 
(0.03 g, 0.28 mmol, 10% by weight) and the flask evacuated by house vacuum and back-
filled with an H2 balloon 3 times before being allowed to stir vigorously under an H2 
balloon at 23 °C for 2 h. The crude reaction mixture was filtered over a pad of celite and 
concentrated under reduced pressure to a dark oil. Purification by semi-preparative 
reverse-phase HPLC on a Phenomenex Gemini 10 μm C18 110 Å (250 × 10.0 mm) 
column at a flow rate of 5 mL/min isocratic at 35% MeCN in 10 mM aqueous 
triethylammonium bicarbonate for 10 min, followed by 70% MeCN for 5 min. The 
retention time of the product was 5.4 minutes (k′ = 1.2) and the appropriate fractions were 
pooled and lyophilized to afford the title compound (90.0 mg, 42%) as a white solid. Rf = 
0.18 (10% MeOH/DCM with 1% Et3N); 1H NMR (600 MHz, CD3OD) δ 1.23 (t, J = 7.2 
Hz, 9H), 2.00 (s, 3H), 2.10 (s, 3H), 3.03 (q, J = 7.2 Hz, 6H), 4.44 (dd, J = 12.0, 3.0 Hz, 
1H), 4.47 (dd, J = 11.4, 3.6 Hz, 1H), 4.53 (q, J = 3.6 Hz, 1H), 5.70 (dd, J = 5.4, 3.6 Hz, 
1H), 5.89 (t, J = 6.0 Hz, 1H), 6.27 (d, J = 6.6 Hz, 1H), 6.75–6.79 (m, 2H), 7.28 (t, J = 7.2 
Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 8.18 (s, 1H), 8.56 (s, 1H); 1H NMR (600 MHz, 
DMSO-d6) δ 1.17 (t, J = 7.2 Hz, 9H), 1.99 (s, 3H), 2.10 (s, 3H), 3.09 (q, J = 7.2 Hz, 6H), 
4.25 (dd, J = 11.4, 4.8 Hz, 1H), 4.33 (dd, J = 11.4, 4.2 Hz, 1H), 4.44 (q, J = 4.2 Hz, 1H), 
5.56 (dd, J = 5.4, 4.2 Hz, 1H), 5.90 (t, J = 6.0 Hz, 1H), 6.20 (d, J = 6.0 Hz, 1H), 6.72–
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6.75 (m, 2H), 7.26 (t, J = 7.2 Hz, 1H), 7.36 (br s, 2H), 7.81 (d, J = 7.8 Hz, 1H), 8.14 (s, 
1H), 8.46 (s, 1H), 13.5 (s, 1H); 13C NMR (150 MHz, CD3OD) δ 9.9, 20.3, 20.6, 47.8, 
69.1, 73.0, 75.3, 82.7, 87.1, 118.0, 119.4, 120.2, 120.7, 131.6, 134.5, 141.3, 150.8, 154.2, 
157.5, 162.3, 171.0, 171.5, 175.3; HRMS (ESI–): calculated for C21H21N6O10S [M – H]– 
549.1045, found 549.1048 (0.5 ppm error). 
 
2.6.16 Procedures for the measurement of oral bioavailability of siderophore 
inhibitors in Sprague-Dawley rats 
 
Sprague-Dawley rats (female, 250–274 g, Harlan Laboratories, Inc. Indianapolis, IN), 
were obtained with surgically implanted in-dwelling dual jugular vein/femoral vein 
catheters for compound infusion and blood withdrawal, respectively. Catheters were 
maintained by following the Harlan Surgically Modified Animal Models: Catheter 
Maintenance Recommendations provided by Harlan Laboratories. All animal care, 
housing, and laboratory procedures were approved by the University of Minnesota 
Institutional Animal Care and Use Committee (IACUC) prior to these investigations 
(IACUC #1208A18543). The animal care and housing was maintained by University of 
Minnesota Research Animal Resources (RAR) and veterinarian staff. Rats were allowed 
to acclimate for 7 days prior to participation in a study to ensure proper patency of the 
catheter lines as well as to observe that there were no adverse effects on the animals due 
to surgery or shipping. Oral doses of investigational compounds (25 mg/kg) were 
suspended in either 0.5% sodium carboxymethylcelluose (Aldrich, St. Louis, MO; 
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compounds 2-1, 2-6, 2-34, and 2-41) or dissolved in 25% wt/vol hydroxypropyl β-
cyclodextrin (Cargill, Inc. Cedar Rapids, IA; 2-50, 2-51, and 2-52) in sterile water as 
solubility allowed. Animals were sampled in triplicate and initially dosed via oral gavage 
with a ball-tipped feeding needle inserted through the mouth and esophagus with a 10 
mg/mL solution of compound. The rats were restrained by holding them with 2 fingers 
over their shoulders with the thumb wrapped around underneath their shoulders to tilt 
their head up, and solution dispensed over 15–20 seconds. Rats were returned to their 
cages after drug administration with access to food and water ad libitum, and blood was 
removed in 0.25 mL aliquots from the left femoral vein catheter via tuberculin syringe 
with a sterile 22 gauge blunted needle (SAI Infusions, Inc. Lake Villa, IL) at the 
following time points: 0, 15, 30, 45, 60, 120, 240, and 480 min. Blood was immediately 
injected into a 2 mL vacutainer (Becton Dickinson, Franklin Lakes, NJ) containing 3.6 
mg K2 EDTA. Subsequently, blood was centrifuged at 2,000 × g in a microcentrifuge 
(Eppendorf, Enfield, CT) to separate the plasma from the hematocrit. Plasma was 
separated into two 50 µL aliquots that were immediately chilled on ice and transferred to 
-80 °C within 2 h. 
Rats were given a 3 day period to wash any remaining compound from their system. 
Intravenous doses of investigational compounds (2.5 mg/kg) were prepared in either 
0.05% sodium carboxymethylcellulose (Aldrich, St. Louis, MO; 2-1, 2-6, 2-34, and 2-41) 
or 25% wt/vol hydroxypropyl β-cyclodextrin (Cargill, Inc. Cedar Rapids, IA; 2-50, 2-51, 
and 2-52) in sterile water as solubility allowed. The same triplicate set was then dosed via 
infusion in the right jugular vein catheter over 5 seconds via a tuberculin syringe with a 
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sterile 22 gauge blunted needle (SAI Infusions, Inc). Rats were returned to their cages 
after drug administration with access to food and water ad libitum, and 0.25 mL aliquots 
of blood were removed from the left femoral vein catheter via tuberculin syringe with a 
sterile 22 gauge blunted needle (SAI Infusions, Inc. Lake Villa, IL) at the following time 
points: 0, 5, 10, 15, 30, 45, 60, 120, 240, and 480 min. Blood was immediately injected 
into a 2 mL vacutainer (Becton Dickinson, Franklin Lakes, NJ) containing 3.6 mg K2 
EDTA and then transferred to a microcentrifuge tube. Subsequently, blood was 
centrifuged at 2,000 × g in a microcentrifuge (Eppendorf, Enfield, CT) to separate the 
plasma from the hematocrit. Plasma was separated into two 50 µL aliquots that were 
immediately chilled on ice and transferred to -80 °C within 2 h. 
All plasma samples were analyzed by LC‒MS/MS by Dr. Benjamin Duckworth of the 
Center for Drug Design, University of Minnesota. 
Instrumentation 
LC‒MS/MS analysis was performed using a Agilent (Santa Clara, CA) 1260 Infinity 
gradient solvent delivery system, an Agilent 1260 Infinity HiP ALS autosampler, an 
Agilent 1260 column oven, and an AB SCIEX QTRAP 5500 (Framingham, MA) mass 
spectrometer fitted with an electrospray ionization source. The instruments were run 
using Analyst Software (version 1.5.2, AB SCIEX).  
Chromatography 
Reverse-phase HPLC analysis was performed by gradient HPLC on a Kinetix C18 
column (50 mm × 2.1 mm, 2.6 µm particle size; Phenomenex, Torrance, CA) for Sal-
AMS derivatives and a Synergy Hydro RP (250 mm × 2.0 mm, 4 µm particle size; 
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Phenomenex) for isoniazid. Mobile phase A was 0.1% aqueous formic acid while mobile 
phase B was 0.1% formic acid in acetonitrile. Initial conditions were 5% B from 0 to 0.5 
min, after which the %B was increased to 95% from 0.5 to 1 min. The column was 
washed in 95% B for 3 min, returned to 5% over 0.2 min, and allowed to re-equilibrate 
for 3.8 min in 5% B to provide a total run time of 8 min. The flow rate was 0.5 mL/min 
and the column oven was maintained at 40 °C. The injection volume was 10 µL.  
Mass spectrometry 
All analytes were analyzed in positive ionization mode by Multiple Reaction Monitoring 
(MRM) with the following mass spectrometry settings: entrance potential = 10 V; curtain 
gas = 40 psi; collision gas = medium; ionspray voltage = 5500 V; temperature = 600 °C; 
ion source gas 1 = 45 psi; ion source gas 2 = 40 psi. Nitrogen was used for the nebuliser 
and collision gas. To determine the optimum MRM settings (Table 1), each analyte was 
infused at a concentration of 10 µM (in 1:1 water:acetonitrile containing 0.1% formic 
acid) onto the MS by a syringe pump at a flow of 10 µL/min. 
Compound Parent Ion (m/z) 
Fragment 
Ion (m/z) 
Declustering 
Potential (V) 
Collision 
Energy (V) 
Collision Cell Exit 
Potential (V) 
INH 138.0 177.2 40 19 24 
Nicotinamide 123.0 106.1 40 21 14 
2-1 467.1 347.2 130 25 16 
2-6 466.1 267.1 60 23 14 
2-34 506.1 369.1 79 30 14 
2-41 481.0 136.1 140 51 18 
2-50 583.0 252.2 90 70 30 
2-51 593.0 352.1 80 26 20 
2-52 551.0 352.2 140 23 19 
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Plasma Sample Preparation 
Plasma (20 µL) was protein-precipitated with acetonitrile (ACN, 200 µL) containing 
internal standard. For compounds 2-1, 2-6, 2-34, 2-41, 2-51, and 2-52, compound 2-50 
was used as the internal standard at a final concentration of 100 nM in ACN. Compound 
2-1 (500 nM) was used as the internal standard for the analysis of 2-50 in plasma 
samples. For INH analysis, nicotinamide (50 µM) was used as the internal standard. After 
adding ACN containing internal standard, samples were vortexed for 5 seconds, 
centrifuged at 14,000 × g for 1 min at 4 °C, and the supernatant was analyzed via 
LC‒MS/MS. Standards were prepared in pooled female Sprague-Dawley rat plasma in 
K2EDTA (BioChemed, Winchester, VA) and processed in a similar fashion as animal 
plasma samples.  
Data Analysis 
Analyte and internal standard peak areas were calculated with MultiQuant Software 
(version 2.0.2, AB SCIEX, Framingham, MA). Analyte peak areas were normalized to 
internal standard peak areas, and the concentrations were calculated with the appropriate 
standard curve. Standard curves displayed good linearity with R2 = 0.99. Pharmacokinetic 
parameters were calculated from concentration-time profiles by non-compartamental 
analysis using Phoenix WinNonLin (version 6.3, Pharsight). 
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2.6.17 Procedure for the measurement of stability of prodrugs 2-51 and 2-52 in 
simulated gastric fluid (SGF) 
 
Prodrugs (100 µM final concentration) were incubated at 37 °C in simulated gastric fluid 
(SGF, pH 1.2).48 In triplicate, SGF samples (980 µL) were pre-incubated for 5 min at 37 
°C followed by the addition of 20 µL of a 5 mM DMSO stock solution of the compound. 
The final incubation volume was 1.0 mL and aliquots (100 µL) were removed from the 
incubation solution at 0, 15, 30, 45, 60, 90, and 120 min, and immediately injected (25 
µL) onto the HPLC. Analysis was conducted on an HPLC system composed of an 
Agiletn 1,100 Liquid Chromatograph (Agilent Technologies, Santa Clara, CA) using a 
Phenomenex Gemini 5 μm C18 110 Å (250 × 4.6 mm) column (Phenomenex, Torrance, 
CA) and a Shimadzu UV/Vis detector (Shimadzu, Kyoto, Japan) at a wavelength of 254 
nm operated at a flow rate of 1 mL/min isocratic at 35% MeCN in 10 mM aqueous 
triethylammonium bicarbonate for 6.5 min. Compound 2-51 had a retention time of 4.1 
min (kʹ = 1.4), and compound 2-52 had a retention time of 5.4 min (kʹ = 2.2). The mono-
acetate degradation product was identified by low resolution LC‒MS on an Agilent TOF 
II TOF/MS (Agilent Technologies, Santa clara, CA) instrument equipped with an ESI 
interface with a retention time of 3.3 min (kʹ = 0.94). Stability was determined by 
calculating the percentage of the prodrug remaining after the final incubation time point. 
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Chapter 3. A Light-Activated Probe for the Study of Adenylation 
Domains in Mycobacterium tuberculosis 
 
 
The following chapter involves original work designed by Dr. Benjamin Duckworth and 
Dr. Courtney C. Aldrich. The synthesis of the probes was first performed by Dr. 
Duckworth, with improvement and full characterization performed by Kathryn M. 
Nelson. The biological assays were performed by Dr. Duckworth and Daniel Wilson. 
KMN compiled the LC–MS/MS data into Table 3.1 and analyzed this data for the 
purposes of this thesis. This work was published in ACS Chemical Biology, and some 
figures and excerpts are reproduced with permission from that journal (see preface 
above). 
 
3.1 Introduction 
 
3.1.1 Chemical probes for investigation of target enzymes 
 
Chemical probes are becoming an increasingly common tool in medicinal chemistry 
research. The design and application of these probes varies across different disciplines. 
Small fluorescent probes find use in bioimaging. By using small-molecule synthetic 
organic dyes that specifically interact with a target of interest, researchers can observe 
biomolecules in their native environments.1 These probes further our understanding of the 
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biological roles (including production, trafficking, etc) of biomolecules in living systems. 
Probes have also found great application in proteomics. The field of proteomics aims to 
not only identify all members of the protein, but also attempts to assign protein function, 
protein localization, and the mapping of regulatory pathways and networks for those 
proteins. Chemical techniques aide this process by chemically separating or modifying 
the proteome to facilitate analysis of smaller fractions of proteins within the proteome, 
splitting the data into more manageable pieces.2 As discussed in Chapter 1, target 
identification is becoming increasingly important in modern drug discovery. Chemical 
probes have become a critical tool for many in identifying and confirming a therapeutic 
target, as well as identifying secondary targets for efforts to reduce side effects.  
As the popularity of chemical probes grows, so have trends in generally successful or 
problematic techniques emerged. Recent publications have generated some general 
guidelines that should be followed when designing a chemical probe for any of the above 
applications, the details of which are beyond the scope of this discussion.3–6 Workman 
and Collins have summarized these guidelines into four general categories (Figure 3.1): 
1) chemical properties, 2) biological potency, 3) biological selectivity, and 4) context for 
use.4 While these general considerations seem obvious, the practical challenge of 
addressing all four in one molecule can mount quickly.  
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From a chemical perspective, a probe must be easy to access synthetically with good 
purity, solubility, and stability‒particularly to any acidic or basic environments it may 
experience in an assay. Chemical probes should be used in cellular assays whenever 
possible to evaluate membrane permeability and toxicological effects. The biological 
potency of a probe is largely dependent on its intended use, however the selectivity of a 
probe can be the most limiting factor for its design. Probes need to be evaluated for their 
selectivity in a broad manner to ensure that the observed effects are not due to off-target 
activity, but solely the intended target(s). Finally, the design and use of a probe must be 
tailored to permeate both mammalian and bacterial cells, and cannot necessarily be 
extracted from another design and system (e.g. probes investigating cancer chemotherapy 
Figure 3.1. Guidelines for the design of new chemical probes broken into four general 
categories. Adapted from Workman and Collins.4 
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targets). While it is true that chemical tools need to meet at least some basic criteria in 
order to be useful for their particular purpose, the above guidelines need to be evaluated 
in a dynamic manner with the intended application. Especially when investigating a new 
target, iterative probe design may be necessary as more is learned about the ligand-target 
system, as well as the pharmacokinetic properties of the parent structure. New designs 
should not be discarded because they do not fit all the "rules", but assessed for their 
usefulness by these guidelines. 
 
3.1.2 Investigating a secondary target of Sal-AMS (3-1) in Mtb 
 
As discussed in Chapter 2, the inhibition of siderophore biosynthesis has emerged as a 
novel strategy for the development of new antibacterial agents for Mtb and other 
pathogenic bacteria.7–9 While Mtb requires iron for its survival; the concentration of free 
iron is highly restricted in biological fluids, due in large part to the insolubility of iron 
under aerobic conditions and the sequestration by iron-binding proteins such as 
transferrin and lactoferrin.10,11 To survive these limiting conditions, Mtb biosynthesizes, 
excretes, and re-uptakes mycobactins; the family of siderophores responsible for iron 
acquisition in Mtb.12 Several observations have established the necessity of mycobactins 
for Mtb pathogenesis, which were discussed in Chapter 2 and will not be repeated 
here.13,14 Our lab and others have developed a potent nanomolar bisubstrate inhibitor of 
MbtA, 5′-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS, 3-1), as a mimic of the acyl-
adenylate intermediate that has impressive antitubercular activity under iron-deficient 
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conditions with a minimum inhibitory concentration (MIC) of 0.39 μM.7,15,16 The design 
of this inhibitor takes advantage of both the salicylic acid and ATP binding domains, but 
replaces the labile acyl phosphate with a more stable isosteric acyl sulfamate (Figure 
3.2). 
 
Sal-AMS also shows activity in iron-replete conditions (MIC = 1.56 μM), suggesting a 
potential secondary mechanism of action due to off-target binding.8 Adenylation 
(activation of a carboxylic acid as the AMP ester) in Mtb is a ubiquitous process in both 
primary and secondary metabolic pathways including protein synthesis, glycolysis, lipid 
metabolism, and cofactor biosynthesis. There are 67 putatively encoded adenylation 
enzymes in Mtb, any of which may represent potential off-targets of Sal-AMS.18 
Furthermore, Sal-AMS could potentially bind any one of the numerous adenosine-
binding proteins in Mtb. 
 
Figure 3.2. Design of 5'-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS, 3-1). The bisubstrate 
mimic incorporates a stable acyl sulfamate isotere in replacement of the labile acyl 
phosphate. Partially adapted from Vannada, et. al.17 
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3.1.3 Design of a clickable photoaffinity probe for the study of MbtA 
 
When we first reported Sal-AMS, we hypothesized it would only be active against Mtb 
under iron-limiting conditions, mimicking the environment seen by the bacteria when 
infecting a human host. It has been shown that under these iron-limiting conditions, 
siderophore biosynthesis is heavily upregulated.14 Since the bacteria should be able to 
acquire iron through other mechanisms in iron-replete conditions, we did not expect to 
see whole-cell activity against Mtb in these conditions. What we observed, however, was 
activity against the bacteria under both conditions (Table 3.1, Section 3.3.3 below). 
Adenylation (activation of a carboxylic acid as the AMP ester) is a ubiquitous process in 
both primary and secondary metabolic pathways in Mtb, including protein synthesis, 
glycolysis, lipid metabolism, and cofactor biosynthesis. In fact, Mtb putatively encodes 
for at least 67 enzymes that catalyze adenylation, any of which may represent potential 
off-targets of Sal-AMS.18 Furthermore, Sal-AMS could also potentially bind any one of 
the numerous adenosine-binding proteins in Mtb. A comprehensive understanding of the 
mechanism of action of Sal-AMS will facilitate the design of improved chemical probes 
to unequivocally chemically validate siderophore biosynthesis as a virulence target, and 
improve the selectivity of our inhibitors as antitubercular agents. 
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Of the several strategies available for identifying and/or validating drug targets, affinity-
based protein profiling (ABPP) has proven highly effective for target discovery.19–22 A 
successful ABPP experiment begins with the design of a chemical probe that can both 
bind and cross-link to the target enzyme (Figure 3.3). 
 
The Sal-AMS probe (3-2, Figure 3.3) mimics the substrate Sal-AMS. The portion of the 
probe colored in black (Sal-AMS) imparts the binding selectivity for MbtA and potential 
off-target proteins. Previously mentioned SAR studies from our lab indicated that MbtA 
tolerates modification of Sal-AMS at the C-2 position of the adenine base.24 Therefore, 
the reactive and reporter groups were tethered at the C-2 position. For a reactive group, 
we chose to use the photoreactive benzophenone moiety that has seen previous success in 
cross-linking photoaffinity probes to proteins.25 Prior to UV activation, this photo-
Figure 3.3. Photoaffinity probe design. A photoaffinity probe generally has three parts: (1) 
Specificity Group - imparts selectivity for your enzyme of interest, (2) Reactive Group - a 
photoreactive group that can be selectively activated to covalently cross-link to the enzymes 
that have bound the probe, and (3) Reporter Group - any group that can be used directly or 
as a handle for labeling with a fluorescent or other tagged group. Shown below is the 
structure of the Sal-AMS probe (3-2) used in this study. 
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activatable group must be stable and allow the probe to bind its protein target(s). 
Exposure of the benzophenone group to 365 nm (UV) light generates a reactive species 
that covalently cross-links to any amino acid residues in close proximity.26, 27 While the 
benzophenone is a relatively bulky group, SAR studies suggest that it would be well 
tolerated for MbtA binding. Furthermore, it is generally accepted that the photocross-
linking efficiency of benzophenone is higher than that of aryl azides.26 Therefore, a small 
alkyne handle was incorporated, onto which a fluorescent- or biotin-azide could be 
installed via the copper-mediated [3+2] cycloaddition ("click" reaction) post-photolysis 
to aid in visualization and enrichment, respectively.28 
To elucidate the protein targets of an inhibitor, the photoaffinity probe is first incubated 
with the proteome through incubation with whole cells or cell lysate (Figure 3.4A). 
Ultraviolet irradiation with the appropriate wavelength allows the probe to covalently 
cross-link to proteins bound by the probe. After UV photolysis, the labeled proteins are 
then separated by gel electrophoresis or by liquid chromatography coupled with mass 
spectrometry (LC−MS). In a separate experiment, the proteome is pre-incubated with 
excess inhibitor (in this case, Sal-AMS will be used) prior to probe incubation and 
photolysis (Figure 3.4B). Protein targets are identified by the disappearance of 
fluorescent labeling upon pre-incubation with inhibitor. In order to successfully apply 
ABPP to target discovery, careful attention must be given to developing and validating 
the chemical probe. The probe reported herein represents the first photoaffinity probe 
developed for an adenylating enzyme in Mtb. Since Mtb and other pathogenic bacteria 
contain numerous adenylating enzymes involved in a multitude of essential cellular 
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functions, we expect the strategy outlined here for our probe development will be broadly 
useful for proteomic profiling of adenylating enzymes. 
 
3.2 Research Objectives 
 
A light-activated benzophenone molecule was developed for use as a probe to determine 
the target specificity of our lead compound Sal-AMS (3-1) against the adenylating 
enzyme MbtA from the mycobactin biosynthetic pathway in Mtb. Previous structure-
activity relationship studies from our lab have shown that MbtA tolerates modification at 
the C-2 position of the adenine base in Sal-AMS. We chose this position to link the 
photoactive benzophenone and a small alkyne handle through which we plan to attach a 
fluorescent-azide reporter group or biotin-azide enrichment group via a copper-mediated 
[3+2] cycloaddition ("click" reaction). This probe will used to confirm MbtA as a cellular 
A 
B 
Figure 3.4. (A) General strategy for photoaffinity labeling of a class of enzymes using a 
photoaffinity probe and gel electrophoresis as the detection method. (B) Preincubation with 
excess inhibitor before labeling with a probe. Adapted from Duckworth, et al.23 
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target of Sal-AMS, and investigate other potential targets for Sal-AMS action. 
 
3.3 Results 
 
3.3.1 Synthesis of a clickable photoaffinity probe for the study of MbtA 
 
The original synthesis was performed by Dr. Benjamin Duckworth of the Aldrich lab. His 
synthesis was relatively inefficient (0.4% overall yield), so the synthesis was improved to 
generate more probe for the whole cell assays, as well as generate characterization data 
acceptable for publication. The synthesis of probe 3-2 began with a peptide coupling 
between the known acid 3-329 and the symmetrical 4,4'-diaminobenzophenone 3-4. 
Initially, this coupling was carried out by standard DCC coupling conditions, with poor 
yields (Scheme 3.1). A scan of coupling conditions found that reaction with 3-
(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT, 3-5) and triethylamine 
(Et3N) as a base for 72 hours gave greatly improved yield of the yneamide 3-6. The long 
reaction time required for acceptable yield is hypothesize to be due to the inherent low 
reactivity of the aromatic amine, however the robust activity DEPBT of allowed for good 
overall yield. It was also possible to recover much of the unreacted starting materials for 
continued reaction.  
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The free aromatic amine of 3-6 was then coupled to 2-iodo-2ʹ,3ʹ-isopropylideneadenosine 
(3-7) under Buchwald-Hartwig coupling conditions to achieve the 2-substituted 
adenosine 3-8 in moderate yield (Scheme 3.2). The palladium catalyst was added in two 
portions 2.5 hours apart to avoid charring. Optimization of this reaction also showed a 
high sensitivity to the purity of the 1,4-dioxane used as solvent. Highly pure, dry solvent 
was required to avoid high rates of homo-coupling of the iodo reagent. The silyl 
protecting group was then removed from the alkyne with standard tetrabutylammonium 
fluoride conditions to obtain intermediate 3-9. 
 
 
 
 
 
 
Scheme 3.1. Improved coupling conditions for step 1 of the synthesis of Sal-AMS 
photoaffinity probe 3-2. 
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The initial sulfamoylation conditions involved DME as the solvent, and resulted in only 
moderate yields (47%). Changing the solvent to DMA led to sulfamoylation in high 
yields (80%) without a basic catalyst yielding intermediate 3-10 (Scheme 3.3). It is 
hypothesized that the starting material (3-9) and sulfamoyl chloride are better solubilized 
in DMA, leading to higher catalytic turnover of the reaction. DMA is also mildly basic 
(pKa = 9.1), which may facilitate the reaction. Cesium carbonate-mediated coupling of 
the free amine with N-hydroxysuccinimidyl-2-(methoxymethyloxy)benzoate 3-11 gave 
the protected penultimate intermediate. Acidic deprotection with aqueous trifluoroacetic 
acid revealed the final probe 3-2. The probe was isolated as the triethylammonium salt in 
Scheme 3.2. First steps in the  improved synthesis of Sal-AMS photoaffinity probe 
3-2. Initial synthetic yields are shown the top line, improved yields are shown on the 
bottom. 
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high purity (> 97%) by RP-HPLC. This ensured that no contamination was introduced 
into the assay from the synthesis of the probe. The overall yield was improved by 13.5-
fold to 5.4%. 
 
3.3.2 Control experiments with photoaffinity probe 3-2 and recombinant MbtA 
 
A photoaffinity probe that is useful in studying the properties of its parent inhibitor must 
recapitulate both the in vitro and in vivo activities. Therefore, the ability of probe 3-2 to 
inhibit MbtA was measured by Daniel Wilson of our lab with a [32P]PPi-ATP exchange 
assay.15 The apparent inhibition constant (appKi) of probe 3-2 with MbtA was 0.94 nM 
Scheme 3.3. Completed improved synthesis of Sal-AMS photoaffinity probe 3-2. Initial 
synthetic yields are shown the top line, improved yields are shown on the bottom. 
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(Table 3.1), roughly 7-fold lower than that of Sal-AMS (3-1).15 This result is not 
surprising, since it was found that C-2 modifications of Sal-AMS led to enhanced binding 
affinity.24 To ensure that the probe displays a similar phenotype to Sal-AMS (3-1), the 
antitubercular activity of compound 3-2 was evaluated against Mtb H37Rv. 
 
Under iron-deficient conditions, the minimum inhibitory concentration of probe 3-2 that 
resulted in complete inhibition of observable cell growth (MIC) is 3−6 μM, as compared 
to 0.39 μM for Sal-AMS (3-1).24  Under iron-rich conditions, the MIC was 50 μM for 
probe 3-2, as compared to 1.56 μM for Sal- AMS (3-1). From these data, one can extract 
the selectivity factor (S), which is the ratio of activity under iron-rich over activity in 
iron-deficient conditions. Assuming that Sal-AMS is not inhibiting MbtA in iron-rich 
conditions, this selectivity factor should be high. However, the selectivity is relatively 
low (S = 1.56/0.39 = 4), indicating Sal-AMS may inhibit other targets. The selectivity 
factor for probe 3-2 is 8−17. These data confirm probe 3-2 displays a similar phenotype 
to the parent inhibitor, suggesting it is an acceptable probe for photoaffinity proteomic 
profiling.  
Table 3.1. Inhibition of MbtA and M. tuberculosis H37Rv by Sal-AMS 1 and photoaffinity 
probe 3-2. 
 MbtA appKi 
(nM)b 
MIC (µM) 
(Iron-deficient)c  
MIC (µM) 
(Iron-rich)d 
Selectivity 
Factor (S) 
Sal-AMS (3-1)a 6.6 0.39 1.56 4 
Probe (3-2) 0.94 3–6 50 8–17 
aSee reference 24. bAssay performed by Daniel Wilson with 7 nM MbtA, 10 mM ATP, 250 
µM salicylic acid, 1 mM PPi. cGrown and tested by Dr. Helena I. Boshoff in normal pH 6.6 
glycerol-alanine-salts (GAS) medium without ferric ammonium citrate. dGrown and tested 
by Dr. Helena I. Boshoff in normal pH 6.6 glycerol-alanine-salts (GAS) medium 
supplemented with 200 µM ferric ammonium citrate. 
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To evaluate the ability of the photoaffinity probe to photolabel pure recombinant MbtA, 
Dr. Benjamin Duckworth in our lab first incubated the enzyme with probe 3-2 and 
photolyzed at 365 nm. Coupling with a rhodamine-azide conjugate (TAMRA-N3) under 
standard click chemistry conditions,28 followed by denaturing gel electrophoresis allowed 
the proteins to be separated and visualized by in-gel fluorescence scanning (Figure 3.5). 
 
Pre-incubation of excess Sal-AMS (1) prior to the addition of probe 3-2 results in no 
observed protein labeling, indicating that probe 3-2 binds to the active site of MbtA 
competitively (Figure 3.5A). After determining the optimal concentration of probe for 
MbtA labeling, and demonstrating specificity by minimal labeling of BSA, maximum 
incubation time (30 minutes) and labeling efficiency (20%) were both determined 
(Figure 3.5B and C). To assess the sensitivity of probe 3-2, in-gel fluorescence scanning 
was used to determine the lower limit of MbtA that could be detected. Dr. Duckworth 
Figure 3.5. In vitro labeling of pure MbtA with probe 3-2 by Dr. Benjamin Duckworth of 
our lab. (A) Labeling of MbtA and competition with excess Sal-AMS (3-1). (B) 
Concentration dependence of probe 3-2. (C) UV photolysis time studies. (D) Limit of 
detection of MbtA labeling. FL = fluorescence, C = Coomassie. Reprinted with 
permission.23 
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found that the fluorescent detection of probe 3-2 had a sensitivity of 6 pmol of MbtA 
(Figure 3.5D). Lastly, a dose−response curve was created by incubating varying 
concentrations of Sal-AMS (3-1) with a fixed concentration of MbtA and probe 3-2 prior 
to photolysis and TAMRA conjugation (Figure 3.6A). The fluorescent band intensities 
were plotted against Sal-AMS (3-1) concentration (Figure 3.6B) to provide an IC50 value 
of 0.26 μM for Sal-AMS (3-1) against probe 3-2. 
 
3.3.3 Photoaffinity probe 3-2 labeling MbtA from cell lysates in expression and 
native systems 
 
Dr. Duckworth next used probe 3-2 to label MbtA overexpressed in E. coli cell lysates. E. 
coli was transformed with an IPTG-inducible pET-SUMO-MbtA plasmid and the pGRO7 
plasmid. E. coli cells were then grown either in the absence or presence of IPTG, 
photolabeled with probe 3-2, and subjected to the click reaction with TAMRA-N3. In the 
absence of IPTG, MbtA is not expressed (lane 1, Figure 3.7A). However, when IPTG is 
added to the growth media, a strong fluorescent band corresponding to the molecular 
Figure 3.6. (A) Dose-response curve of Sal-AMS (3-1) competition with probe 3-2. (B) 
Dose-response of fractional amount of probe 3-2 bound (determined from band intensities 
in panel A) versus Sal-AMS concentration. FL = fluorescence, C = Commassie. Reprinted 
with permission.23 
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weight of MbtA (∼73 kDa) was observed (lane 3, Figure 3.7A, arrow). Probe labeling 
was completely inhibited by pre-incubation with excess Sal-AMS (3-1) (lane 4, Figure 
3.7A). Notably, probe 3-2 labeled the GroEL chaperone protein as indicated by the star in 
lane 3 of Figure 3.7A, however this labeling was nonspecific as preincubation with Sal-
AMS (3-1) did not inhibit this labeling. These results highlight the remarkable specificity 
of probe 3-2 toward MbtA in crude mixtures. 
 
Encouraged by the ability of probe 3-2 to label MbtA in crude cell lysate, we were 
curious about the applicability of this photoaffinity probe to related adenylating enzymes. 
EntE from E. coli is the aryl acid adenylating enzyme involved in the biosynthesis of 
enterobactin, which activates 2,3-dihydroxybenzoic acid analogous to MbtA's activation 
of salicylic acid. Sal-AMS had already been shown to be a tight-binding inhibitor of 
EntE, with a Ki of 0.47 nM.30 Dr. Duckworth assayed overexpressed EntE analogous to 
the protocol for expression and assay of MbtA thruogh the IPTG-inducible pET15b-EntE 
plasmid for expression in E. coli. Minimal labeling of EntE occurs in the absence of 
B A 
MWM 
20 
25 
37 
50 
75 
100 
150 
250 
Fluorescence                  Coomassie 
25 
75 
Sal-AMS 
IPTG 
-      +     -     +     -      +     -    + 
-      -     +     +     -     -      +    + 
MWM 
Fluorescence               Coomassie           
25 
75 
Sal-AMS 
IPTG 
-     +     -     +       -     +     -     + 
-      -    +     +      -      -     +     + 
Figure 3.7. Labeling of adenylating enzymes in crude cell lysates. (A) Labeling of 
overexpressed MbtA in E. coli cell lysate. (B) Labeling of overexpressed EntE in E. coli 
cell lysate. Reprinted with permission.23 
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IPTG, however, a strong fluorescent signal was observed (lane 3, Figure 3.7B, arrow) 
after induction by IPTG. When lysate containing overexpressed EntE was preincubated 
with excess Sal-AMS (3-1), the fluorescence signal is largely attenuated (lane 4, Figure 
3.7B). These studies indicate the potential utility of our photoaffinity probe in studying 
aryl acid adenylating enzymes from different organisms.  
Finally, Dr. Duckworth and Daniel Wilson tested the ability of probe 3-2 to label native 
(uninduced) MbtA in mycobacterial cell lysates. Mycobacterium smegmatis cultures were 
grown in iron-deficient media, lysed, and incubated with either DMSO or Sal-AMS. 
After UV irradiation in the presence of probe 3-2, alkyne-labeled proteins were modified 
with a biotin-azide group via click chemistry. Biotin-tagged proteins were enriched with 
streptavidin beads, trypsin digested, and analyzed by LC−MS/MS.31 In the absence of 
Sal-AMS, MbtA was identified by LC−MS/MS with an average spectral count of 4 from 
triplicate experiments. In the presence of excess Sal-AMS, MbtA was not enriched and 
identified by LC−MS/MS as evidenced by zero spectral counts in all three replicates 
tested (Table 3.2). These results indicate that MbtA, present at low concentrations in cell 
lysate, can be labeled in mycobacterial species. Additional targets of 3-2 were not 
positively identified. Other proteins reported in the hit list either have inconsistent results 
among the triplicate samples (as evidenced by large standard deviations), or are high 
abundance proteins that are likely victims of non-specific labeling. None of these 
additionally identified proteins are likely to be true targets of Sal-AMS (3-1). 
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Protein 
Accession # MW 
0 µM 2 + Sal-AMS – Sal-AMS + Sal-
AMS/–
Sal-AMS 
0 µM 2/–
Sal-AMS + Sal-AMS 
– Sal-
AMS 
10 µM 
2 1 µM 2 
0.1 µM 
2 
10 µM 
2 1 µM 2 
0.1 µM 
2 
unnamed protein 
product 
gi|118469108|ref|YP_
886179.1| 63 kDa 
220.6±
42.8 
137.5±
31.3 
168.2±
46.4 
194.3±
73.1 
211.7±
20.8 
160.1±
22.3 
164.9±
142.0 
221.1±
56.4 1.1±0.4 1.0±0.1 
ribosomal protein L2  gi|118173550|gb|ABK74446.1| (+2) 30 kDa 
45.7 ± 
14.8 
41.1 ± 
18.1 
50.3 ± 
9.3 
46.5 ± 
21.1 
33.9 ± 
10.7 
38.1 ± 
7.8 
45.4 ± 
54.7 
46.4 ± 
14.5 1.0±0.3 1.0±0.1 
ribosomal protein S12  gi|118172589|gb|ABK73485.1| (+5) 14 kDa 
8.3 ± 
7.1 
4.6 ± 
2.9 
13.3 ± 
12.2 
4.8 ± 
2.3 
4.7 ± 
2.0 
9.3 ± 
3.4 
4.9 ± 
7.2 
2.6 ± 
1.9 1.4±2.1 1.2±1.1 
groEL gene product  gi|118469510|ref|YP_885283.1| 56 kDa 
13.6 ± 
9.7 
11.0 ± 
9.9 
12.2 ± 
1.3 
17.8 ± 
18.8 
3.3 ± 
2.4 
5.3 ± 
4.4 
12.3 ± 
11.9 
8.0 ± 
5.6 1.3±2.4 1.4±0.0 
unnamed protein 
product 
gi|118468949|ref|YP_
888976.1| 70 kDa 
12.6 ± 
3.2 
4.8 ± 
1.9 
7.4 ± 
9.8 
5.0 ± 
3.2 
5.3 ± 
0.9 
2.1 ± 
2.3 
7.9 ± 
7.9 
8.8 ± 
1.7 0.9±1.4 1.4±0.3 
glyoxalase family 
protein  
gi|118171233|gb|ABK
72129.1| (+1) 16 kDa 
0.7 ± 
1.3 
0.8 ± 
0.7 
10.6 ± 
9.5 
6.2 ± 
2.3 
0.0 ± 
0.0 
19.1 ± 
2.6 
4.5 ± 
6.5 
0.9 ± 
1.0 0.7±1.8 0.1±0.1 
acyl carrier protein  gi|118172814|gb|ABK73710.1| (+1) 11 kDa 
14.1 ± 
7.1 
8.5 ± 
6.3 
13.0 ± 
12.5 
6.2 ± 
2.1 
2.2 ± 
1.9 
5.2 ± 
2.9 
1.7 ± 
1.4 
4.8 ± 
0.8 1.8±5.7 2.9±0.5 
ribosomal protein S3  gi|118174447|gb|ABK75343.1| (+2) 30 kDa 
0.8 ± 
0.8 
0.9 ± 
1.1 
22.0 ± 
4.8 
1.4 ± 
0.5 
1.1 ± 
1.2 
1.6 ± 
1.5 
21.6 ± 
36.0 
0.6 ± 
1.1 1.0±0.1 0.1±0.0 
unnamed protein 
product 
gi|118468034|ref|YP_
886648.1| (+2) 81 kDa 
2.8 ± 
2.5 
3.5 ± 
2.2 
2.7 ± 
3.2 
3.0 ± 
2.4 
0.7 ± 
0.6 
4.2 ± 
2.9 
7.4 ± 
8.6 
5.3 ± 
6.3 0.4±0.5 0.6±0.1 
integral membrane 
protein  
gi|118171629|gb|ABK
72525.1| (+1) 36 kDa 
7.9 ± 
7.0 
3.3 ± 
3.2 
4.1 ± 
3.7 
4.0 ± 
5.7 
0.7 ± 
0.6 
4.5 ± 
2.4 
1.8 ± 
0.7 
4.3 ± 
2.7 0.8±2.4 1.6±2.5 
ribosomal protein L3 gi|118174477|gb|ABK75373.1| (+2) 23 kDa 
3.5 ± 
5.4 
1.7 ± 
1.1 
1.3 ± 
1.4 
4.0 ± 
3.0 
1.1 ± 
1.2 
0.8 ± 
0.9 
2.2 ± 
1.3 
2.5 ± 
1.3 1.2±3.9 1.4±12.0 
pyruvate carboxylase gi|118174374|gb|ABK75270.1| (+1) 121 kDa 
2.3 ± 
3.2 
0.6 ± 
1.0 
1.7 ± 
2.9 
0.3 ± 
0.5 
2.1 ± 
3.6 
0.0 ± 
0.0 
1.3 ± 
2.3 
0.0 ± 
0.0 3.1±1.2 3.2±1.2 
translation elongation 
factor Tu  
gi|118172375|gb|ABK
73271.1| (+1) 44 kDa 
1.8 ± 
1.9 
1.8 ± 
1.8 
3.2 ± 
2.8 
3.3 ± 
3.0 
0.4 ± 
0.7 
1.4 ± 
2.4 
1.1 ± 
0.3 
2.6 ± 
4.4 1.4±0.6 1.0±0.0 
ribosomal protein S5 gi|118170928|gb|ABK71824.1| (+2) 22 kDa 
1.9 ± 
2.6 
2.4 ± 
1.6 
6.6 ± 
6.2 
2.8 ± 
1.1 
1.1 ± 
1.2 
1.0 ± 
0.3 
2.9 ± 
3.1 
0.6 ± 
1.1 2.3±2.0 1.4±0.5 
chaperonin GroS  gi|118171718|gb|ABK72614.1| (+1) 11 kDa 
2.3 ± 
2.7 
2.9 ± 
2.9 
1.8 ± 
1.9 
1.9 ± 
1.7 
1.4 ± 
1.3 
0.0 ± 
0.0 
0.4 ± 
0.7 
1.3 ± 
0.3 3.0±0.8 4.5±0.4 
fatty acid synthase gi|118169207|gb|ABK70103.1| (+1) 330 kDa 
0.0 ± 
0.0 
0.2 ± 
0.4 
4.9 ± 
7.7 
0.5 ± 
0.8 
0.0 ± 
0.0 
0.5 ± 
0.8 
12.7 ± 
21.2 
2.0 ± 
2.5 0.4±0.4 0.0±0.0 
Table 3.2. LC–MS/MS identification by spectral counts of proteins labeled by photoaffinity probe 3-2 from M. smegmatis cell lysates grown under 
iron-limiting conditions to simulate the upregulation of MbtA in an infected individual. 
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unnamed protein 
product 
gi|118472788|ref|YP_
890017.1| (+5) 31 kDa 
0.8 
0.7± 
0.5 ± 
0.4 
0.6 ± 
1.1 
1.3 ± 
2.2 
0.3 ± 
0.6 
0.3 ± 
0.4 
4.5 ± 
7.9 
1.1 ± 
1.0 0.4±0.2 0.3±0.1 
isocitrate 
dehydrogenase, 
NADP-dependent  
gi|118168719|gb|ABK
69615.1| (+1) 83 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
5.3 ± 
4.7 
0.3 ± 
0.6 
0.0 ± 
0.0 
2.9 ± 
2.3 
2.9 ± 
4.0 
0.6 ± 
1.1 0.9±1.8 0.0±0.0 
ribosomal protein S10  gi|118174744|gb|ABK75640.1| (+1) 11 kDa 
0.0 ± 
0.0 
0.2 ± 
0.4 
2.8 ± 
2.4 
2.2 ± 
0.6 
0.8 ± 
1.3 
3.2 ± 
2.1 
1.8 ± 
2.0 
2.6 ± 
2.3 0.7±6.6 0.0±2.1 
3-deoxy-7-
phosphoheptulonate 
synthase  
gi|118170211|gb|ABK
71107.1| (+2) 51 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
6.1 ± 
5.6 
2.3 ± 
1.8 
0.0 ± 
0.0 
4.2 ± 
1.1 
0.4 ± 
0.7 
0.0 ± 
0.0 1.8±5.2 0.0±0.0 
2,3-
dihydroxybenzoate-
AMP ligase (MbtA) 
gi|118169731|gb|ABK
70627.1| (+1) 59 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
2.3 ± 
1.3 
1.9 ± 
1.7 
4.5 ± 
2.4 0.0±0.0 0.0±0.0 
peptidyl-prolyl cis-
trans isomerase B  
gi|118169709|gb|ABK
70605.1| (+1) 19 kDa 
2.4 ± 
0.8 
1.0 ± 
0.4 
2.5 ± 
3.4 
1.8 ± 
1.0 
1.1 ± 
1.2 
0.0 ± 
0.0 
1.3 ± 
1.3 
0.6 ± 
1.1 2.8±1.9 2.6±0.4 
glutathione peroxidase 
family protein  
gi|118172613|gb|ABK
73509.1| (+1) 17 kDa 
1.1 ± 
1.9 
1.4 ± 
1.9 
1.5 ± 
1.9 
1.8 ± 
1.0 
0.8 ± 
1.3 
1.0 ± 
0.3 
1.7 ± 
1.5 
1.3 ± 
2.2 1.0±0.5 0.9±0.0 
glutamine synthetase, 
type I  
gi|118169243|gb|ABK
70139.1| (+2) 54 kDa 
0.5 ± 
0.5 
0.7 ± 
0.1 
1.0 ± 
0.9 
2.5 ± 
1.5 
0.4 ± 
0.7 
1.2 ± 
1.4 
3.2 ± 
2.8 
1.4 ± 
1.4 0.7±0.6 0.3±0.4 
ribosomal protein 
S13p/S18e  
gi|118175274|gb|ABK
76170.1| (+1) 14 kDa 
3.1 ± 
3.2 
1.7 ± 
1.1 
0.8 ± 
1.4 
0.3 ± 
0.5 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.4 ± 
0.8 
1.1 ± 
1.0 0.7±1.4 4.8±2.9 
Chain A, Msreca 
Q196n Atpgs Form Iv 
gi|217035320|pdb|2ZR
E|A (+2) 37 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
12.8 ± 
12.8 
0.6 ± 
1.0 
0.0 ± 
0.0 
3.0 ± 
1.2 
1.2 ± 
2.1 
0.0 ± 
0.0 3.2±6.6 0.0±0.0 
glycerol kinase  gi|118171208|gb|ABK72104.1| (+1) 55 kDa 
1.0 ± 
0.9 
1.9 ± 
3.3 
0.4 ± 
0.7 
0.6 ± 
1.1 
0.0 ± 
0.0 
0.8 ± 
1.3 
1.2 ± 
2.1 
1.7 ± 
1.9 0.3±1.3 1.2±4.1 
2-oxoglutarate 
dehydrogenase, E1 
component 
gi|118173342|gb|ABK
74238.1| (+2) 136 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
9.1 ± 
15.8 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
7.0 ± 
12.2 
0.0 ± 
0.0 1.3±1.3 0.0±0.0 
3-oxoacyl-[acyl-
carrier-protein] 
synthase 1  
gi|118172459|gb|ABK
73355.1| (+1) 44 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
3.6 ± 
3.2 
0.5 ± 
0.8 
0.0 ± 
0.0 
1.2 ± 
1.4 
0.4 ± 
0.7 
0.3 ± 
0.6 2.1±3.6 0.0±0.0 
chaperonin GroL  gi|118170503|gb|ABK71399.1| (+2) 56 kDa 
0.0 ± 
0.0 
1.2 ± 
0.3 
0.8 ± 
1.4 
0.6 ± 
0.5 
0.0 ± 
0.0 
0.0 ± 
0.0 
2.5 ± 
4.3 
1.0 ± 
1.7 0.4±0.3 0.5±0.1 
NAD-dependent malic 
enzyme 
gi|118168853|gb|ABK
69749.1| (+1) 39 kDa 
1.0 ± 
1.7 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.9 ± 
1.6 
2.1 ± 
3.6 
0.3 ± 
0.6 0.2±0.5 0.5±0.8 
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ribosomal protein L18 gi|118173154|gb|ABK74050.1| (+1) 14 kDa 
0.0 ± 
0.0 
1.2 ± 
1.5 
0.0 ± 
0.0 
1.1 ± 
0.3 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.9 ± 
0.7 
1.0 ± 
1.7 0.6±0.2 1.0±1.3 
ribosomal protein 
L7/L12  
gi|118169903|gb|ABK
70799.1| (+1) 13 kDa 
0.3 ± 
0.4 
1.0 ± 
1.1 
0.7 ± 
0.6 
2.5 ± 
3.7 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.3 ± 
0.6 
10.2±6.
1 5.8±1.5 
universal stress protein 
family protein, 
putative  
gi|118174190|gb|ABK
75086.1| (+1) 15 kDa 
0.0 ± 
0.0 
0.7 ± 
1.2 
0.6 ± 
1.1 
0.9 ± 
1.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
3.3 ± 
5.7 
0.0 ± 
0.0 0.5±0.2 0.3±0.3 
DNA-directed RNA 
polymerase, beta' 
subunit  
gi|118171055|gb|ABK
71951.1| (+1) 147 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
2.9 ± 
5.0 
1.0 ± 
1.7 0.0±0.0 0.0±0.0 
methyltransferase gi|118168887|gb|ABK69783.1| (+2) 35 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
2.7 ± 
3.2 
0.6 ± 
1.0 
0.0 ± 
0.0 
0.8 ± 
0.8 
0.4 ± 
0.8 
0.0 ± 
0.0 2.6±3.7 0.0±0.0 
conserved hypothetical 
protein 
gi|118174182|gb|ABK
75078.1| (+1) 24 kDa 
0.0 ± 
0.0 
0.2 ± 
0.4 
0.0 ± 
0.0 
1.4 ± 
0.5 
0.4 ± 
0.7 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.6 ± 
1.1 1.2±0.5 0.2±0.4 
MaoC like domain 
protein  
gi|118172341|gb|ABK
73237.1| (+1) 31 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
4.0 ± 
3.7 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.8 ± 
0.8 
0.0 ± 
0.0 
0.0 ± 
0.0 5.0±4.8 0.0±0.0 
DNA-directed RNA 
polymerase, beta 
subunit  
gi|118169416|gb|ABK
70312.1| (+2) 129 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
5.0 ± 
8.6 
0.0 ± 
0.0 
0.0 ± 
0.0 0.0 ± 0.0 
ribosomal protein S11  gi|118168714|gb|ABK69610.1| (+4) 15 kDa 
1.1 ± 
1.9 
0.5 ± 
0.4 
1.2 ± 
2.1 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.5 ± 
0.9 
0.4 ± 
0.8 
0.0 ± 
0.0 1.3±2.6 2.5±2.1 
chaperone protein 
DnaK  
gi|118173710|gb|ABK
74606.1| (+1) 67 kDa 
0.8 ± 
0.8 
0.5 ± 
0.8 
0.3 ± 
0.5 
0.6 ± 
1.1 
0.4 ± 
0.7 
0.0 ± 
0.0 
1.2 ± 
2.1 
0.0 ± 
0.0 1.1±0.2 1.6±0.0 
ribonucleoside-
diphosphate reductase, 
beta subunit  
gi|118170519|gb|ABK
71415.1| (+3) 37 kDa 
0.0 ± 
0.0 
0.3 ± 
0.5 
0.0 ± 
0.0 
0.6 ± 
1.1 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.3 ± 
0.6 0.6±0.9 0.4±0.5 
putative non-ribosomal 
peptide synthetase  
gi|118171058|gb|ABK
71954.1| (+1) 125 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
1.7 ± 
2.9 
0.3 ± 
0.6 0.0±0.0 0.0±0.0 
polyketide synthase  gi|118170878|gb|ABK71774.1| (+1) 194 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
2.5 ± 
4.6 
0.3 ± 
0.6 0.0±0.0 0.0±0.0 
glycine oxidase ThiO  gi|118171481|gb|ABK72377.1| (+1) 36 kDa 
0.3 ± 
0.4 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.3 ± 
0.6 0.7±1.1 0.3±0.4 
ABC transporter, 
ATP-binding protein 
SugC  
gi|118174334|gb|ABK
75230.1| (+1) 44 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
1.8 ± 
1.9 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.3 ± 
0.5 
0.0 ± 
0.0 
0.0 ± 
0.0 6.3±3.7 0.0±0.0 
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replicative DNA 
helicase 
gi|118174455|gb|ABK
75351.1| (+1) 112 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
1.7 ± 
2.9 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.3 ± 
0.6 5.2±5.2 0.0±0.0 
putative 
adenosylhomocysteina
se  
gi|116266924|gb|ABJ9
6308.1| (+1) 53 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.6 ± 
1.1 0.0±0.0 0.0±0.0 
[NADP+] succinate-
semialdehyde 
dehydrogenase 
gi|118174982|gb|ABK
75878.1| (+1) 48 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.3 ± 
0.4 
0.0 ± 
0.0 
0.6 ± 
1.1 0.0±0.0 0.0±0.0 
transcription 
termination factor Rho  
gi|118172484|gb|ABK
73380.1| (+1) 72 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
1.2 ± 
2.1 
0.0 ± 
0.0 0.0±0.0 0.0±0.0 
conserved hypothetical 
protein 
gi|118169265|gb|ABK
70161.1| (+1) 95 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.0 ± 
0.0 0.0±0.0 0.0±0.0 
phosphoribosylformyl
glycinamidine 
synthase II 
gi|118174875|gb|ABK
75771.1| (+1) 81 kDa 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.0 ± 
0.0 
0.8 ± 
1.4 
0.0 ± 
0.0 0.0±0.0 0.0±0.0 
 
 
Values are number of counts recorded by the MS from an N of 3 (mean ± standard deviation). 
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3.4 Discussion 
 
The above results indicate that there are no major targets for Sal-AMS under iron-rich 
conditions that would explain the cytotoxic effects we see in growth assays. After 
consulting literature and experts in this field, we believe we may have an explanation for 
the activity seen under both growth conditions. 
Recently, great strides have been made in the understanding of the cell biology of iron 
acquisition by pathogenic bacteria. In 2011, both Celica Goulding and Michael 
Niederweis independently showed that mycobacteria are capable of uptaking and 
utilizing heme from a human host as an iron source, even when the biosynthesis of 
mycobactins is knocked out.32,33 Both groups constructed completely siderophore 
deficient strains of Mtb through the knockout of mbtB or mbtD, respectively. Dr. 
Niederweis showed that the growth of a ΔmbtD mutant could be rescued by adding 
carboxymycobactins to the growth media.32 This mutant was unable to grow in iron-
deficient media, even with the addition of ferric citrate (a ferrous iron source). Dr. 
Goulding's group showed that a ΔmbtB mutant can uptake human Fe-heme complexes for 
use as an iron source, and identified a gene cluster important for this active transport.33 
This does require the bacteria to encounter a heme complex outside of a red blood cell 
where it is normally sequestered. There is no evidence at this time to suggest that this 
heme uptake system would be enough to sustain growth and virulence. Dr. Goulding's 
group has also been a pioneer in showing that siderophores are important not only for the 
chelation of iron, but also for its transport across the mycobacterial cell membrane 
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(Figure 3.8).  
 
 
The heme complex is too large and too toxic to simply diffuse through the cellular 
membrane, so a transport system of some kind must be involved. Other research is 
continuing to study siderophore export and iron import pathways, and some evidence for 
the essentiality of siderophore transport out of the cell for virulence has been reported.34 
Together, this data suggests that our ability to knockdown siderophore production with 
Sal-AMS, even in iron replete conditions, may strongly affect the bacteria's ability to 
grow. This could help explain our Mtb MIC results (Table 3.2). While more work still 
Figure 3.8. Proposed pathways for the uptake of transferrin iron and heme iron in Mtb. 
Reproduced and used with permission from the Goulding lab.33 
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needs to be done to completely understand this pathway, evidence continues to grow 
showing the iron acquisition pathway as attractive for drug development. Our 
prototypical inhibitor Sal-AMS (3-1) is therefore a promising lead compound for the 
development of novel antitubercular agents. 
 
3.5 Conclusions 
 
This work highlights the design and development of a photoaffinity probe for the study of 
the adenylating enzyme MbtA and how its inhibition affects the pathogenic bacteria Mtb. 
We were able to successfully synthesize a light-activated benzophenone probe that was 
used to determine the target specificity of Sal-AMS (3-1) against MbtA from the 
mycobactin biosynthetic pathway in Mtb with M. smegmatis as a model mycobacterial 
organism. The overall synthetic yield was improved by 13.5-fold through two key 
modifications in the synthesis. A small alkyne handle was used to attach a fluorescent-
azide group and separately a biotin-azide group via a copper-mediated [3+2] 
cycloaddition ("click" reaction) for visualization and enrichment, respectively. This probe 
confirmed MbtA as a cellular target of Sal-AMS, but no other significant target enzymes 
were identified. Further literature analysis suggests to us that our compound may be 
highly selective for MbtA, and this could account for all the cellular activity we have 
observed, both in iron-deficient and iron-replete conditions. This data points to Sal-AMS 
as an ideal probe for the validation of siderophore biosynthesis as essential for virulence 
and growth, as well as a lead compound for the development of new antitubercular 
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therapeutics. 
 
3.6 Experimental Data 
 
3.6.1 General procedures for the synthesis of a photoaffinity probe against MbtA 
 
All commercial reagents (Sigma-Aldrich, Fisher, Fluka, Quanta Biochem, Strem) were 
used as provided. Sulfamoyl chloride was prepared by the method of Heacock without 
recrystallization.35 An anhydrous solvent dispensing system (JC Meyer Solvent Systems, 
Laguna Beach, CA) with two packed columns of neutral alumina was used for drying 
THF, DMF and DCM and the solvents were dispensed under argon. Anhydrous DMA 
(Sigma-Aldrich) was used as provided. All reactions were performed under an inert 
atmosphere of dry Argon in oven-dried (150 °C) glassware. Flash chromatography was 
performed on an ISCO Combiflash Companion® purification system (Teledyne Isco, 
Lincoln, NE) with prepacked silica gel cartridges and the indicated solvent system. 
Reverse-phase HPLC was performed on a Varian Prostar 210 solvent system equipped 
with a UV/Vis detector (Varian, Inc./Agilent Technologies, Santa Clara, CA) with the 
indicated column and solvent system. 1H NMR and 13C NMR experiments were recorded 
on a Varian 600 MHz spectrometer or a Bruker 850MHz spectrometer with a 5 mm TCI 
Z-gradient cryoprobe. Proton chemical shifts are reported in ppm from an internal 
standard of residual chloroform (7.26 ppm), or methanol (3.31 ppm). Carbon chemical 
shifts are reported from an internal standard of residual chloroform (77.0 ppm), or 
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methanol (49.1 ppm). Proton chemical data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, 
ovlp = overlapping), coupling constant, and integration. High-resolution mass spectra 
were acquired on an Agilent TOF II TOF/MS instrument (Agilent Technologies, Santa 
Clara, CA) equipped with either an APCI or ESI interface. 
 
3.6.2 Synthesis of 5-(Triisopropylsilyl)pent-4-ynoic acid (3-3).  
 
The title compound was prepared as described. 1H NMR, 13C NMR, and HRMS data 
agree with reported values.29 
 
3.6.3 N-[4-(4-Aminobenzoyl)phenyl]-5-(triisopropylsilyl)pent-4-ynamide (3-6)  
 
To a stirring solution of 3-3 (470 mg, 1.8 mmol, 1.0 equiv) in DMF (18.5 mL) at 23 °C 
was added 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT, 3-5) (1.1 
g, 3.7 mmol, 2.0 equiv) and triethylamine (520 μL, 3.7 mmol, 2.0 equiv). After 10 min, 
3-4 (590 mg, 2.8 mmol, 1.5 equiv) was added as a solid and the mixture stirred at 23 °C 
for 72 h. The reaction was diluted with H2O (400 mL) and extracted with CHCl3 (3 × 400 
mL). The combined organic extracts were washed with saturated aqueous NaCl (400 
mL), dried (MgSO4), and concentrated under reduced pressure to an orange oil. 
Purification by flash chromatography (step gradient CHCl3 to 30% EtOAc/CHCl3 to 50% 
EtOAc/CHCl3) yielded the title compound (570 mg, 71%) as an orange solid. Rf = 0.38 
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(30% EtOAc/CHCl3); 1H NMR (CDCl3, 600 MHz) δ 1.02 (s, 18H), 1.03 (s, 3H), 2.63 (t, 
J = 6.6 Hz, 2H), 2.69 (t, J = 6.6 Hz, 2H), 6.68 (d, J = 6.6 Hz, 2H), 7.61 (d, J = 8.4 Hz, 
2H), 7.67 (d, J = 7.2 Hz, 2H), 7.72 (d, J = 7.8 Hz, 2H), 8.02 (br s, 1H); 13C NMR (CDCl3, 
150 MHz) δ 11.3, 16.5, 18.8, 37.3, 82.5, 106.9, 114.0, 119.1, 127.9, 131.2, 133.0, 134.5, 
141.1, 150.8, 170.1, 194.6; HRMS (ESI+): calculated for C27H37N2O2Si [M + H]+ 
449.2619, found 449.2646 (error 6.0 ppm). 
 
3.6.4 2′,3′-O-Isopropylidene-2-{N-[4-(4-{N-[5-(triisopropylsilyl)pent-4- 
ynoyl]amino}benzoyl)phenyl]amino}adenosine (3-8).  
 
A solution of Pd2(dba)3 (0.012 g, 0.011 mmol, 0.10 equiv) and BINAP (0.022 g, 0.035 
mmol, 0.15 equiv) in 1,4-dioxane (1.6 mL) that had been pre-mixed for 10 min was 
added to a Schlenk flask containing 7 (0.100 g, 0.23 mmol, 1.0 equiv). The mixture 
changed from opaque, dark red to transparent yellow over 10 min. Next, 3-6 (0.155 g, 
0.35 mmol, 1.5 equiv) and Cs2CO3 (0.113 g, 0.35 mmol, 1.5 equiv) were added and the 
resulting mixture was heated at reflux. After 2.5 h, a second portion of Pd2(dba)3 (0.012 
g, 0.011 mmol, 0.10 equiv) and BINAP (0.022 g, 0.035 mmol, 0.15 equiv) in 1,4-dioxane 
(1.6 mL) was added to the refluxing reaction. After an additional 4 h at reflux, the 
reaction was cooled to room temperature, filtered, and the filtrate concentrated under 
reduced pressure to a dark brown oil. The oil was redissolved in EtOAc (100 mL), 
washed with H2O (3 × 50 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure to a yellow oil. Purification by three successive flash columns (linear gradient 0–
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10% MeOH/EtOAc) yielded the title compound (0.074 g, 43%) as a yellow amorphous 
solid. Rf = 0.47 (10% MeOH/EtOAc); 1H NMR (CDCl3, 600 MHz) δ 1.03–1.04 (m, 
21H), 1.38 (s, 3H), 1.63 (s, 3H), 2.66 (t, J = 6.6 Hz, 2H), 2.71 (t, J = 6.6 Hz, 2H), 3.81 (d, 
J = 11.4 Hz, 1H), 3.95 (d, J = 11.4 Hz, 1H), 4.48 (s, 1H), 5.07 (d, J = 6.0 Hz, 1H), 5.34 (t, 
J = 4.8 Hz, 1H), 5.88 (d, J = 4.2 Hz, 1H), 5.93 (br s, 1H), 7.29 (br s, 1H), 7.61 (d, J = 8.4 
Hz, 2H), 7.67 (d, J = 7.8 Hz, 2H), 7.71 (d, J = 7.8 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 8.05 
(s, 1H); 13C NMR (CDCl3, 150 MHz) δ 11.4, 16.5, 18.8, 25.5, 27.7, 37.3, 63.2, 81.6, 
82.6, 83.3, 86.4, 93.0, 106.9, 114.4, 116.1, 118.0, 119.2, 130.9, 131.4, 131.7, 134.0, 
138.6, 141.4, 144.2, 150.1, 155.4, 155.9, 170.1, 194.7; HRMS (ESI+): calculated for 
C40H52N7O6Si [M + H]+ 754.3743, found 754.3748 (error 0.7 ppm). 
 
3.6.5 2′,3′-O-Isopropylidene-2-[N-(4-{4-[N-(pent-4-
ynoyl)amino]benzoyl}phenyl)amino]adenosine (3-9).  
 
To a solution of 3-8 (0.044 g, 0.06 mmol, 1.0 equiv) in THF (1 mL) was added a 1.0 M 
solution of tetrabutylammonium fluoride in THF (0.116 mL, 0.12 mmol, 2.0 equiv) and 
the mixture stirred at 23 °C for 6 h. The reaction mixture was concentrated under reduced 
pressure to a dark yellow oil and purified directly by flash chromatography (linear 
gradient 0–10% MeOH/EtOAc) to yield the title compound (0.029 g, 82%) as a yellow 
amorphous solid. Rf = 0.20 (10% MeOH/EtOAc); 1H NMR (CD3OD, 600 MHz) δ 1.39 
(s, 3H), 1.61 (s, 3H), 2.30 (t, J = 3.0 Hz, 1H), 2.57 (td, J = 6.6, 2.4 Hz, 2H), 2.64 (t, J = 
7.2 Hz, 2H), 3.68 (dd, J = 12.0, 5.4 Hz, 1H), 3.72 (dd, J = 12.0, 4.2 Hz, 1H), 4.33 (dd, J = 
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7.8, 4.8 Hz, 1H), 5.03 (dd, J = 6.0, 3.0 Hz, 1H), 5.43 (dd, J = 6.0, 3.0 Hz, 1H), 6.12 (d, J 
= 3.0 Hz, 1H), 7.72–7.74 (m, 6H), 7.90 (d, J = 9.0 Hz, 2H), 8.07 (s, 1H); 13C NMR 
(CD3OD, 150 MHz) δ 15.5, 25.8, 27.7, 37.1, 63.5, 70.5, 83.1, 83.6, 85.8, 88.6, 92.6, 
115.3, 116.1, 118.8, 120.2, 130.9, 132.2, 132.7, 134.9, 139.5, 143.9, 147.3, 151.7, 157.6, 
172.7, 196.8 (missing 1 carbon, likely due to overlap); HRMS (ESI+): calculated for 
C31H32N7O6 [M + H]+ 598.2409, found 598.2415 (error 1.0 ppm). 
 
3.6.6 2′,3′-O-Isopropylidene-2-[N-(4-{4-[N-(pent-4-
ynoyl)amino]benzoyl}phenyl)amino]-5′-O-(sulfamoyl)adenosine (3-10).  
 
To a stirring solution of 3-9 (0.016 g, 0.025 mmol, 1.0 equiv) in dimethylacetamide (1.0 
mL) at 0 °C was added solid sulfamoyl chloride (0.012 g, 0.10 mmol, 4.0 equiv). The 
mixture was warmed to 23 °C over approximately 3 h and then stirred for 17 h at 23 °C. 
The reaction was diluted with EtOAc (15 mL) and washed successively with DI H2O (4 × 
15 mL). The organic layer was dried (MgSO4), filtered, and concentrated under reduced 
pressure to a yellow oil. Purification by flash chromatography (linear gradient 0–5% 
MeOH/EtOAc) afforded the title compound (0.0145 g, 80%) as an amorphous off-white 
solid. Rf = 0.41 (10% MeOH/EtOAc); 1H NMR (CD3OD, 600 MHz) δ 1.40 (s, 3H), 1.62 
(s, 3H), 2.29 (s, 1H), 2.57 (t, J = 7.2 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 4.21 (dd, J = 10.8, 
5.4 Hz, 1H), 4.35 (dd, J = 10.2, 4.8 Hz, 1H), 4.53 (d, J = 2.4 Hz, 1H), 5.16 (d, J = 6.0 Hz, 
1H), 5.49 (d, J = 6.0 Hz, 1H), 6.17 (s, 1H), 7.75–7.76 (m, 6H), 7.91 (d, J = 8.4 Hz, 2H), 
8.01 (s, 1H); 13C NMR (CD3OD, 150 MHz) δ 15.5, 25.7, 27.6, 37.1, 70.0, 70.5, 83.2, 
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83.6, 85.7, 85.9, 92.5, 115.5, 116.1, 119.0, 120.2, 131.0, 132.3, 132.8, 134.9, 139.5, 
143.9, 147.3, 151.7, 157.67, 157.72, 172.8, 196.9; HRMS (ESI+): calculated for 
C31H33N8O8S [M + H]+ 677.2137, found 677.2127 (error 1.5 ppm). 
 
3.6.7 5ʹ-O-[N-(2-Hydroxybenzoyl)sulfamoyl]-2-[N-(4-{4-[N-(pent-4- 
ynoyl)amino]benzoyl}phenyl)amino]adenosine triethylammonium salt (3-2).  
 
To a solution of 3-10 (14.5 mg, 0.02 mmol, 1.0 equiv) in DMF (1.0 mL) was added 3-118 
(9.0 mg, 0.03 mmol, 1.5 equiv) and Cs2CO3 (21 mg, 0.06 mmol, 3.0 equiv) and the 
reaction stirred for 20 h at 23 °C. The reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure to a colorless residue. A solution of 80% aqueous 
TFA (1.0 mL) was added the crude residue and the mixture was stirred at 23 °C for 2 h, 
then concentrated under reduced pressure to remove all traces of TFA. Purification by 
preparative reverse-phase HPLC on a Phenomenex Gemini 10 μm C18 110 Å (250 × 
21.2 mm) column (Phenomenex, Torrance, CA) at a flow rate of 30 mL/min with a 
gradient of 5–80% MeCN in 20 mM aqueous triethylammonium bicarbonate over 30 
min, and then held at 80% MeCN for 5 min. The retention time of the product was 16.7 
minutes (k′ = 4.9) and the appropriate fractions were pooled and lyophilized to afford the 
title compound (5.0 mg, 27%) as a light yellow solid: 1H NMR (CD3OD, 600 MHz) δ 
1.20 (t, J = 7.2 Hz, 9H), 2.30 (s, 1H), 2.57 (t, J = 7.2 Hz, 2H), 2.64 (t, J = 7.2 Hz, 2H), 
2.94 (d, J = 3.0 Hz, 6H), 4.31 (d, J = 2.4 Hz, 1H), 4.37 (d, J = 11.4 Hz, 1H), 4.42–4.45 
(br m, 1H), 4.47 (dd, J = 11.4, 1.8 Hz, 1H), 4.82–4.83 (m, 1H), 6.06 (d, J = 6.0 Hz, 1H), 
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6.75–6.79 (m, 2H), 7.27 (t, J = 8.4 Hz, 1H), 7.75–7.77 (m, 6H), 7.93–7.96 (m, 3H), 8.26 
(s, 1H); 13C NMR (CD3OD, 213 MHz) δ 8.7, 15.7, 37.2, 47.8, 69.9, 70.6, 72.9, 75.9, 
83.7, 84.7, 89.4, 115.9, 118.1, 118.6, 119.5, 120.3, 120.9, 130.8, 131.7, 132.3, 133.0, 
134.6, 135.1, 139.5, 143.9, 147.7, 152.8, 157.6, 157.8, 162.3, 172.9, 175.3, 197.1; HRMS 
(ESI−): calculated for C35H31N8O10S [M − H]− 755.1889, found 755.1916 (error 3.6 
ppm). 
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Chapter 4. Total Synthesis and Biological Evaluation of Four 
Diastereomers of the Natural Product Transvalencin Z 
 
 
The following chapter is original work designed by Kathryn M. Nelson and Dr. Courtney 
C. Aldrich. All of the included work was completed by KMN with the exception of the 
MIC activity data against Mycobacterium tuberculosis which was completed by Dr. 
Helena I. Boshoff at the NIH. This work was published in the Journal of Natural 
Products, and some figures and excerpts are reproduced with permission from that 
journal (see preface above). 
 
4.1 Introduction 
 
As discussed in previous chapters, there is a dire need for new antitubercular agents that 
act via new mechanisms of action. Natural products have been a great source of both new 
compounds and lead compounds for antibacterial development. Most of the major classes 
of antibiotics are either natural products, or derived from natural products. Beginning 
with penicillin in the early 1900s, β-lactams, macrolides, aminoglycosides, 
glycopeptides, tetracyclines, and vancomycin are all natural products or natural product-
derived antibiotics that have been successfully brought to clinical use. The success of 
natural products for the development of antibiotics has not been limited to broad 
spectrum agents. Many of the clinically used antitubercular agents are also natural 
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products or derivatives of natural products. Streptomycin is an aminoglycoside antibiotic 
isolated as a fermentation product from Streptomyces griseus.1 This was the first 
successful chemotherapeutic against Mycobacterium tuberculosis (Mtb) infection. 
Streptomycin is still a second-line treatment option for tuberculosis (TB) patients as it is 
only injectable due to its high polarity and lack of oral bioavailability (4-1, Figure 4.1).2 
Other aminoglycoside natural products that also find use as antibiotics include the natural 
product kanamycin (4-2) and its synthetic derivative amikacin (4-3), which have broad 
spectrum activity against drug-sensitive strains of Mtb.3,4 Naturally occurring 
antitubercular agents, including the well-known products cycloserine and aminoglycoside 
capreomycin, are also still included on the list of second-line agents available for 
treatment. In addition to these natural products, the first line anti-TB agent rifampin (RIF) 
is a semisynthetic derivative of the ansamycin antibiotic rifamycin B.5 Additional 
discussion of RIF as an antitubercular agent can be found in Chapter 1. Other natural 
product-derived antitubercular agents include pyrazinamide (PZA), which is a derivative 
of nicotinamide (vitamin B3), and para-aminosalicylic acid, which is an analogue of 
salicylic acid. Natural product screening has lost some of its popularity in favor of target-
based rational drug design strategies (see Chapter 1 above), but natural products continue 
to show activity against a variety of indications, including TB. 
 
 
 
 
  160 
 
Mukai and co-workers isolated the natural product transvalencin Z (4-4, Figure 4.2) from 
a clinical strain of Nocardia transvalensis.6 The isolated compound exhibited potent and 
specific inhibition of Mycobacterium smegmatis with an MIC (minimum inhibitory 
concentration that results in > 99% reduction in observable growth) of 0.34 µM (0.125 
µg/mL). There was also some activity against other acid-fast Nocardia spp., but no 
activity was seen against Gram-negative bacilli, fungi, or mammalian cell lines.6 Our 
group became interested in this report as compound 4-4 also shows striking structural 
similarity to the mycobactin siderophores produced by Mtb (Figure 4.2). Mycobactins 
are a mycobacterial-specific class of siderophores, which are small molecule iron (Fe3+) 
chelators produced by nearly all bacteria.7  
 
Figure 4.1. Natural products and derivative antibiotics active against Mtb. 4-1, 
streptomycin; 4-2, kanamycin; and 4-3, amikacin (derivative of kanamycin) 
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Iron is necessary for bacterial cell processes in virtually every pathogen, with a few 
notable exceptions, including B. burgdorferi.9 Bacteria have evolved pathways to 
synthesize, secrete, and re-import siderophores that scavenge iron in limiting 
environments such as a human host. The inhibition of the biosynthesis of these molecules 
has emerged as a promising strategy for the development of new antibacterial agents.7,10 
The mycobactins in Mtb are essential for growth and virulence in iron-limiting 
conditions, making their biosynthetic pathway especially attractive as a drug target.11 The 
structural similarity of 4-4 to the core structure of the mycobactins suggests that it may 
exert its activity against mycobacteria by interfering with mycobactin-mediated iron 
scavenging. Snow originally proposed that mycobactin analogs may antagonize 
Figure 4.2. (A) Reported structure of transvalencin Z (4-4)6. (B) Structure of mycobactin-T. 
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mycobacterial growth in 1970.8,12 Miller and co-workers reinforced that hypothesis with 
two different studies. In the first, they found that mycobactin S, produced by M. 
smegmatis and differing from mycobactin T by only one stereocenter (Figure 4.3), 
inhibits the grown of Mtb.13,14 
 
Additionally, an analog of mycobactin T that replaces the β-hydroxybutyrate substitution 
with a 2,3-diaminoproprionate exhibited antimycobacterial activity.15 In addition to these 
very similar molecules, Miller's group has demonstrated that organic molecules derived 
from a phenyloxazoline, which mimic the head group of the mycobactins, possess 
antimycobacterial activity, although they suggest this is unrelated to the antagonism of 
iron acquisition.14 Quadri and co-workers recently reported a series of small molecules 
that incorporate a 2-hydroxyphenyl moiety that show iron-dependent antimycobacterial 
Figure 4.3. Structural differences between mycobactin S and T. Mycobactin T is a native 
siderophore to Mtb, while Mycobactin S is native to M. smegmatis. Mycobactin S has an 
MIC of 12.5 µg/mL against Mtb H37Rv. 
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activity, suggesting some interference with mycobactin-mediated iron acquisition.16 
 
4.2 Research Objectives 
 
The principle aim of this research was to identify and fully characterize the 
stereochemical assignments and antimycobacterial activity of the natural product 
transvalencin Z. To accomplish this, the four possible diastereomers will be synthesized 
from optically pure starting materials and carefully designed synthetic schemes to ensure 
enantiopurity of the final products. Comparative analysis of the characterization data and 
the reported data for transvalencin Z will be used to unequivocally assign the 
stereochemistry of the natural product, if possible. The four diastereomers will then be 
tested against M. smegmatis in an effort to determine if the activity of the natural product 
is dependent upon the stereochemistry. If only one of the four diastereomers is active to 
the same extent as reported in literature, assignment could be made based on 
microbiological activity. Finally, these compounds will be tested against M. tuberculosis 
H37Rv to see if the M. smegmatis activity reported will translate to Mtb activity. 
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4.3 Results  
 
4.3.1 Synthesis of transvalencin Z diastereomers 
 
Retrosynthetically, transvalencin Z can be disconnected into two major building blocks: a 
2-hydroxyphenyl oxazoline acid 4-5 and an ε-formyl lysine 4-6, as shown in Scheme 4.1. 
Building block 4-5 is a common intermediate in the synthesis of known mycobactins and 
their analogues previously reported by Miller and co-workers. 12–14 A dehydrative ring 
closure and peptide bond coupling between salicylic acid and an appropriately protected 
serine derivative can lead back to commercially available starting materials 4-7 and 4-8. 
Building block 4-6 is derived from lysine 4-9. Each building block can be readily 
synthesized in both R and S enantiomers.  
Scheme 4.1 Retrosynthetic analysis of transvalencin Z. The commercially available 
enantiopure serine and lysine starting materials help set the stereocenters in the final 
compounds. 
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The synthesis of building blocks 4-5a and 4-5b began with the benzylation of salicylic 
acid 4-7,17 followed by peptide coupling with L- or D-serine benzyl esters as previously 
described by Miller and co-workers to yield the serine adducts 4-12 in 90% average yield 
(Scheme 4.2).13  
 
Miller and co-workers employed Burgess' reagent (4-14) under refluxing conditions to 
give the dehydrated product 4-13. However, we elected to use the a reported 
molybdenum catalyst, ammonium molybdenum tetrahydrate ((NH4)6Mo7O24•4H2O).18 
Molybdenum activation was reported to retain the stereochemistry at the β-position of 
serine/threonine analogues, which would be useful if analogues are synthesized for 
structure-activity relationships in the future. This biomimetic dehydrative cyclization 
procedure contrasts with the Burgess' reagent method that electrophilically activates the 
serine hydroxyl group, followed by nucleophilic displacement by the amide carbonyl 
(Scheme 4.3).19,20  
Scheme 4.2. Synthesis of the oxazoline building blocks 4-5a and 4-5b for transvalencin Z 
diastereomer synthesis. 
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The molybdenum catalyst acts by first coordinating to the amide carbonyl thereby 
electrophilically activating the carbon center for intramolecular attack by the serine 
hydroxyl nucleophile. Dehydration of the system then affords the heterocycle 4-13 
(Scheme 4.4).18 Enantiopurity was confirmed by measurement of optical rotation and 
matching to literature values.13 Global deprotection of 4-13 by hydrogenolysis provided 
acids 4-5 in nearly quantitative yields (Scheme 4.2). Deprotection of the phenol ether 
was required for the penultimate peptide coupling reaction, a phenomenon that has been 
documented in multiple siderophore syntheses.14,21 
 
 
 
 
Scheme 4.3. Mechanism for dehydrative cyclization using Burgess' reagent 4-14. 
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Commercially available Nα-Fmoc- L- or D-lysine 4-15 was formylated by the mixed 
anhydride method reported by Hughes and Waters to give acid 4-16 (Scheme 4.5).22,23 
Elaboration of 4-16 to the fully protected lysine conjugate 4-17 was possible under a 
number of common conditions for benzyl ester formation; however, conditions involving 
direct alkylation (DIPEA, BnBr) were ultimately chosen to prevent possible racemization 
at the α-stereocenter.24 Fmoc deprotection of 4-17 with excess piperidine afforded the 
free amine 4-6. 
 
 
 
 
 
Scheme 4.4. Proposed mechanism for molybdenum catalyzed dehydrative cyclization. 
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Peptide coupling of acid 4-5a and lysine 4-6a with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) resulted in epimerization at position C-9 to 
afford 4-18a and 4-18c in a 4.2:1 ratio as determined by HPLC (Figure 4.4).  
18a 
18c 
Scheme 4.5. Synthesis of the lysine building blocks 4-6a and 4-6b for transvalencin Z 
diastereomer synthesis. 
Figure 4.4. HPLC trace of epimerized product in initial peptide coupling of 4-5a and 4-6a 
using EDC coupling conditions. 
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Therefore, the penultimate step was performed with 3-(diethoxyphosphoryloxy)-1,2,3- 
benzotriazin-4(3H)-one (DEPBT) 4-19, a reagent known for minimizing racemization at 
sensitive stereocenters (Scheme 4.6).25 Hydrogenolysis of 4-18a provided free acid 4-4a. 
The remaining diastereomeric products 4-4b–d were prepared in an analogous fashion as 
described for 4-4a. 
 
 
 
Scheme 4.6. Penultimate DEPBT coupling and final hydrogenolysis completed the total 
synthesis the four transvalencin Z diastereomers. 
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4.3.2 Biological evaluation of transvalencin Z diastereomers 
 
In attempting to assign the stereochemistry for transvalencin Z, we also sought to confirm 
the biological activity reported by Mukai and co-workers.6 We were especially interested 
in its potential use against mycobacteria, so we began with biological evaluation of 4-4a–
d against Mycobacterium smegmatis MC24517 readily available in the Aldrich 
laboratory. The minimum inhibitory concentration (MIC) was greater than 100 μM for all 
four diastereomers (Table 4.1). Because there can be variations in protein expression 
levels in different strains of bacteria, we then tested the diastereomers against the 
identical M. smegmatis strain (ATCC 607) reported, but again observed no activity. The 
four compounds were also tested against a panel of ten additional pathogens 
(Enterococcus faecalis, Staphylococcus aureus, Acinetobacter baumannii, Escherichia 
coli, Klebsiella pneumoniae, Bacillus subtilis, Pseudomonas aeruginosa, Candida 
albicans, Mycobacterium bovis BCG, and Mycobacterium tuberculosis) and 4-4a–d were 
inactive (MIC ≥ 100 μM) against all strains evaluated. Five of these pathogens from our 
screen (M. smegmatis, S. aureus, B. subtilis, E. coli, and C. albicans) were also screened 
by Mukai and co-workers,6 who reported MIC values of 0.34, 3.0, 44, >175, and >175 
μM, respectively, which are inconsistent with our data (Table 4.1). 
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Strain Classification Reported MIC 4-4 (µM)6 
MIC 4-4a–d 
(µM) 
M. smegmatis (ATCC 607) Acid-fast 0.344 > 100 
E. coli (ATCC 25922) Gram-negative > 175 > 100 
B. subtilis (ATCC 6633) Gram-positive 44 > 100 
S. aureus (MRSA, ATCC 
43300) 
Gram-positive 3 > 100 
C. albicans (ATCC 10231) Fungal > 175 > 100 
A. baumannii (ATCC 
19606) 
Gram-negative n.d.
a > 100 
K. pneumoniae (ATCC 
13883) 
Gram-negative n.d. > 100 
P. aeruginosa (ATCC 
27853) 
Gram-negative n.d. > 100 
E. faecalis (ATCC 51299) Gram-positive n.d. > 100 
M. smegmatis (MC24517) Acid-fast n.d. > 100 
M. tuberculosis (H37Rv)b Acid-fast n.d. > 100 
M. bovis BCG strain TMC 
1011 Pasteur (ATCC 
35734) 
Acid-fast n.d. > 100 
S. aureus (MRSA, clinical 
IDRL 6169) 
Gram-positive n.d. > 100 
S. aureus (MSSA, clinical 
IDRL 8545) 
Gram-positive n.d. > 100 
Vero Mammalian n.d. > 100 
 
4.3.3 Characterization of transvalencin Z diastereomers 
 
Synthetic transvalencins 4-4a–d were isolated as amorphous white solids. The spectral 
data collected including 1H and 13C NMR, high resolution mass spectrometry, and IR 
Table 4.1. MIC activity data for isolated transvalencin Z (4-4)6 and synthetic 4-4a-d. 
an.d.: not determined, bTesting performed by Dr. Helena I. Boshoff 
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absorbance were similar to those reported by Mukai and co-workers.6 We are certain of 
the absolute configuration of our compounds based on the use of chiral starting materials 
and knowledge of the chemical transformations for the synthesis of 4-4a–d. The methods 
were chosen to reduce racemization of stereocenters in all steps, as noted above. 
Diastereomers of compounds 4-18a–d could be identified by distinct retention times on 
reverse-phase HPLC. A similar HPLC method was able to differentiate between the 
diastereomers of compounds 4-4a-d as well (Figure 4.5). We observed nearly equal and 
opposite optical rotations for each set of enantiomers, giving further support to their 
enantiopurity. 
 
Most of the 1H NMR chemical shifts for 4-4a–d match those reported for transvalencin Z 
(Table 4.2). The C-2, 2-NH, and 6-NH protons show significant differences in chemical 
shift for 4-4a–d compared to the reported natural product.6 The C-2 shift at the chiral 
center is significant and concerning, however amide protons can be highly variable due to 
pH, sample concentration, and temperature of the solution, so these shifts may not be 
Figure 4.5. Stack plot of synthetic transvalencins 4-4a-d. While the enantiomers overlap 
and are indistinguishable by retention time, the sets of diastereomers are distinct. 
4-4a/b 4-4c/d 
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diagnostic.26 The optical rotation values for 4-4a–d also do not match the reported value 
(+15.3°) for transvalencin Z;6 the sets of enantiomers 4-4a–b (+29.2°/−31.6°) and 4-4c–d 
(−2.0°/+6.0°) are nearly equi-distant from this value.  
 
δH and δC (ppm), mult. (J in Hz) 
Position transvalencin Z
6 4-4a/b 4-4c/d 
δH δC δH δC δH δC 
1 11.76, br s 173.1 11.80, br s 173.3 11.81, br s 173.8 
2 3.85, q-like (6.0) 53.8 4.18, m 52.1 4.17, m 51.9 
2-NH 7.75, d (6.0)  7.87, ovlp m  7.85,ovlp m  
3 1.54, m 31.7 1.61, m 30.4 1.65, m 30.8 
3' 1.68, m 1.71, m 1.74, m 
4 1.2, m 22.5 1.26, m 22.8 1.31, m 22.7 
5 1.32, m 28.8 1.34, m 28.5 1.40, m 28.4 
6 2.98, q-like (6.0) 37.1 3.05 m 36.8 3.05, t (6.0) 36.7 
6-NH 7.94, br t (6.0)  8.50, d (6.6)  8.51, d (7.2)  
7 7.92, s 160.7 7.91, s 160.9 7.98, s 160.8 
8  168.6  169.7  169.5 
9 4.99, dd (8.0, 10.0) 67.4 4.98, t (7.8) 67.1 5.01, t (8.4) 67.0 
10 4.48, t (8.0) 69.7 4.48, t (7.8) 69.2 4.50, t (7.8) 69.2 
10' 4.63, dd (8.0, 10.0) 4.60, t (7.8) 4.63, t (8.4) 
11  165.9  165.8  165.7 
12  159.1  159.1  158.9 
13  109.8  109.8  109.8 
14 7.0, br d (8.0) 116.5 6.95, d (8.4) 116.6 7.0, d (8.4) 116.4 
15 6.94, br t (7.5) 119.1 6.89, t (7.8) 119.1 6.95, t (7.8) 118.9 
16 7.46, ddd (1.5, 7.5, 8.0) 134.0 7.41, t (7.8) 134.0 7.46, t (7.2) 133.9 
17 7.63, dd (1.5, 7.5) 128.0 7.59, d (7.8) 128.0 7.64, d (7.8) 127.9 
Table 4.2. 1H and 13C data for transvalencin Z6 and compounds 4-4a-d in d6-DMSO 
at 600 MHz. 
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In attempting to further confirm the properties of transvalencin Z, 4-4a–d were screened 
against a panel of representative organisms (Table 4.1, above). We were particularly 
interested in expanding the number of mycobacteria strains tested to give a more 
complete picture of the compound's selectivity displayed in the original screen.6 In 
contrast to the potent antimycobacterial activity reported for transvalencin Z, none of the 
four synthetic diastereomers inhibited the growth of several species of mycobacteria, 
including M. smegmatis MC24517 and ATCC607, M. bovis BCG and additional testing 
against M. tuberculosis H37Rv by Dr. Helena I. Boshoff at the NIH.  
 
4.4 Discussion 
 
Analysis of the literature describing natural products produced by Nocardia sp. and other 
structurally related natural products (e.g. siderophores such as mycobactins from M. 
tuberculosis, acinetobactin from A. baumannii, and nocardichelins from Nocardia sp.) 
does not reveal a trend or preference for stereochemistry. Several studies of salicyl and 
oxazoline/thiazoline motifs show this stereocenter (C-9 in transvalencin Z) to be S, 
resulting from naturally occurring L-serine.19,20,27,28 However, other natural products, 
including brasilibactin from Nocardia brasiliensis, show an R stereocenter, which would 
suggest the incorporation of an epimerase in the biosynthetic machinery or the use of the 
less common D-serine.29 Other natural products including amamistatins, formobactin, and 
nocobactin NA contain a completely saturated oxazole ring system, negating the 
stereocenter at this position.30 Less work has been done on similar lysine motifs. 
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Biosynthetic feeding studies of natural products containing lysine motifs (C-2 in 
transvalencin Z) have demonstrated the S configuration is achieved by incorporation of 
predominantly L-lysine.27 Further complicating matters, the absolute configuration has 
not been assigned to the only other transvalencin isolated to date (transvalencin A).31 
These conflicting literature data, combined with the lack of correlation between our 
activity and spectral data with the original report, make the assignment of 
stereochemistry in transvalencin Z impossible without the authentic isolated sample for 
comparison study. 
 
4.5 Conclusions 
 
This work highlights the development of an efficient synthesis to access the four possible 
diastereomers of the natural product transvalencin Z, and the attempt to assign the native 
stereochemistry based on spectroscopic and biological activity data. The synthetic route 
developed here introduces a new dehydrative ring closure to form the oxazoline that 
would allow for stereocontrol in future analogue syntheses.18 Spectroscopic 
characterization of the synthetic diastereomers did not match the reported data for the 
natural product.6 Attempted confirmation by biological activity also proved inconclusive.  
These results suggest that the original natural product may have been contaminated with 
a small amount of a highly active compound. Alternatively, the slight discrepancies in the 
spectroscopic data between the four synthetic diastereomers compared to the natural 
product suggest that the reported structure of transvalencin Z may be incorrect. It is 
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especially concerning that the C-2 stereocenter did not match the reported data. The 
synthetic methods for 4-4a–d unequivocally produced the pure enantiomers, as 
confirmed by extensive NMR and HPLC analysis. It is possible that small differences in 
bond connections may have caused a mistake in the assignment of the natural product 
structure. Chemical derivatization of the freshly isolated natural product may aide in 
elucidating the true structure. Attempts to obtain the isolated compound or the producing 
strain from the Mukai research group have thus far been unsuccessful. 
 
4.6 Experimental Data 
 
4.6.1 General procedures for the synthesis of transvalencin Z diastereomers 
 
All commercial reagents were used as provided unless otherwise indicated. An anhydrous 
solvent dispensing system (JC Meyer Solvent Systems, Laguna Beach, CA) with two 
packed columns of neutral alumina was used for drying THF and CH2Cl2 while two 
packed columns of molecular sieves were used to dry DMF and the solvents were 
dispensed under argon. Anhydrous grade MeOH and toluene were purchased from 
Aldrich. Flash chromatography was performed on a Combiflash Companion® system 
(Teledyne Isco, Lincoln, NE) equipped with flash column silica cartridges with the 
indicated solvent system. All reactions were performed under an inert atmosphere of dry 
Ar or N2 in oven-dried (150 °C) glassware. 1H and 13C NMR spectra were recorded on a 
Varian 600 MHz spectrometer. Proton chemical shifts are reported in ppm from an 
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internal standard of residual chloroform (7.26), methanol (3.31), dichloromethane (5.32), 
or dimethylsulfoxide (2.50), and carbon chemical shifts are reported in ppm from an 
internal standard of residual chloroform (77.23), methanol (49.15), dichloromethane 
(54.00), or dimethyl sulfoxide (39.51). Proton chemical data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
br = broad, ovlp = overlapping), coupling constant, integration. High-resolution mass 
spectra were obtained on an Agilent TOF II TOF/MS instrument (Agilent Technologies, 
Santa Clara, CA) equipped with either an ESI or APCI interface. Optical rotations were 
measured on a Rudolph Autopol III polarimeter (Rudolph Research Analytical, 
Hackettstown, NJ). Melting points were measured on an electrothermal Mel-Temp 
manual melting apparatus (Electrothermal, Bibby Scientific, Staffordshire, UK) and are 
uncorrected. IR spectra were obtained on a Jasco FT/IR-4100 (Jasco Analytical 
Instruments, Easton, MD). 
 
4.6.2 General procedures for microbiological evaluation of transvalencin Z 
diastereomers 
 
M. smegmatis (MC24715) was a generous gift of Dr. William R. Jacobs, Jr. of the 
Howard Hughes Medical Institute and Department of Microbiology and Immunology, 
Albert Einstein College of Medicine, Bronx, NY. S. aureus (MRSA) clinical IDRL 6169 
and S. aureus (MSSA) IDRL 8545 were the kind gifts of Dr. Robin Patel, Department of 
Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN; 
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other pathogens were obtained from the ATCC (A. baumannii ATCC 19606, C. albicans 
ATCC 10231, E. faecalis (VRE) ATCC 51299, E. coli ATCC 25922, K. pneumoniae 
ATCC 13883, P. aeruginosa ATCC 27853, S. aureus (MRSA) ATCC 43300, M. 
smegmatis ATCC 607, M. bovis BCG strain TMC1011 Pasteur ATCC 35734) and 
cultured as follows. Bacterial strains were streaked from frozen glycerol stocks onto solid 
agar plates before being subcultured in liquid medium for assay. Agar plates consisted of 
the following media plus agar (Difco) to a 1.5% concentration: E. coli, P. aeruginosa, 
and all S. aureus, trypticase soy; A. baumannii, K. pneumoniae, M. bovis BCG, and all M. 
smegmatis, nutrient broth; E. faecalis, brain heart infusion; and C. albicans, YM broth. 
Bacteria were cultured on agar plates overnight at 37 °C, while C. albicans was cultured 
overnight at 30 °C. After 24 h incubation, single colonies were picked and grown in broth 
(listed above) to an OD600 of 1.0, diluted to an OD600 of 0.003 and plated in 96-well 
sterile plates with 1% DMSO and varying concentrations of 4-4a–d. Plates were read at 
24 and 48 h at 600 nm on a plate reader (Molecular Devices Spectramax M5e); plate 
background (690 nm) was subtracted out and values were standardized to the DMSO 
controls. In initial microbiological testing against M. smegmatis, it was observed that the 
bacteria would often clump together during growth, causing large variations in optical 
density readings. Addition of the supplemental detergent Tyloxapol (Sigma, St. Louis, 
MO) at 0.05% by volume prevented clumping of the mycobacteria without the potentially 
toxic side effects observed when using Tween detergents with mycobacteria.32 Mukai and 
co-workers did not report the use of any detergents for M. smegmatis growth.  
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4.6.3 General procedures for mammalian cell toxicity measurements 
 
Cytotoxicity of each compound was determined with a standard tetrazolium assay against 
Vero green monkey kidney cells (ATCC CCL-81).33,34 All tissue culture reagents were 
purchased from Gibco, Invitrogen (Carlsbad, California). Cells were grown in MEM 
media supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 
1% Glutamax. Cells were seeded at 3.0 × 104 cells per well in a 96-well microtiter plate 
(Corning Life Sciences, Lowell, MA) and allowed to adhere overnight. Medium was 
carefully aspirated and replaced with 195 µL fresh medium, and compound solutions in 
DMSO (5 µL) were added to give a final concentration ranging from 100–0.16 µM. All 
concentrations were tested in triplicate. Plates were incubated for 72 h at 37 °C and 4.5% 
CO2 in a humidified chamber. The solutions were carefully removed and RPMI without 
phenol red containing 1.0 mg/mL 3-(4,5-dimethyl-thiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) was added (200 µL) and incubated for 3 h, after which the MTT medium 
was carefully removed. Isopropyl alcohol (200 µL) was added to dissolve the precipitated 
purple formazan crystals and the plates were read at 570 nm with a plate reader 
(Molecular Devices Spectramax M5e); plate background (690 nm) was subtracted out 
and cell viability was estimated as the percentage absorbance relative to the DMSO 
control. Dose response curves were generated using GraphPad Prism 5 software 
(GraphPad Software, San Diego, CA) and used to determine the MIC50 concentrations 
(minimal concentration that inhibits 50% of growth). 
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4.6.4 2-(Benzyloxy)benzoic acid (4-10) and N-[2-(Benzyloxy)benzoyl]-L/D-serine 
benzyl esters (4-12a and 4-12b) 
 
Compounds 4-10, 4-12a, and 4-12b were prepared according to literature procedures.7,13 
 
4.6.5 (4S) and (4R)-Benzyl-2-[2-(benzyloxy)phenyl]-Δ2-1,3-oxazoline-4-carboxylate 
(4-13a and 4-13b) 
 
To a stirring solution of N-[2-(benzyloxy)benzoyl]-L-serine benzyl ester (4-12a), (2.0 g, 
4.9 mmol, 1.0 equiv) or N-[2-(benzyloxy)benzoyl]-D-serine benzyl ester (4-12b) in 
toluene (50 mL) was added ammonium molybdate (VI) tetrahydrate 
((NH4)6MoO24•4H2O) (2.4 g, 1.9 mmol, 0.39 equiv), and the solution was refluxed for 18 
h on a Dean-Stark trap to remove the generated water. The reaction was concentrated 
under reduced pressure to a dark, green oil and partitioned between EtOAc and 5% 
aqueous NaHCO3. The organic layer was washed with saturated aqueous NaCl (100 mL), 
dried (MgSO4), and concentrated under reduced pressure to an off-white amorphous 
solid. Purification by flash chromatography (linear gradient 0–50% EtOAc/hexanes) on 
silica gel afforded the title compound (1.00 g, 55%) as an off-white solid. mp = 68–71 
°C; 4-13a [α]23D  = + 79.1 (c 1.0, CHCl3); 4-13b [α]
23
D  = − 81.7 (c 1.0, CHCl3); Rf = 0.33 
(30% EtOAc/hexanes); 1H NMR, 13C NMR, and HRMS identical to reported values.13 
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4.6.6 (4S) and (4R)-2-[2-Hydroxyphenyl]-Δ2-1,3-oxazoline-4-carboxylic acid (4-5a 
and 4-5b) 
 
(4S)-Benzyl-2-[2-(benzyloxy)phenyl]-Δ2-1,3-oxazoline-4-carboxylate (4-13a) or (4R)-
Benzyl-2-[2-(benzyloxy)phenyl]-Δ2-1,3-oxazoline-4-carboxylate (4-13b) (0.385 g, 1.00 
mmol) was dissolved in anhydrous methanol (10 mL) and added to a Parr flask 
containing 10% by weight Pd/C (0.039 g) under Ar. The reaction vessel was evacuated, 
then backfilled with hydrogen gas to 3 atm, and the mixture was shaken at 25 °C for 1 h. 
The reaction vessel was opened, and the reaction mixture was filtered through Celite. The 
filtrate was concentrated under reduced pressure to a dark red-orange oil (190 mg, 91%) 
and used directly in the next step without further purification. However, for analytical 
characterization, purification by flash chromatography (isocratic 50% EtOAc/hexanes 
with 1% formic acid) afforded the title compound as a clear, colorless oil. 4-5a [α]23D   
+39.2 (c 1.0, MeOH); 4-5b [α]23D  −27.5 (c 1.0, MeOH); Rf = 0.22 (1:1 EtOAc/hexanes 
with 1% formic acid); 1H NMR (CD3OD, 600 MHz) δ 4.54−4.59 (m, 2H), 4.92 (apparent 
br t, J value not discernible due to broadening, 1H), 6.81 (t, J = 7.8 Hz, 1H), 6.89 (d, J = 
8.4 Hz, 1H), 7.33 (t, J = 7.2 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H); 13C NMR (CD3OD, 150 
MHz) δ 68.4, 70.7, 111.3, 117.7, 120.1, 129.5, 135.2, 161.1, 168.5, 174.1; HRMS (ESI−) 
calculated for C10H8NO4 [M − H]− 206.0459, found 206.0435 (error 11.6 ppm), C9H8NO2 
[M − CO2]− 162.0561, found 162.0552 (error 5.6 ppm). 
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4.6.7 (2S) and (2R)-({[(9H-Fluoren-9-yl)methyloxy]carbonyl}amino)-6-
formamidohexanoic acid (4-16a and 4-16b) 
 
Formic acid (1.5 mL, 39 mmol, 5.7 equiv) was added dropwise to acetic anhydride (4.5 
mL, 48 mmol, 7.1 equiv) at 0 °C followed by heating to 60 °C for 2 h. The mixture was 
cooled back to 0 °C and a slurry of 2-N-fluorenylmethyloxycarbonyl-L-lysine (4-15a) or 
2-N-fluorenylmethyloxycarbonyl-D-lysine (4-15b) (2.5 g, 6.79 mmol, 1.0 equiv) in 
CH2Cl2 (26.6 mL) was added. The reaction was allowed then warmed to 25 °C and 
stirred for 3 h. The reaction mixture was partitioned between EtOAc (75 mL) and H2O 
(75 mL), and the organic layer was washed successively with H2O (75 mL) and saturated 
aqueous NaCl (75 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure. Purification by flash chromatography (linear gradient 0–7% MeOH/CH2Cl2 
with 1% formic acid) afforded the title compound (1.61 g, 60%) as a foamy, yellow oil. 
1H NMR, 13C NMR, and HRMS identical to reported values.22 
 
4.6.8 (2S) and (2R)-Benzyl-2-({[(9H-fluoren-9-yl)methyloxy]carbonyl}amino)-6-
formamidohexanoate (4-17a and 4-17b) 
 
To a stirring slurry of 2-(N-fluroenylmethyloxycarbonyl)-6-N-formyl-L-lysine (4-16a) or 
2-(N-fluroenylmethyloxycarbonyl)-6-N-formyl-D-lysine (4-16b) (1.00 g, 2.52 mmol, 1.0 
equiv) in CH2Cl2 (25 mL) was added diisopropylethylamine (0.66 mL, 3.78 mmol, 1.5 
equiv) followed by benzyl bromide (0.45 mL, 3.78 mmol, 1.5 equiv) to afford a 
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homogenous clear solution. The reaction was stirred for 20 h at 25 °C, then partitioned 
between EtOAc (100 mL) and H2O (100 mL) and the organic layer was washed 
successively with saturated aqueous NaHCO3 (100 mL), saturated aqueous NaCl (100 
mL), dried (MgSO4), and concentrated under reduced pressure. Purification by flash 
chromatography (linear gradient 10–100% EtOAc/hexanes) on silica gel provided the 
title compound (740 mg, 60%) as a yellow oil. 4-17a [α]23D  = − 6.2 (c 1.0, CHCl3) and 4-
17b [α]23D  = + 7.9 (c 1.0, CHCl3); Rf = 0.38 (1:1 CH2Cl2/EtOAc with 1% formic acid); 1H 
NMR (CD2Cl2, 600 MHz) δ 1.17–1.30 (m, 2H), 1.32–1.42 (m, 2H), 1.57–1.63 (m, 1H), 
1.71–1.78 (m, 1H), 3.05–3.12 (m, 2H), 4.12 (t, J = 6.6 Hz, 1H), 4.22–4.32 (m, 3H), 5.03 
(d, J = 12.6 Hz, 1H), 5.08 (d, J = 12.6 Hz, 1H), 7.19–7.27 (m, 7H), 7.30 (t, J = 7.8 Hz, 
2H), 7.52 (t, J = 6.6 Hz, 2H), 7.67 (d, J = 7.2 Hz, 2H), 7.95 (s, 1H); 13C NMR (CD2Cl2, 
150 MHz) δ 22.9, 29.4, 32.4, 37.8, 47.8, 54.4, 67.3, 67.5, 120.5, 125.6, 127.6, 128.2, 
128.6, 128.8, 129.1, 136.2, 141.8, 144.4, 156.5, 161.6, 172.8; HRMS (APCI+): calculated 
for 17a C29H31N2O5+ [M + H]+ 487.2227, found 487.2228 (error 0.2 ppm). 
 
4.6.9 (2S) and (2R)-Benzyl-2-amino-6-formamidohexanoate (4-6a and 4-6b) 
 
To a stirring solution of (2S)-benzyl-2-[([(9H-fluoren-9-yl)methyloxy]carbonyl)amino]-
6-formamidohexanoate (4-17a) or (2R)-benzyl-2-[([(9H-fluoren-9-
yl)methyloxy]carbonyl)amino]-6-formamidohexanoate (4-17b) (0.600 g, 1.23 mmol, 1.0 
equiv) in DMF (12 mL) was added piperidine (0.61 mL, 6.17 mmol, 5.0 equiv) and the 
mixture stirred for 1 h at 25 °C. The reaction was concentrated by rotary evaporation 
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under high vacuum to remove DMF and the crude residue was partitioned between H2O 
(40 mL) and hexanes (40 mL). The hexanes layer was discarded and the aqueous layer 
was adjusted to pH = 10 with saturated aqueous NaHCO3, extracted with 6:1 
EtOAc/MeOH (3 × 40 mL), and the combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure. Purification by flash chromatography (linear 
gradient 0–10% MeOH/EtOAc) over basic alumina yielded the title compound (140 mg, 
50%) as a yellow oil. 4-6a [α]23D  = + 3.9 (c 1.0, CH3OH) and 4-6b [α]
23
D  = − 1.2 (c 1.0, 
CH3OH); Rf = 0.13 (10% MeOH/EtOAc with 1% Et3N); 1H NMR (CD3OD, 600 MHz) δ 
1.31–1.40 (m 2H), 1.46–1.51 (m, 2H), 1.65–1.67 (m, 1H), 1.72–1.77 (m, 1H), 3.17 (t, J = 
7.2 Hz, 2H), 3.52 (t, J = 6.6 Hz, 1H), 5.15 (d, J = 12.6 Hz, 1H), 5.21 (d, J = 12.6 Hz, 1H), 
7.32–7.39 (m, 5H), 8.00 (s, 1H); 13C NMR (CD3OD, 150 MHz) δ 23.8, 30.2, 35.0, 38.8, 
55.1, 67.9, 129.5, 129.6, 129.7, 137.5, 163.9, 176.1; HRMS (ESI+): calculated for 
C14H21N2O3 [M + H]+ 265.1547, found 265.1546 (error 0.4 ppm). 
 
4.6.10 (2S, 9S) and (2R, 9R)-Benzyl-6-formamido-2-[(2-hydroxyphenyl)-Δ2-1,3-
oxazoline-4-carboxamido]hexanoate (4-18a and 4-18b) 
 
To a stirring solution of (4S)-2-[2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-carboxylic acid (4-
5a) (31 mg, 0.15 mmol, 1.0 equiv), and (2S)-benzyl-2-amino-6-formamidohexanoate (4-
6a) or (4R)-2-[2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-carboxylic acid (4-5b) and (2R)-
benzyl-2-amino-6-formamidohexanoate (4-6b) (40 mg, 0.15 mmol, 1.0 equiv) and 
DEPBT (49 mg, 0.16 mmol, 1.06 equiv) in THF (2.5 mL) was added Et3N (40 μL, 0.30 
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mmol, 2.0 equiv) at 25 °C. After 48 h, the reaction mixture was concentrated and the 
residue was partitioned between EtOAc (50 mL) and H2O (50 mL). The organic layer 
was washed with saturated aqueous NaCl (50 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure to a yellow oil. Purification by flash 
chromatography (linear gradient 0–10% MeOH/CH2Cl2) afforded the title compound 
(16.6 mg, 24%) as an amorphous colorless solid. 4-18a [α]23D  = + 6.0 (c 1.0, CH3OH) and 
4-18b [α]23D  = − 6.0  (c 1.0, CH3OH).; Rf = 0.65 (10% MeOH/DCM); 1H NMR (CD3OD, 
600 MHz) δ 1.37–1.42 (m, 2H), 1.47–1.54 (m, 2H), 1.75–1.82 (m, 1H), 1.87–1.93 (m, 
1H), 3.16 (t, J = 7.2 Hz, 2H), 4.48 (dd, J = 9.0, 4.8 Hz, 1H), 4.58 (d, J = 9.0 Hz, 2H), 
5.00 (t, J = 9.0 Hz, 1H), 5.15 (d, J = 12.6 Hz, 2H), 5.21 (d, J = 12.6 Hz, 1H), 6.90 (t, J = 
7.8 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 7.30–7.33 (m, 1H), 7.34–7.38 (m, 4H), 7.41 (td, J = 
7.2, 1.2 Hz, 1H), 7.67 (d, J = 7.8, 1.2 Hz, 1H), 7.97 (s, 1H); 13C NMR (CD3OD, 150 
MHz) δ 24.2, 29.9, 32.0, 38.7, 54.1, 68.2, 69.3, 70.5, 111.6, 117.8, 120.1, 129.46, 129.52, 
129.6, 129.7, 135.2, 137.3, 161.1, 163.9, 168.6, 173.1, 173.3; HRMS (ESI+) calculated 
for C24H28N3O6 [M + H]+ 454.1973, found 454.1994 (4.6 ppm error). 
 
4.6.11 (2S, 9R) and (2R, 9S)-Benzyl-6-formamido-2-[(2-hydroxyphenyl)-Δ2-1,3-
oxazoline-4-carboxamido]hexanoate (4-18c and 4-18d) 
 
Reaction conditions identical to those for 4-18a and 4-18b, except for the use of (4S)-2-
[2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-carboxylic acid (4-5a) and (2R)-benzyl-2-amino-
6-formamidohexanoate (4-6b) or (4R)-2-[2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-
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carboxylic acid (4-5b) and (2S)-benzyl-2-amino-6-formamidohexanoate (4-6a). 
Purification by flash chromatography (linear gradient 0–10% MeOH/DCM) afforded the 
title compound (49.9 mg, 58%) as an amorphous colorless solid. 4-18c [α]23D  = – 6.7 (c 
1.0, CH3OH) and 4-18d [α]23D  = + 10.8 (c 1.0, MeOH); Rf = 0.61 (10% MeOH/DCM); 1H 
NMR (CD3OD, 600 MHz) δ 1.38–1.42 (m, 2H), 1.50–1.55 (m, 2H), 1.78–1.82 (m, 1H), 
1.89–1.92 (m, 1H), 3.20 (t, J = 7.2 Hz, 2H), 4.85 (dd, J = 9.0, 5.4 Hz, 1H), 4.56–4.64 (m, 
2H), 5.01 (dd, J = 10.6, 7.8 Hz, 1H), 5.09 (d, J = 12 Hz, H), 5.17 (d, J = 12 Hz, H), 6.91 
(t, J = 7.2 Hz, 1H), 6.98 (d, J = 9.0 Hz, 1H), 7.27–7.32 (m, 5H), 7.42 (t, J = 7.2 Hz, 1H), 
7.69 (d, J = 7.8 Hz, 1H), 8.01 (s, 1H); 13C NMR (CD3OD, 150 MHz) δ 24.2, 29.9, 32.0, 
38.7, 54.1, 68.1, 69.3, 70.5, 111.7, 117.8, 120.1, 129.3, 129.4, 129.6, 129.7, 133.6, 135.1, 
137.2, 161.0, 163.9, 168.6, 173.1, 173.2; HRMS (ESI+) calculated for C24H28N3O6 [M + 
H]+ 454.1973, found 454.2004 (error 6.8 ppm). 
 
4.6.12 (2S, 9S) and (2R, 9R)-6-Formamido-2-[(2-hydroxyphenyl)-Δ2-1,3-oxazoline-4-
carboxamido]hexanoic acid (4-4a and 4-4b) 
 
Solid Pd/C (10% by weight, 1.7 mg) was added to a solution of (2S, 9S)-benzyl-6-
formamido-2-([2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-carboxamido)hexanoate 4-18a or 
(2R, 9R)-benzyl-6-formamido-2-([2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-
carboxamido)hexanoate 4-18b (16.6 mg, 0.037 mmol) in MeOH (10 mL) under Ar. The 
reaction vessel was evacuated then back-filled with hydrogen gas to 3 atm and the 
mixture was shaken at 25 °C for 2 h. The reaction vessel was opened and the reaction 
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mixture was filtered through Celite and the filtrate concentrated under reduced pressure. 
Purification by flash chromatography (linear gradient 0–10% EtOH/DCM plus 1% formic 
acid) afforded the title compound (13 mg, 100%) as an amorphous colorless solid. 4-4a 
[α]23D  = + 29.2 (c 0.1, MeOH), and 4-4b [α]
23
D  = − 31.6 (c 0.1, MeOH); Rf = 0.59 (10% 
MeOH/CH2Cl2 with 1% formic acid); 1H NMR (DMSO-d6, 600 MHz) δ 1.26–1.35 (m, 
2H), 1.35–1.44 (m, 2H), 1.64–1.67 (m, 1H), 1.75–1.79 (m, 1H), 3.00–3.10 (m, 2H), 4.16–
4.20 (m, 1H), 4.48 (t, J = 7.8 Hz, 1H), 4.60 (t, J = 7.8, 1H), 4.98 (t, J = 7.8 Hz, 1H), 6.89 
(t, J = 7.8 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 7.41 (t, J = 8.4 Hz, 1H), 7.59 (d, J = 7.8 Hz, 
1H), 7.83–7.90 (ovlp m, 1H), 7.91 (ovlp s, 1H), 8.50 (d, J = 6.6 Hz, 1H), 11.80 (br s, 
1H); 13C NMR (DMSO-d6, 150 MHz) δ 22.8, 28.5, 30.4, 36.8, 52.1, 67.1, 69.2, 109.8, 
116.6, 119.1, 128.0, 134.0, 159.1, 160.9, 165.8, 169.7, 173.3; HRMS (ESI−) calculated 
for C17H20N3O6 [M − H]− 362.1358, found 362.1331 (7.5 ppm error). 
 
4.6.13 (2S, 9R) and (2R, 9S)-6-Formamido-2-[(2-hydroxyphenyl)-Δ2-1,3-oxazoline-4-
carboxamido]hexanoic acid (4-4c and 4-4d) 
 
Reaction conditions identical as those for 4-4a and 4-4b, except for the use of (2S, 9R)-
benzyl-6-formamido-2-([2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-carboxamido)hexanoate 
4-18c or (2R, 9S)-benzyl-6-formamido-2-([2-hydroxyphenyl]-Δ2-1,3-oxazoline-4-
carboxamido)hexanoate 4-18d (15.5 mg, 0.03 mmol). Purification by flash 
chromatography (linear gradient 0–10% EtOH/CH2Cl2 with 1% formic acid) afforded the 
title compound (5.8 mg, 53%) as an amorphous solid. 4-4c [α]23D  = − 2.0 (c 0.1, MeOH) 
  188 
and 4-4d [α]23D  = + 6.0 (c = 0.1, MeOH); Rf = 0.59 (10% MeOH/CH2Cl2 with 1% formic 
acid); 1H NMR (DMSO-d6, 600 MHz) δ 1.31–1.34 (m, 2H), 1.37–1.41 (m, 2H), 1.64–
1.68 (m, 1H), 1.74–1.78 (m, 1H), 3.05 (t, J = 6.0 Hz, 2H), 4.15–4.21 (m, 1H), 4.50 (t, J = 
7.8, 1H), 4.63 (t, J = 8.4 Hz, 1H), 5.01 (t, J = 8.4 Hz, 1H), 6.95 (t, J = 7.8 Hz, 1H), 7.00 
(d, J = 8.4 Hz, 1H), 7.46 (t, J = 7.2 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.85 (olvp m, 1H), 
7.98 (olvp s, 1H), 8.51 (d, J = 7.2 Hz, 1H), 11.81 (br s, 1H); 13C NMR (DMSO-d6, 150 
MHz) δ 23.0, 28.9, 31.0, 37.2, 53.0, 67.5, 69.6, 110.2, 116.8, 119.2, 128.3, 134.2, 159.4, 
161.3, 166.3, 169.9, 173.8; HRMS (ESI−) calculated for C17H20N3O6 [M − H]− 362.1358, 
found 362.1360 (0.55 ppm error). 
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Chapter 5. Biotinylated Probes for the Study of Adenylation Domains in 
Bacillus subtilis 
 
 
The following chapter details an assay that was originally designed by Dr. Jun Yin of the 
University of Chicago. The probe molecules (5-1, 5-2, and 5-3) were designed by Dr. Yin 
with help from Dr. Courtney C. Aldrich. Probe 5-1 was synthesized by Dr. Kimberly D. 
Grimes and Kathryn M. Nelson, with the material from Dr. Grimes being used for Dr. 
Yin's assay. Probes 5-2 and 5-3 were both synthesized by KMN. The yeast cell display 
assay was performed in Dr. Yin's assay. This work was published in Chemistry and 
Biology, and some figures and excerpts are reproduced with permission from that journal 
(see preface above). 
 
5.1 Introduction 
 
As discussed previously, chemical probes are becoming more common in the study of 
proteins and their function. In Chapter 3, we used a chemical probe to study the 
specificity of an inhibitor for an enzyme. In this chapter, the synthesis of a biotinylated 
probe to study the specificity of an enzyme for different substrates was developed. 
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5.1.1 Nonribosomal peptide synthetases (NRPS) 
 
Nonribosomal peptide synthetases (NRPSs) are large multifunctional enzymes in bacteria 
that synthesize peptide natural products known as nonribosomal peptides (NRPs), which 
are diverse in structure and often possess important medicinal activities.1,2 NRPSs do not 
use the mRNA-templated ribosomal machinery, and so are not restricted to the 20 
proteinogenic amino acids. Their products often contain D-amino acids and unnatural α-
amino acids, as well as N-methylation and cyclization of the peptide backbone, which 
enhances proteolytic stability. NRPSs utilize a modular architecture where each module 
is responsible for the incorporation of one amino acid substrate into the final molecule.3,4 
Each module contains three core domains: a condensation (C) domain, an adenylation 
(A) domain, and a peptidyl carrier protein (PCP) domain (Figure 5.1). The adenylation 
domain is responsible for the selection, activation, and loading of its substrate onto the 
downstream PCP domain where it is covalently attached via a thioester linkage. The thiol 
of the PCP domain is not from cysteine, but rather from the terminal thiol of an 
approximately 20 Ǻ-long phosphopantetheine (Ppant) cofactor moiety that modifies a 
conserved serine residue of the PCP domain. The Ppant arm then delivers the amino acid 
substrate to the C domain that catalyzes peptide bond coupling between substrate 
molecules loaded on neighboring modules. This leads to the elongation of the peptide 
chain in the N to C direction. Once it reaches the final module, the full-length peptide 
chain is released by a thioesterase domain, followed by macrocyclization or hydrolysis to 
afford the final product. 
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5.1.2 Adenylation domains 
 
Adenylation domains, as the selectivity unit for chain elongation, usually activate an 
appropriate amino acid, but are also known to activate aryl acids as found in 
siderophorea, fatty acids for lipopeptides, or hydroxy acids for peptide ester containing 
Figure 5.1. The NRPS pathway for the synthesis of bacillibactin in Bacillus subtilis. 
The adenylation (A) domains load the cognate substrates onto the peptidyl carrier 
protein domains (PCP). The condensation (C) domains catalyze peptide bond 
formation, elongating the growing peptide chain. Final release of the product is 
achieved through macrocyclization of a thioesterase (TE) domain. Figure adapted 
from May, et al.5 
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non-ribosomal peptides.4,6 These domains are 55–60 kDa and contain a large N-terminal 
subdomain and a small C-terminal subdomain with the active site located at the domain 
interface. These proteins are conformationally dynamic and exist in an open apo 
conformation as well as two different closed holo conformations. The specificity of an 
adenylation domain is imparted by a substrate binding pocket lined by approximately 10 
important residues (a "nonribosomal code") that comprise interactions that can enable in 
silico prediction of substrate specificity.7–9 The adenylation-thioesterification reaction 
catalyzed by adenylation domains is a two-step process; in the first step, the substrate 
acid and ATP bind to afford a ternary complex, then their condensation affords an acyl-
adenylate intermediate.10 Following release of pyrophosphate, the C terminus of the 
adenylation domain undergoes a 140° rigid body rotation to allow insertion of the Ppant 
cofactor arm from the downstream PCP domain into the active site.6 Acylation of the 
Ppant moiety, followed by release of the thioacylated PCP and AMP, completes the 
catalytic cycle. 
 
5.1.3 Analogues of natural products through native synthetases 
 
A number of strategies have been employed to attempt to modify the specificity of 
adenylation domains in order to incorporate nonnative building blocks into natural 
products. Utilizing biological machinery to produce such analogues would relieve the 
heavy burden felt by organic chemists when attempting SAR studies on natural product 
scaffolds. Some of the first attempts at utilizing NRPS scaffolds for analogue 
  196 
development involved domain swapping from various assembly lines to stitch together 
the desired segments. This approach suffers from suboptimal interactions between these 
different domains, resulting in low catalytic turnover and even premature truncation of 
the peptide chain in some cases.11, 12 Walsh and co-workers developed a method of 
directed evolution to improve these chimeric assembly lines, achieving a 10-fold 
improvement in catalytic activity.11 Additional methods include the reengineering of 
adenylation domain specificity while preserving the native domain sequence. The 
nonribosomal code mentioned above has also been studied through computational 
mutation and modeling to predict mutants with altered substrate specificity.13,14 
 
5.1.4 DhbE as a model system 
 
This study aims to be another step in the development of methods to reengineer the 
specificity of adenylation domains in an effort to more easily access analogues of natural 
products. The model system chosen for this study was DhbE from the NRPS for 
bacillibactin biosynthesis in Bacillus subtilis (see Figure 5.1 above). This system is ideal 
for an initial study due to the readily available 2.15 Å X-ray co-crystal structure with the 
acyl-adenylate,5 the availability of known inhibitors,15 and the detailed report of the 
kinetic mechanism for this enzyme.10 DhbE is also active when expressed alone, and does 
not require the expression of a large multidomain NRPS to study its catalytic activity. 
Therefore, this study was designed to reengineer the binding affinity of the enzyme, but 
also study the catalytic turnover of loading of the nonnative substrate onto the carrier 
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protein through addition of stoichiometric amounts of DhbE's carrier protein DhbB. 
 
5.2 Research Objectives 
 
We developed a biotinylated probe that was then used by our colleague Dr. Jun Yin at the 
University of Chicago to re-engineer the specificity of the adenylating enzyme DhbE 
from the bacillibactin biosynthetic pathway in Bacillus subtilis, for which crystal 
structures and kinetic data were already reported.5, 10 The probe was designed to mimic 
the acyl-adenylate intermediate in DhbE, with a long, flexible linker attached to biotin for 
enrichment with streptavidin. The long linker was necessary to keep the biotin far enough 
away from the enzyme binding domain so as not to interfere with activity. Dr. Yin and 
co-workers developed a yeast cell surface display assay to express fluorescently-labeled 
DhbE so that fluorescent-activated cell sorting (FACS) could be used to identify the 
correctly displayed enzyme. Mutant libraries of DhbE enzyme were incubated with our 
chemical probes, and biotin-streptavidin enrichment selected for binders of the non-
natural probe substrates. By iteratively enriching, they were able to select for mutant 
DhbE enzymes that could be expressed, purified, and were shown to have dramatically 
shifted selectivity for non-natural substrates.  
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5.3 Results 
 
5.3.1 Synthesis of chemical probes for the study of DhbE 
 
The design of the chemical probes for the re-engineering of DhbE specificity grew from 
mimicking the acyl adenylate intermediate that would interact with both the acid and 
ATP substrate binding pockets to improve the affinity of the probe for the enzyme. The 
labile acyl phosphate was replaced with the isosteric sulfamate, and previous structure-
activity relationship studies indicated that we could modify the C-2 position of the 
adenine base without severely compromising binding affinity.16 Based on these 
principles, we targeted the salicyl-AMS probe 1 with a biotin attached at the C-2 position 
of the base with a long, flexible linker for reporting DhbE binding (Figure 5.2). Although 
the native substrate for DhbE is dihydroxybenzoic acid (DHB), we developed the probe 
with salicylic acid (5-1) due to the oxidative instability of the catechol of DHB. Two 
additional probes were developed that included a 3-hydroxybenzoic acid (3-HBA, 5-2) 
and a 2-aminobenzoic acid (2-ABA, 5-3) at the salicyl position to select for enzymes that 
preferentially recognize those substrates.  
Figure 5.2. Chemical probes 5-1–3 targeted for the re-engineering of DhbE selectivity. 
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Scheme 5.1. Synthesis of DhbE probe 5-1. 
The synthesis of probe 5-1 began from commercially available 2-iodoadenosine (5-4, 
Scheme 5.1). Sonogashira coupling with alkyne linker 5-5 gave 5-6 in excellent yield. 
Protection of the 2'- and 3'-hydroxyls with 2,2'-dimethoxypropane, followed by 
sulfamoylation of the 5'-hydroxyl provided sulfamate 5-7 in moderate yield. Coupling of 
the sulfamate with N-hydroxysuccinimidyl-2-(methoxymethyloxy)benzoate 5-8 
generated the fully protected intermediate 5-9. Global deprotection with 80% aqueous 
trifluoroacetic acid (TFA), followed directly by cesium carbonate mediated coupling with 
the commercially available succinimide 5-10 yielded the crude final probe. The final 
material was purified by reverse-phase HPLC to afford the final probe 5-1. 
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Probes 5-2 and 5-3 were synthesized in a similar way. We first prepared N-
hydroxysuccinimidyl-3-(methoxymethyloxy)benzoate 5-12 in good yield from methyl-3-
(methoxymethyloxy)benzoate 5-11 in two steps (Scheme 5.2). Hydrolysis of the methyl 
ester was achieved using sodium hydroxide and water. The crude intermediate was 
directly coupled to N-hydroxysuccinimide using standard DCC coupling conditions. 
 
Cesium carbonate-mediated coupling of succinimide 5-12 to the sulfamate 5-7 yielded 
the penultimate intermediate 5-13. Deprotection followed by coupling with 5-10 gave the 
final probe compound that was purified by reverse-phase HPLC to give 3-HBA probe 5-2 
as the triethylammonium salt (Scheme 5.3).  
 
 
 
 
 
 
Scheme 5.2. Synthesis of N-hydroxysuccinimidyl-3-(methoxymethyloxy)benzoate for the 
synthesis of probe 5-2 
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The final probe molecule, 2-ABA 5-3, is also accessible from intermediate 5-7 (Scheme 
5.4). Isatoic anhydride 5-14 was coupled to the sulfamate with catalytic cesium carbonate 
to give amino intermediate 5-15. Acid-mediated deprotection followed again with 
coupling to 5-10 generated the final probe molecule which was purified by reverse-phase 
HPLC, resulting in 2-ABA probe 5-3 as the triethylammonium salt. 
 
 
 
 
 
 
 
Scheme 5.3. Synthesis of 3-hydroxybenzoic acid (3-HBA) probe 5-2. 
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5.3.2 Construction of an adenylation domain library of DhbE displayed on yeast 
cells 
 
While our group was synthesizing probes 5-1–3, Dr. Jun Yin of the University of 
Chicago was developing a unique yeast cell surface display assay that could be used to 
express bacterial proteins (Figure 5.3). While yeast cell surface display has been 
extensively exploited in the engineering of antibody specificity, its application to 
bacterial proteins is recent.17,18 Briefly, the yeast vector pCTCON2 expresses a library of 
mutants of the protein of interest as a fusion to the yeast agglutinin protein Aga2p 
attached through disulfide bonds to Aga1p protein as part of the yeast cell wall. The yeast 
cell library is incubated with a fluorescently labeled antigen to allow the binding of 
antigen molecules to the protein displayed on the yeast surface. FACS is then used to 
Scheme 5.4. Synthesis of 2-aminobenzoic acid (2-ABA) probe 5-3. 
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isolate yeast cells displaying protein mutants with high affinities with the antigen. For 
this application, Dr. Yin's lab cloned DhbE into the pCTCON2 vector to display the dual-
tagged DhbE enzyme on the yeast cell surface. This fusion was engineered with a 
hemagglutinin (HA) tag and a Myc tag at the N and C termini, respectively, of DhbE to 
enable the detection of properly displayed protein on the cell surface. Upon binding of a 
biotinylated probe, the mutant enzyme will be bound to streptavidin-linked phycoerithrin 
(PE) beads. 
Figure 5.4. Yeast cell display. The mutant DhbE enzymes are expressed on the yeast surface 
as fusions through Aga2p connected through disulfide bonds to Aga1p on the cell surface. 
The mutants have a hemagglutinin (HA) tag on the N terminus and a Myc tag on the C 
terminus. These tags are detected by incubation first with mouse anti-HA and chicken anti-
Myc antibodies, followed by incubation with goat anti-mouse antibody conjugated with 
Alexa Fluor 647 and goat anti-chicken antibody conjugated with Alexa Fluor 488. These 
fluorophores allow the confirmation of full length adenylation domain expression. The 
mutant libraries are then incubated with probe compounds 5-1, 5-2, or 5-3. After binding, the 
biotin moiety is captured by streptavidin that is tethered to phycoeyrithrin (PE) beads for 
detection by flow cytometry. Reproduced with permission from Zhang, et. al.19 
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Studying the published co-crystal structure of DhbE complexed with DHB, Dr. Yin and 
co-workers were able to select residues for mutation that they hypothesized would be 
important for substrate recognition (His234, Asn235, Ala333, and Val337).5 Figure 5.5 
shows the residues in the DhbE active site, highlighting those chosen for randomization. 
This randomization allowed Dr. Yin to construct an adenylation domain library with a 
size of 5 × 106, large enough to cover all the possible mutants in a library with four 
randomized residues (1.6 × 105). 
 
5.3.3 Identification of DhbE mutants with altered specificity for 3-HBA and 2-ABA 
 
Dr. Yin and co-workers performed the yeast cell selection assay according to the protocol 
of Wittrup and Miller, with some modifications (for details see ref. 19).17,18 After 5 
Figure 5.5. Co-crystal structure of wtDhbE and DHB-AMP. Residues important for 
binding are highlighted (nonribosomal code for DhbE). Randomized residues: Asn235, 
His234, Ala333, and Val337. (PDB 1MD8)5 Reprinted with permission from Zhang, et. 
al.19 
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rounds of selection, 30 mutants with specificity for 3-HBA and 2 mutants with specificity 
for 2-ABA were cloned and expressed (Table 5.1). All of the mutants had a His234Trp 
mutation. Specificity for 3-HBA favored an Asn235Ala mutation (also Asn235Ser > 
Asn235 or Asn235Gln), and an Ala333 mutation to Ser or Thr. Specificity for 2-ABA 
converged on a Val337 mutation to Lys or Arg, but also showed a preference for Ala333 
to be replaced by Thr. 
 
The Yin lab then expressed the most abundant mutants selected and tested their catalytic 
activities. Detailed kinetic analysis of these mutants was performed in the Yin lab, and 
are reported in our publication, but will not be discussed here.19 A summary of the results 
are shown below in Table 5.2. 
Table 5.1. Alignment of DhbE mutants selected with probes 5-2 and 5-3 by yeast cell 
surface display. 
wtDhbE 
Number of 
times 
selected 
Residue number 
234 235 333 337 
H N A V 
Clones selected by 5-2  
KZ1 6 W S A V 
KZ2 14 W A A V 
KZ3 4 W N S V 
KZ4 2 W Q T V 
KZ5 2 W Q S V 
KZ6 1 W T A V 
KZ7 1 W C A V 
KZ8 1 W V A V 
Clones selected by 5-3  
KZ11 10 W D T R 
KZ12 9 W D T K 
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5.4 Discussion 
 
The increases seen in the specificity of the mutant enzymes for 3-HBA and 2-ABA are 
likely based on increased affinity for these substrates, as the measure kcat of 
KZ12(Trp234His) for 2-ABA was 0.12 min-1, which is similar to the kcat measured for 2-
ABA with wtDhbE (0.34 min-1). Similarly, the kcat for KZ4(Trp234His) for 3-HBA was 
1.14 min-1, which is only 2-fold higher than the wtDhbE with 3-HBA (0.56 min-1). This 
illustrates a limitation to this technique for re-engineering the substrate specificity of the 
adenylation domain: while mutants are selected based on improved binding interactions 
with substrate probes, this type of selection may not improve the kcat of the engineered 
enzyme with the nonnative substrate. These results agree with previous work on 
Table 5.2. Pyrophosphate (PPi) release rate of the aryl acid adenylation reaction catalyzed by 
wtDhbE and mutants. 
Enzyme and 
substrate Km (µM) kcat (min
-1) kcat/Km  (min-1mM-1) 
Ratio of kcat/Km with 
same substrate 
(Mutant/wtDhbE) 
wtDhbE  
DHB 4.3 ± 0.4 4.61± 0.09 1,100  
Salicylic acid 14 ± 2.2 1.90 ± 0.07 140  
3-HBA 25 ± 7.7 0.56 ± 0.02 22  
2-ABA 62 ± 17 0.34 ± 0.03 5.5  
KZ4(Trp234His)  
DHB 3.5 ± 0.8 1.45 ± 0.08 410 0.37 
Salicylic acid 46 ± 4.8 0.84 ± 0.01 18 0.13 
3-HBA 4.8 ± 0.7 1.14 ± 0.02 240 11 
KZ12(Trp234His)  
DHB 38 ± 12 1.25 ± 0.14 33 0.03 
Salicylic acid 56 ± 14 0.37 ± 0.03 6.6 0.047 
2-ABA 3.5 ± 0.3 0.12 ± 0.01 34 6.2 
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engineering catalytic antibodies that showed tighter binding with the transition state 
analogue by the antibody does not lead to a higher turnover rate (kcat) of the catalytic 
reactions.20 
The most specific mutant for 3-HBA, KZ4, appeared to have a key Asn235Gln mutation. 
The Gln side chain is one CH2 group longer than the Asn side chain in wtDhbE. This may 
extend the sidechain further into the substrate binding pocket to fill the space that used to 
be occupied by the 2-OH substituent of DHB. The amide NH2 of the Gln residue may 
also form hydrogen bonds with the 3-hydroxyl group in 3-HBA. 
Only 2 mutants were converged upon for 2-ABA specificity: KZ11 and KZ12. The only 
difference between these mutants was a Lys or Arg replacing Val337. The Lys and Arg 
residues at this position may interact with the 2-NH2 group of 2-ABA. Ala333 was not 
assigned as a nonribosomal code residue for A-domain binding with the aryl acid 
substrates,21 however a preference was shown after yeast selection for an Ala333 to  Ser 
or Thr residues. Both mutations position hydroxyl side chains favorably for hydrogen 
bond interactions with the 2-ABA substrate. 
Some of these mutations may have been predicted from the crystal structure. Some 
groups are currently using computer-aided docking programs to design mutant proteins 
with altered substrate specificity.13,22 While this in silico technique can potentially save 
time on protein expression, purification, and testing, it cannot take into account 
differences in protein folding or active site arrangement that may occur upon residue 
replacement. This random mutation approach devised by Dr. Yin and co-workers allows 
for large groups of mutants to be screened in their native folded state. The enrichment 
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steps allow for the "purification" of proteins that bind the nonnative substrates with 
specificity, eliminating time that could be wasted on expression and purification of 
mutants that may prove to be ineffective binders. Care should be taken to carefully 
examine mutant proteins identified by the techniques detailed here,19 however, as this 
study illustrates the possibility that altering the binding of the enzyme may also impact its 
catalytic efficiency. Scrutiny of the binding, catalytic efficiency, and overall 
incorporation of the nonnative substrate into the final natural product pathway must be 
verified for this approach to be a complete success. 
 
5.5 Conclusions 
 
In this study, we were able to synthesize three biotinylated probes that were used by our 
colleague Dr. Jun Yin at the University of Chicago to re-engineer the specificity of the 
adenylating enzyme DhbE from the bacillibactin biosynthetic pathway in Bacillus 
subtilis. These probes were designed with a long, flexible linker attached to biotin for 
enrichment with streptavidin. The long linker was necessary to keep the biotin far enough 
away from the enzyme binding domain so as not to interfere with activity. Dr. Yin's 
group was able to successfully develop a yeast cell surface display assay to display 
mutant libraries of DhbE that were then incubated with our chemical probes. Biotin-
streptavidin enrichment selected for mutant enzymes that bound the non-natural probe 
molecules. By iteratively enriching, they were able to select for mutant DhbE enzymes 
that could be expressed, purified, and were shown to have dramatically shifted selectivity 
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towards non-natural substrates. 
 
5.6 Experimental Data 
 
5.6.1 General procedures for the synthesis of biotinylated probes against DhbE 
 
All reactions were performed under an inert atmosphere of dry argon in oven-dried (150 
°C) glassware. 1H and 13C NMR experiments were recorded on a Varian 600 MHz 
spectrometer. Proton chemical shifts are reported in ppm from an internal standard of 
residual chloroform (7.26 ppm) or methanol (3.31 ppm). Carbon chemical shifts are 
reported using an internal standard of residual chloroform (77.0 ppm) or methanol (49.1 
ppm). Proton chemical data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, ovlp = 
overlapping), coupling constant, and integration. High resolution mass spectra were 
acquired on an Agilent TOF II TOF/MS instrument (Agilent Technologies, Santa Clara, 
CA) equipped with either an ESI or APCI interface. Semi-preparative reverse-phase 
HPLC was performed on a Phenomenex Gemini 10 µm C18 110 Å (250 × 10.0 mm) 
column (Phenomenex, Torrance, CA) operating at 5.0 mL/min with detection at 254 nm. 
Flash chromatography was performed on an ISCO Combiflash Companion® purification 
system (Teledyne Isco, Lincoln, NE) with prepacked silica gel cartridges and the 
indicated solvent system.  
All commercial reagents (Sigma-Aldrich, Fisher, Fluka, Strem) were used as provided. 
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NHSdPEG®4-biotin was purchased from Quanta BioDesign, Ltd. (Powell, OH, USA) and 
2-iodoadenosine from Tokyo Chemical Industry Co. (Portland, OR, USA). Sulfamoyl 
chloride was prepared by the method of Heacock without recrystallization.23 Compound 
5-7 was prepared according to literature procedure and all spectral data agree with 
reported values.24 An anhydrous solvent dispensing system (JC Meyer Solvent Systems, 
Laguna Beach, CA) with two packed columns of neutral alumina was used for drying 
THF, DMF and DCM and the solvents were dispensed under argon. Anhydrous DME 
(Sigma-Aldrich) was used as provided. Compound 5-1 was completed by Dr. Kimberly 
Grimes of the Aldrich lab, with experimental data reported elsewhere.19 
 
5.6.2 N-Hydroxysuccinimidyl 3-(methoxymethyloxy)benzoate (5-12) 
 
A solution of LiOH (328 mg, 7.65 mmol, 3.0 equiv) in MeOH (27 mL) and water (3 mL) 
was added to methyl 3-(methoxymethyloxy)-benzoate 5-1125 (500 mg, 2.55 mmol, 1.0 
equiv), and the reaction mixture was refluxed for 2 h. The reaction mixture was 
concentrated, the residue was dissolved in H2O (25 mL), the pH was adjusted to 2, and 
then extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed 
with saturated aqueous NaCl (50 mL), then concentrated under reduced pressure to afford 
3-(methoxymethyloxy)-benzoic acid (440 mg, 95%), which was directly carried onto the 
next step. 
To a solution of the crude product (440 mg, 2.41 mmol, 1.0 equiv) from above in dry 
THF (25 mL) at 0 °C was added N-hydroxysuccinimide (306 mg, 2.66 mmol, 1.1 equiv) 
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and DCC (498 mg, 2.41 mmol, 1.0 equiv). The resulting mixture was stirred for 30 min at 
0 °C and then 16 h at 23 °C. The reaction mixture was filtered to remove the DCU 
precipitate, and the filtrate was concentrated under reduced pressure. Purification by flash 
chromatography (4:1 EtOAc/hexanes) afforded the title compound (620 mg, 92%) as a 
viscous, colorless oil. 
 
5.6.3 2-[3-(2-{2-[2-(tert-Butoxycarbonylamino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-
2′,3′-O-isopropylidene-5′-O-{N-[3-(methoxymethoxy)benzoyl]sulfamoyl}adenosine 
(5-13)  
 
To a solution of 5-724 (16 mg, 0.024 mmol, 1.0 equiv) in DMF (2.5 mL) was added 5-12 
(10 mg, 0.036 mmol, 1.5 equiv) and Cs2CO3 (23 mg, 0.071 mmol, 3.0 equiv) and the 
reaction was stirred at 23 °C for 22 h. The reaction mixture was filtered and concentrated 
under reduced pressure to a pale yellow film. Purification by flash chromatography 
(linear gradient 0–15% MeOH/EtOAc) gave the title compound (17.2 mg, 86%) as a 
colorless oil. Rf = 0.36 (10% MeOH/EtOAc); 1H NMR (600 MHz, CD3OD) δ 1.35, (s, 
3H), 1.41 (s, 9H), 1.60 (s, 3H), 3.22 (t, J = 5.4 Hz, 2H), 3.43 (s, 3H), 3.51 (t, J = 5.4 Hz, 
2H), 3.61–3.62 (m, 2H), 3.64–3.65 (m, 2H), 3.70–3.71 (m, 2H), 3.78–3.79 (m, 2H), 4.34 
(t, J = 4.8 Hz, 2H), 4.45 (s, 2H), 4.57 (s, 1H), 5.14 (d, J = 5.4 Hz, 1H), 5.19 (s, 2H), 5.34 
(q, J = 3.6 Hz, 1H), 6.22 (d, J = 2.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.25 (t, J = 7.2 Hz, 
1H), 7.64 (d, J = 7.8 Hz, 1H), 7.69 (s, 1H), 8.53 (s, 1H); 13C NMR (150 MHz, CD3OD) δ 
25.7, 27.7, 28.9, 41.4, 56.4, 59.5, 70.0, 70.6, 71.2, 71.4, 71.5, 71.7, 80.1, 82.8, 83.5, 86.0, 
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86.5, 91.8, 95.7, 115.5, 117.7, 119.8, 120.4, 123.6, 130.0, 140.6, 142.3, 147.3, 150.8, 
157.2, 158.5, 174.7 (missing 2 carbons, likely due to overlap); HRMS (ESI−) calculated 
for C36H48N7O14S [M − H]− 834.2985, found 834.2965 (error 2.4 ppm). 
 
5.6.4 2-[3-(2-{2-[2-({dPEG®4-biotinyl}amino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-5′-
O-{N-[3-(hydroxy)benzoyl]sulfamoyl}adenosine triethylammonium salt (5-2) 
 
To 5-13 (17.2 mg, 0.021 mmol, 1.0 equiv) was added 80% aqueous TFA (2 mL). The 
mixture was stirred at 23 °C for 4 h, then concentrated under reduced pressure to remove 
all traces of TFA. To the resulting crude residue in DMF (1 mL) was added triethylamine 
(0.100 mL, 0.717 mmol, 34 equiv) and 5-10 (18.2 mg, 0.031 mmol, 1.5 equiv). The 
mixture was stirred at 23 °C for 13 h, then concentrated under reduced pressure. 
Purification by semi-preparative reverse-phase HPLC using a Phenomenex Gemini 10 
µm C18 110 Å (250 × 10.0 mm) column (Phenomenex, Torrance, CA) and a gradient of 
5–35% MeCN–10 mM aqueous triethylammonium bicarbonate over 20 minutes, 
followed by 35% for 8 minutes. The retention time of the product was 18.5 minutes (kʹ = 
3.6) and the appropriate fractions were pooled and lyophilized to afford the title 
compound (8 mg, 34%) as an off-white solid. 1H NMR (600 MHz, CD3OD) δ 1.36–1.38 
(m, 2H), 1.53–1.61 (m, 2H), 1.67–1.69 (m, 2H), 2.16 (t, J = 7.2 Hz, 2H), 2.42 (t, J = 6.0 
Hz, 2H), 2.65 (d, J = 12.6 Hz, 1H), 2.87 (dd, J = 12.6, 4.8 Hz, 1H), 3.09–3.14 (m, 4H), 
3.19 (s, 1H), 3.48–3.52 (m, 4H), 3.55–3.57 (m, 6H), 3.58–3.60 (m, 6H), 3.62–3.64 (m, 
2H), 3.66–3.68 (m, 4H), 3.74–3.76 (m, 2H), 4.25 (q, J = 4.2 Hz, 1H), 4.29 (d, J = 3.0 Hz, 
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1H), 4.34 (d, J = 2.4 Hz, 1H), 4.36 (d, J = 3.0 Hz, 1H) 4.38–4.39 (m, 1H), 4.41 (s, 2H), 
4.44 (q, J = 4.2 Hz, 1H), 4.65 (t, J = 5.4 Hz, 1H), 6.05 (d, J = 5.4 Hz, 1H), 6.82 (dd, J = 
7.8, 2.4 Hz, 1H), 7.13 (t, J = 7.8 Hz, 1H), 7.43 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 8.57 (s, 
1H); 13C NMR (150 MHz, CD3OD) δ 10.4, 27.0, 29.6, 29.9, 36.9, 37.7, 40.5, 40.6, 41.2, 
47.5, 57.1, 59.6, 61.8, 63.5, 68.4, 69.3, 70.5, 70.6, 70.7, 70.78, 70.80, 71.37, 71.45, 71.56, 
71.60, 71.65, 71.69, 71.73, 72.5, 76.4, 83.4, 84.9, 89.3, 92.6, 116.8, 118.3, 119.2, 121.4, 
130.0, 142.1, 147.2, 151.1, 157.1, 157.2, 158.3, 166.2, 174.2, 175.3, 176.3; HRMS 
(ESI−) calculated for C47H67N10O18S2 [M – H]– 1123.4082, found 1123.4126 (error 3.9 
ppm). 
 
5.6.5 2-[3-(2-{2-[2-(tert-Butoxycarbonylamino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-
2′,3′-O-isopropylidene-5′-O-{N-[2-(amino)benzoyl]sulfamoyl}adenosine 
triethylammonium salt (5-15) 
 
To a solution of 5-724 (16 mg, 0.02 mmol, 1.0 equiv) in DMF (3 mL) at 23 ºC was added 
5-14 (8 mg, 0.05 mmol, 2.5 equiv) and Cs2CO3 (23 mg, 0.07 mmol, 3.5 equiv) and the 
reaction stirred for 16 h. The reaction mixture was filtered and the filtrate concentrated 
under reduced pressure. Purification by flash chromatography (linear gradient 0–20% 
MeOH/EtOAc with 1% Et3N) afforded the title compound (12.1 mg, 76%) as a yellow 
oil: Rf = 0.20 (10% MeOH/EtOAc); 1H NMR (600 MHz, CD3OD) δ 1.27 (t, J = 7.2 Hz, 
9H), 1.35 (s, 3H), 1.41 (s, 9H), 1.60 (s, 3H), 3.17 (q, J = 7.8 Hz, 6H), 3.22 (q, J = 6.0 Hz, 
2H), 3.51 (t, J = 6.0 Hz, 2H), 3.60–3.61 (m, 2H), 3.64–3.65 (m, 2H), 3.69–3.70 (m, 2H), 
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3.78 (q, J = 4.2 Hz, 2H), 4.30 (dd, J = 10.8, 3.6 Hz, 1H), 4.34 (dd, J = 10.8, 3.6 Hz, 1H), 
4.44 (s, 2H), 4.57 (d, J = 2.4 Hz, 1H), 5.13 (dd, J = 6.0, 1.8 Hz, 1H), 5.35 (dd, J = 6.0. 3.0 
Hz, 1H), 6.23 (d, J = 3.6 Hz, 1H), 6.54 (t, J = 7.8 Hz, 1H), 6.66 (d, J = 8.4 Hz, 1H), 7.11 
(t, J = 7.2 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 8.55 (s, 1H); 13C NMR (150 MHz, CD3OD) 
δ 9.4, 25.7, 27.7, 28.9, 41.4, 48.0, 55.3, 59.5, 69.9, 70.6, 71.2, 71.4, 71.5, 71.6, 80.2, 82.8, 
83.5, 85.9, 86.0, 86.4, 91.8, 115.5, 116.9, 118.1, 119.8, 120.2, 132.7, 133.2, 142.4, 147.3, 
150.8, 151.4, 157.2, 176.9. 
 
5.6.6 2-[3-(2-{2-[2-({dPEG®4-biotinyl}amino)ethoxy]ethoxy}ethoxy)prop-1-ynyl]-5′-
O-{N-[2-(amino)benzoyl]sulfamoyl}adenosine triethylammonium salt (5-3) 
 
To 5-15 (12.1 mg, 0.015 mmol, 1.0 equiv) was added 80% aqueous TFA (2 mL) and the 
mixture stirred at 23 ºC for 2.5 h, then concentrated under reduced pressure to remove all 
traces of TFA. The crude residue was dissolved in DMF (2 mL) and triethylamine (0.006 
mL, 0.046 mmol, 3.0 equiv) and 5-10 (13 mg, 0.023 mmol, 1.5 equiv) were added. The 
mixture was stirred at 23 ºC for 16 h, then concentrated under reduced pressure to a 
yellow oil. Purification by semipreparative reverse-phase HPLC using a Phenomenex 
Gemini 10 µm C18 110 Å (250 × 10.0 mm) column (Phenomenex, Torrance, CA) and a 
gradient of 5–35% MeCN/10 mM aqueous triethylammonium bicarbonate over 20 min 
followed by 35% MeCN for 3 min. The retention time of the product was 19.8 minutes 
(kʹ = 4.0) and the appropriate fractions were pooled and lyophilized to afford the title 
compound (2.1 mg, 11%) as an off-white solid. 1H NMR (600 MHz, CD3OD) δ 1.27–
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1.32 (m, 9H), 1.40–1.46 (m, 2H), 1.60–1.66 (m, 2H), 1.68–1.73 (m, 2H), 2.20 (t, J = 7.8 
Hz, 2H), 2.46 (t, J = 6.0 Hz, 2H), 2.68 (q, J = 12.6 Hz, 1H), 2.91 (dd, J = 13.2, 4.8 Hz, 
1H), 3.15–3.24 (m, 4H), 3.35–3.38 (m, 6H), 3.42 (br s, 1H), 3.52–3.56 (dt, J = 15.0, 6.0 
Hz, 4H), 3.60–3.64 (m, 14H), 3.66–3.68 (m, 2H), 3.70–3.72 (m, 4H), 3.79–3.80 (m, 2H), 
4.29 (dd, J = 7.8, 4.8 Hz, 1H), 4.32 (d, J = 2.4 Hz, 1H), 4.37 (dd, J = 10.8, 3.0 Hz, 2H), 
4.43 (dd, J = 8.0, 3.6 Hz, 1H), 4.45 (s, 2H), 4.48 (dd, J = 7.8, 4.8 Hz, 1H), 4.70 (t, J = 6.0 
Hz, 1H), 6.09 (d, J = 5.4 Hz, 1H), 6.55 (t, J = 7.2 Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H), 7.10 
(t, J = 8.4 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 8.63 (s, 1H); 13C NMR (150 MHz, CD3OD, 
assigned by HMBC and HSQC) δ 9.8, 25.4, 28.0, 28.3, 35.2, 36.3, 39.1, 39.6, 41.4, 46.5, 
55.5, 57.1, 58.6, 60.0, 60.1, 61.9, 66.7, 67.0, 68.8, 69.0, 69.1, 69.3, 69.75, 69.84, 70.0, 
70.06, 70.07, 70.2, 76.3, 81.1, 84.8, 99.9, 104.6, 116.6, 117.8, 119.2, 131.2, 137.3, 140.6, 
149.59, 149.63, 153.4, 154.1, 158.2, 172.6, 174.7, 178.8 (missing 2 carbons; 1 ethoxy 
linker C and 1 aromatic C, likely due to overlap); HRMS (ESI−) calculated for 
C47H68N11O17S2 [M – H]– 1122.4242, found 1122.4344 (9.1 ppm error). 
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Chapter 6. Conclusions and Future Directions 
 
 
New antitubercular agents are desperately needed for the treatment of increasingly drug 
resistant strains of Mycobacterium tuberculosis (Mtb) that continue to develop. The 
development of new therapeutics can be through the discovery of new compounds for 
validated cellular targets, or through discovery and development of compounds against 
new targets yet to be exploited. A known target can make structure-activity relationships 
easier to study, however overcoming drug resistance at a previously targeted site can 
prevent successful development of new therapeutics. New targets do not have existing 
drug resistance problems, but need extensive validation before a new compound can be 
brought to preclinical development. 
Our work has focused on discovering new ways to target Mtb through the bacteria's need 
for iron. In an effort to probe the biosynthetic pathway of siderophores more fully, our 
group had previously developed small molecule inhibitors of MbtA, the initiating enzyme 
in the biosynthesis of mycobactins. We used this information to synthesize and evaluate 
the parent compound, Sal-AMS, and its analogues in vivo. In Chapter 2 we described the 
synthesis and evaluation of a small set of compounds that we predicted would incorporate 
strong antimycobacterial activity and improved pharmacokinetic parameters. We 
hypothesized that by decreasing the acidity of the linker group and increasing the 
lipophilicity of the compound we could improve the bioavailability through passive 
diffusion. Unfortunately, we did not see very impressive oral bioavailability of our 
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compounds. We were encouraged to see that analogues with decreased acidity in the 
linker did show improvement in bioavailability, albeit moderately so. An acetate prodrug 
of Sal-AMS was also ineffective for improving the bioavailability of the parent 
compound. The tri-acetate prodrug was quickly hydrolyzed in pooled rat plasma, 
however the di-acetate and mono-acetate intermediates were relatively long-lived. We 
would need to re-test these compounds while observing all the intermediates over a 
longer period of time (> 8 hours) in order to accurately determine the true bioavailability 
of these analogues. This work sets the groundwork in the group for an in vivo SAR study 
to build bioavailability into the constraints we have for antimycobacterial potency. Some 
analogues that we are pursuing include some derivatives that incorporate lipophilic or 
fluoro groups at the 2ʹ-position of the glycosyl moiety, as well as prodrugs of the acidic 
nitrogen in the linker group. It may also be useful to make mono-esters of acyloxyalkyl 
esters at the phenol hydroxyl. It appears this position is the most readily cleaved in rat 
plasma, with a half-life approximated at 1 minute. If a sufficiently permeable prodrug at 
this position can be developed, release of the prodrug should be efficient. We would also 
like to evaluate the permeability of these compounds in an additional in vitro assay, e.g. 
Caco-2 or MDCK assay to help us better understand the behavior we have observed in 
vivo. 
In Chapter 3, we described a study to confirm MbtA as the target of our parent 
compound, Sal-AMS, as well as an attempt to identify possible additional targets of Sal-
AMS action. It had previously been suggested that Sal-AMS should only be active 
against the bacteria in an environment where siderophore action was essential to the 
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bacteria's survival, i.e. iron-limiting conditions. We saw activity, however, under both 
iron-deficient and iron-replete conditions. From knowledge we had already gained from 
SAR studies performed previously in our lab, we were able to design and synthesize a 
light-activated probe that still shows good binding to MbtA. This compound incorporated 
a benzophenone as an activatable cross-linking reagent, and a terminal alkyne for use as a 
handle to incorporate either imaging or enrichment tags. Dr. Benjamin Duckworth, a 
post-doc in our lab, successfully used this compound to confirm the binding of the parent 
compound to MbtA, but was unable to positively identify additional proteins to which 
Sal-AMS may be binding. After completion of this study, we learned from our 
collaborator, Dr. Michael Niederweis, and others that the siderophore pathway may be 
necessary at all times for the bacteria's acquisition of iron. There is now some evidence 
that mycobacterial siderophores are in use even in iron-replete conditions in order to 
facilitate the diffusion of iron across the highly complex mycobacterial cell envelope. We 
have an ongoing collaboration with Dr. Niederweis to confirm that our compounds show 
activity under both conditions due to the disruption of iron acquisition by the bacteria. 
Rescuing growth of the mycobacteria in an iron-rich media in the presence of Sal-AMS 
by the addition of mycobactins would help confirm the targeted pathway and its 
importance to bacterial growth. Growth of resistant Mtb mutants would also help confirm 
the relevant target. Finally, efficacy studies in an Mtb animal infection model would be 
the ultimate test as to whether or not these analogues are able to inhibit mycobactin 
biosynthesis to a therapeutically relevant level. 
In Chapter 4, the natural product transvalencin Z reported to be active against 
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mycobacteria was synthesized for study against Mtb. The two previously unassigned 
stereocenters allowed for 4 diastereomeric possibilities, each of which was separately 
synthesized for comparison to the reported spectroscopic data. Transvalencin Z resembles 
the structures of mycobactins in Mtb, siderophores produced by the bacteria for iron 
acquisition. Pioneering work by Dr. Marvin Miller and others has shown that structural 
mimics of siderophore structures can be potent inhibitors of Mtb growth. While we 
hypothesized that the reported activity against mycobacteria was related to disrupting the 
iron acquisition pathway, we were unable to reproduce the activity profile originally 
reported for transvalencin Z. Further, none of the completed diastereomers fully matched 
the limited spectroscopic data reported for the compound. Without an authentic standard 
with which to compare these synthetic transvalencin diastereomers, we were unable to 
draw any conclusions regarding the natural product's stereochemistry or mechanism of 
action. When we reached out to the authors who reported transvalencin Z, we were 
unable to obtain any of the originally isolated sample or the producing strain. We need to 
obtain the producing strain of Nocardia so that we can isolate the natural product and 
compare it to our synthetic diastereomers for absolute stereochemical assignment. This 
may also afford us a better understanding of the antimycobacterial properties of the 
compound. If the Transvalencin Z fraction again proves active against M. smegmatis, it 
would be prudent to attempt to identify the active component of this fraction, as it may be 
a very exciting lead compound for antimycobacterial development. 
Finally, in Chapter 5 we aided our collaborator Dr. Jun Yin in the synthesis of 3 
biotinylated probes for the reengineering of substrate specificity for DhbE, the aryl acid 
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adenylating enzyme in the bacillibactin biosynthetic pathway in B. subtilis. These probes 
were successful in allowing for the identification of mutant DhbE enzymes with 
increased specificity for 3-hydroxybenzoic acid and 2-aminobenzoic acid over the wild-
type substrate 2, 3-dihydroxybenzoic acid. Dr. Yin and co-workers were also able to 
demonstrate that these mutant enzymes were capable of loading the nonnative substrates 
onto the carrier protein DhbB. It would be useful to attempt to express the entire 
bacillibactin pathway, including the mutant enzymes, to evaluate whether the nonnative 
substrates can successfully be incorporated into the natural product. Additional mutants 
that can accept more highly differentiated substrates should also be attempted, in order to 
understand some of the limitations of this technique. 
The development of new antitubercular agents is a continual battle to remain ahead of 
bacterial resistance development. The studies described in this thesis have demonstrated 
the importance of combining synthetic methods with biochemistry, molecular biology, 
and analytical chemistry for the discovery of new therapeutics. This interdisciplinary 
approach is vital to the success of any drug development program in identifying 
promising (and failing) lead compounds before investing heavily in preclinical and 
clinical development. 
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